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Zusammenfassung 
Kardiovaskuläre Erkrankungen gehören zu den häufigsten Erkrankungen und stellen die 
Haupttodesursache weltweit dar. Dabei nimmt die Prävalenz der an kardialer Hypertrophie mit 
Übergang in die Herzinsuffizienz erkrankten Personen, v.a. Frauen, mit dem Alter dramatisch 
zu. Es wird davon ausgegangen, dass der im Alterungsprozess auftretende Funktionsverlust 
des Ubiquitin-Proteasom-Systems (UPS) ein Schlüsselelement in der Verstärkung dieses 
Prozesses darstellt. Weiterhin wird angenommen, dass das UPS in die Entwicklung von 
kardialen Erkrankungen involviert ist, da es durch den zielgerichteten Abbau von Struktur-, 
Funktions- und Signalproteinen sowohl die Struktur, als auch Funktion der Kardiomyozyten 
aufrechterhält. Dennoch ist die Anzahl systematischer Studien, welche die Mechanismen der 
Proteasomregulation im Herzen und deren Rolle in der Pathogenese struktureller 
Herzerkrankungen bzw. beim Alterungsprozess untersuchen, derzeit begrenzt. 
Laufende Untersuchungen unserer Arbeitsgruppe weisen auf eine Verstärkung der durch 
anhaltende Stimulierung kardialer β-Adrenozeptoren verursachten Herzhypertrophie im 
Mausmodell durch Knockout der induzierbaren Proteasomuntereinheit β1i hin. Daher 
beschäftigte sich die vorliegende Arbeit damit, ob vorrangig der fehlende Einbau von β1i in 
aktive kardiale Proteasomkomplexe oder der systemische Verlust von β1i per se für die 
verstärkte Herzhypertrophie in den β1i-defizienten Mäusen nach Isoprenalinbehandlung 
verantwortlich ist. Der Wiedereinbau von β1i in kardiale Proteasomkomplexe von 
β1i-defizienten Mäusen durch Reexpression der Proteasomuntereinheit mit Hilfe 
herzspezifischer (Serotyp 9) adeno-assoziierter Viren führte zu einer Abschwächung der 
Isoprenalin-induzierten Herzhypertrophie in diesen Tieren auf das Niveau 
Isoprenalin-behandelter Wildtyp-Mäuse und verhinderte das Auftreten einer systolischen 
ebenso wie einer diastolischen Dysfunktion. Die verstärkte, durch β-adrenerge 
Überstimulation verursachte Hypertrophieentwicklung in den β1i-defizienten Mäusen ist 
vermutlich nicht auf eine Störung der Sarkomerstruktur bzw. einen dysregulierten Abbau 
kontraktiler Proteine zurückzuführen. Allerdings scheint der Einbau von β1i in aktive 
Proteasomkomplexe des Herzen mit einer erhöhten Menge von intrazellulärem Troponin I als 
in der Kontrollgruppe assoziiert zu sein, was zur Aufrechterhaltung der kardialen Funktion 
beitragen könnte. 
Im Gegensatz zu vorhergehenden Studien konnten im Zusammenhang mit dem 
Alterungsprozess deutliche Änderungen des kardialen Proteoms, welche mit einer starken 
Zunahme der 26S-Proteasomaktivitäten assoziiert waren, festgestellt werden. Des Weiteren 
scheint die Zunahme der 26S-Proteasomaktivitäten adaptiv zu Änderungen im kardialen 
Proteom zu erfolgen und mit einer altersbedingten Verschlechterung des Allgemeinzustands 
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der Tiere assoziiert zu sein. Sie dient damit höchstwahrscheinlich der Aufrechterhaltung der 
Proteinhomöostase und der Herzfunktion im Alterungsprozess. 
Zusammenfassend wurde in der vorliegenden Studie erstmals gezeigt, dass der erhöhte 
Einbau von β1i in kardiale Proteasomkomplexe nach Hypertrophieinduktion ein wichtiger 
Schutzmechanismus bei diesem kardialen Umbauprozess zu sein scheint. Weiterhin könnte 
die Regulation der kardialen Proteasomfunktion im Alterungsprozess wesentlich komplexer 
sein als eingangs vermutet. Daher verdeutlichen die vorliegenden Ergebnisse wie wichtig es 
ist die mutmaßlich wichtige Rolle der Regulation der Proteasomfunktion sowohl beim Altern, 
als auch bei der Entwicklung von Herzmuskelerkrankungen besser zu verstehen. 
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Summary 
Cardiovascular disease causes the highest morbidity and mortality worldwide. Moreover, the 
prevalence of cardiac hypertrophy and failure dramatically increases with aging, most notably 
in women. In this context, impairment of the ubiquitin-proteasome system (UPS) is supposed 
to be a pivotal element in the reinforcement of aging. Moreover, an involvement of the UPS, 
which accounts for the preservation of cardiomyocyte structure and function by the targeted 
degradation of structural, functional as well as signaling proteins, in the development of cardiac 
hypertrophy has been suggested. However, the number of systematic studies with regard to 
mechanisms underlying proteasome regulation in the heart and their role in cardiac 
remodeling, especially in the aging heart, is currently limited.  
Ongoing studies in our group reveal that cardiac hypertrophy due to continuous β-adrenergic 
stimulation in the mouse is exaggerated by knockout of the proteasome subunit β1i. The 
present study therefore addresses the question whether it is the absence of β1i incorporation 
into active cardiac proteasome complexes or its deficiency per se, which augments cardiac 
hypertrophy in β1i-deficient mice upon treatment with isoprenaline. Reintroduction of β1i into 
cardiac proteasome complexes of β1i-deficient mice by way of cardiac-specific (serotype 9) 
adeno-associated viral gene transfer resulted in reduced hypertrophy development, 
comparable to the level in isoprenaline-treated wild type mice, and prevention of a manifest 
systolic and diastolic dysfunction. Presumably, the augmented hypertrophy development in the 
isoprenaline-treated β1i-deficient mice is not related to a disturbance of the sarcomeric 
structure or a dysregulated degradation of contractile proteins. However, reassembly of β1i 
into active cardiac proteasome complexes seems to be associated with higher intracellular 
troponin I levels compared to the control group, which may contribute to the maintenance of 
cardiac function. 
In contrast to previous studies, marked alterations of the cardiac proteome associated with 
strongly increased 26S proteasome activities were detected in aging mouse hearts. Moreover, 
this increase in 26S proteasome activities seemed adaptive with respect to the extent of the 
alterations in the cardiac proteome, which may be associated with the age-related deterioration 
of the general health status of these animals. This increase in 26S proteasome activities may 
thus serve to maintain protein homeostasis and cardiac function during aging. 
In conclusion, the present study revealed for the first time that increased incorporation of β1i 
into active cardiac proteasome complexes following induction of hypertrophy seems to be an 
important protective mechanism in maladaptive cardiac remodeling. Moreover, regulation of 
cardiac proteasome function during aging seems more complex than expected. Collectively, 
the current findings highlight how important it is to gain a better insight into mechanisms that 
regulate proteasome function in the context of aging and the pathogenesis of heart disease. 
 Introduction 
 4 
1 Introduction 
1.1 The cardiovascular system and cardiac hypertrophy 
The cardiovascular system consists of the blood, the heart, the blood vessels and the lymphatic 
system. The heart is an electromechanical pump with a primary function to circulate blood 
through the body via the blood vessels. Blood serves as central transport (e.g. O2, CO2, 
nutrients, hormones), regulatory (e.g. pH, temperature, osmotic pressure) and protection 
system (e.g. against pathogens). The right side of the heart delivers blood to the lungs via the 
pulmonary circuit. Accordingly, venous blood returns from the body to the right atrium through 
the superior and inferior venae cavae. The blood then passes through the tricuspid valve into 
the right ventricle (Figure 1). After entering the pulmonary artery through the pulmonary valve, 
the blood is delivered to the lungs (Figure 1) (Iaizzo 2007). The oxygenated blood returns from 
the lungs to the left atrium through the pulmonary veins and enters the left ventricle through 
the mitral valve (Figure 1). It leaves the left ventricle through the aortic valve into the aorta from 
where it is delivered to the body via the systemic circuit (Figure 1) (Iaizzo 2007). The cardiac 
cycle consist of two phases, the systole and the diastole. The ventricles contract and eject the 
blood into the systemic circulation during systole (Fernandis et al. 2002). In diastole, relaxation 
and passive filling of the ventricles occurs (Iaizzo 2007). 
 
 
Figure 1. Functional anatomy of the 
heart. 
Pathway of blood flow through the 
heart is visualized by arrows. The left 
side of the heart delivers blood via the 
systemic circuit to the entire body, 
whereas the right side of the heart 
delivers blood to the lungs via the 
pulmonary circuit. 
Adapted from reference (Iaizzo 2007). 
 
The pivotal role of the cardiovascular system for all vital functions may be derived from the fact 
that cardiovascular disease is the leading cause of morbidity and mortality worldwide. The term 
cardiovascular disease defines diseases of the heart as well as the blood vessels. Notably, 
heart failure is the most common cardiovascular disease, namely in the elderly and especially 
in women aged 65 years or older. It is defined as a deficiency in the heart’s capability to deliver 
blood to the periphery in response to systemic demands (Heineke et al. 2006). Characteristic 
 Introduction 
 5 
symptoms of heart failure include premature fatigue, dyspnoea, and/or edema. Heart failure is 
commonly considered as the end stage of a number of heart-related diseases such as 
long-term hypertension, myocardial infarction or ischemia associated with coronary heart 
disease, valvular insufficiency and stenosis, familial hypertrophic and dilated 
cardiomyopathies, and arrhythmias (Klein et al. 2003, Lips et al. 2003). Most of these diseases 
result in maladaptive (pathophysiological) cardiac hypertrophy in response to cardiac stress 
(volume or pressure overload) as well as loss of contractile mass due to prior infarction, 
neurohumoral activation, and/or mutations of sarcomeric proteins (Berenji et al. 2005). Thus, 
maladaptive cardiac hypertrophy is a common preliminary stage of heart failure, which 
predisposes individuals to heart failure in the long-term. Accordingly, pathological cardiac 
hypertrophy may be considered as a risk factor for cardiovascular morbidity and mortality (Levy 
et al. 1990, Haider et al. 1998, Sundstrom et al. 2001). 
In contrast, cardiac function is preserved in the long-term in adaptive (physiological) cardiac 
hypertrophy, which is associated with pregnancy or endurance training. The increase in the 
circulatory blood volume to supply the fast growing fetus or the mass of skeletal muscle under 
high burden in case of endurance training is the predominant stimulus for the development of 
physiological cardiac hypertrophy. In addition, development of maladaptive cardiac 
hypertrophy is associated with gender, obesity and diabetes mellitus. Moreover, a quantitative 
study demonstrated that the prevalence of cardiac hypertrophy increases in the context of 
aging (reviewed in (Lakatta et al. 2003)). At 60 years of age or older approximately 15% of 
men and approximately 20% of women were found to be affected by cardiac hypertrophy 
despite having a normal blood pressure (Lakatta et al. 2003). Thus, the prevalence of cardiac 
hypertrophy increases 2-fold and 4-fold in aged men and women, respectively, as compared 
to people 40 years of age or younger (Lakatta et al. 2003). 
Cardiac hypertrophy is characterized by remodeling of the cardiomyocytes and extracellular 
matrix as well as coordinated neovascularization or angiogenesis. The common classification 
of cardiac hypertrophy is based on modification of the heart’s shape and ventricular volume. 
This is commonly due to an alteration in the distribution of the muscle mass, which can be 
symmetrical (concentric) or asymmetrical (eccentric) (reviewed in (Heineke et al. 2006, Maillet 
et al. 2013)) (Figure 2). The alteration in cardiac muscle mass distribution is the pivotal element 
of hypertrophic growth of the heart. It results from an increase in cardiomyocyte size due to 
the addition of sarcomeres either in parallel or in series, which is induced by differing signaling 
pathways in physiological or pathophysiological cardiac hypertrophy. Eccentric hypertrophy is 
characterized by the relatively uniform addition of sarcomeres in parallel to increase the 
cardiomyocyte cell width as well as in series to lengthen the cardiomyocytes. These alterations 
of the geometry of the individual cardiomyoctes result in a uniform increase of the thickness of 
the ventricular wall and the septum along with a coordinated increase in ventricular volume 
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(outward remodeling) (Figure 2). In concentric hypertrophy, sarcomeres are typically added in 
parallel more than in series thus resulting in a non-uniform increase of the thickness of the 
ventricular wall. The ventricular volume may be reduced (inward remodeling) or maintained 
depending on the underlying remodeling processes (Figure 2). Physiological cardiac 
hypertrophy is predominantly eccentric, however concentric hypertrophy may be also induced 
by strength training in a milder form (Pluim et al. 2000). On the contrary, pathological 
hypertrophy is commonly associated with concentric cardiac hypertrophy and a reduction in 
ventricular volume, for example due to prolonged hypertension or aortic stenosis. Pathological 
hypertrophy may also result in what looks like eccentric cardiac growth as a consequence of 
(recurrent) myocardial infarction or dilated cardiomyopathy. However, in these cases 
remodeling of the extracellular matrix has gone wrong (scar tissue formation) so that the 
connective tissue skeleton of the ventricles has become less tear-resistant. If there still exists 
a volume or pressure overload situation for the heart, the hypertrophied ventricles will 
eventually dilate (the extracellular matrix ruptures) and their volume permanently increased 
above the norm. Consequently, the definition of eccentric or concentric cardiac hypertrophy 
cannot be clearly attributed to physiological or pathophysiological hypertrophy as such. 
 
 
Figure 2. Types of cardiac hypertrophy. 
A hypertrophic stimulus results in the alteration of the heart’s 
shape. Symmetric remodeling, i.e. distribution of the muscle 
mass, and the accompanying increase in ventricular volume 
characterize adaptive, mostly physiological eccentric 
hypertrophy. On the contrary, concentric hypertrophy is 
characterized by asymmetric remodeling and the 
maintenance or decrease in ventricular volume. RV and LV 
indicates the right and the left ventricle, respectively. 
Adapted from reference (Heineke et al. 2006). 
 
Non-pathological cardiac hypertrophy is distinguished from pathological cardiac hypertrophy 
by several characteristics (reviewed in (Maillet et al. 2013)). One characteristic feature of 
physiological cardiac hypertrophy is the balanced growth of cardiomyocytes and capillaries 
(angiogenesis). In contrast, disruption of the coordinated increase in cardiac muscle mass and 
angiogenesis contributes to the transition of pathophysiological cardiac hypertrophy to heart 
failure due to the inadequate blood supply to the heart tissue (Shiojima et al. 2005). Moreover, 
one crucial characteristic of physiological cardiac hypertrophy due to pregnancy (Schannwell 
et al. 2002) or exercise (Ehsani et al. 1978, Maron et al. 1993, Pluim et al. 2000) is its complete 
reversibility. Non-pathological cardiac hypertrophy is not significantly associated with 
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remodeling of the extracellular matrix (reactive fibrosis) given that collagen I content is not 
altered in hearts of endurance trained rats (Burgess et al. 1996, Jin et al. 2000) and the 
absence of replacement fibrosis which would normally ensue due to cardiomyocyte apoptosis 
or necrosis (reviewed in (Krenning et al. 2010)). Thus, exessive remodeling of the extracellular 
matrix and/or replacement fibrosis is a pivotal element of maladaptive cardiac hypertrophy 
resulting in increased stiffness of the ventricular wall and diastolic dysfunction. The likewise 
reduced contractility, due to lost cardiomyocytes replaced by scar tissue, predisposes the 
affected individuals to systolic dysfunction and subsequent transition to heart failure. 
Currently, the available drug treatment aims at delaying maladaptive cardiac hypertrophy 
transition into heart failure rather than regressing the hypertrophy as such, because these 
drugs usually inhibit the signaling pathways of the cardiac stress stimuli. In this context, 
neurohumoral signaling for example, which is induced by long-term hypertension, is inhibited 
by drugs such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, 
and/or β-adrenergic receptor blockers (Bisping et al. 2014). Novel therapeutic strategies for 
the treatment of pathological hypertrophy and heart failure include activation of physiological 
hypertrophic signaling cascades (reviewed in (Bernardo et al. 2010)). However, knowledge 
regarding the divergent mechanisms in pathological as compared to physiological cardiac 
hypertrophy is still rather limited. Thus, further investigation will identify new potential target 
molecules and mechanisms for therapeutic intervention. 
 
1.2 Echocardiography – a non-invasive analysis of cardiac function and morphology 
Echocardiography is a non-invasive and reliable method for the analysis of cardiac function 
and morphology. Thus, it is a standard procedure for the diagnosis of heart disease in humans. 
Improvement of the echocardiography instrumentation regarding spatial and temporal 
resolution via high-frequency ultrasound enabled the application of this method also in small 
animals, such as the mouse for which a range of cardiovascular disease models mimicking the 
human condition has been established (reviewed in (Gao et al. 2011)). 
The echocardiographic analysis of the morphology of the heart enables calculation of left 
ventricular size. In humans, augmentation of left ventricular size is commonly used as an 
indicator of cardiac hypertrophy (Levy et al. 1987, Ghali et al. 1992) as well as a prognostic 
marker of heart failure (Lee et al. 1993, Wong et al. 1993). Moreover, the systolic function of 
the heart is analyzed by echocardiography. Currently, stroke volume and cardiac output are 
not commonly used as prognostic values of heart failure in humans. The former is defined as 
the ejected blood volume during systole while the latter is defined as the ejected blood volume 
per minute. Nevertheless, a recent study revealed the prognostic relevance of a decrease in 
stroke volume and cardiac output as predictors of a more severe outcome of heart failure (Agha 
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et al. 2009). In addition, the decrease in ejection fraction, defined as the ratio of stroke volume 
to end-diastolic volume of the ventricle, is commonly used as prognostic marker in patients 
with heart failure (Wong et al. 2004, Grayburn et al. 2005, Hobbs et al. 2007). Thus, patients 
presenting with an ejection fraction of below 0.35 or 35% are commonly considered to have 
established heart failure. 
Moreover, passive filling of the ventricle (E value) and active filling of the ventricle (A value) 
are commonly analyzed to evaluate the diastolic function of the heart. In humans, the E/A ratio 
as well as transmitral inflow patterns are further used as indicators of diastolic function 
(Galderisi 2005, Nagueh et al. 2009). Four different transmitral inflow patterns are associated 
with the progression of normal towards severe diastolic dysfunction in humans. These patterns 
include normal filling (E>A), impaired left ventricular relaxation (E<A), pseudonormal filling 
(E>A) and restrictive filling (E>>A) (Nagueh et al. 2009). Analyzing diastolic function in patients 
with heart failure is of particular interest given that heart failure can be demonstrated in patients 
with preserved systolic function (Vasan et al. 1999, Zile et al. 2001, Hogg et al. 2004). 
 
1.3 Murine models of cardiac hypertrophy 
Various genetic and experimental mouse models of pathological cardiac hypertrophy are used 
to analyze the underlying mechanisms and the effectiveness of pharmacologic interventions 
(reviewed in (Hasenfuss 1998, Gomes et al. 2013)). Most of the commonly utilized murine 
models of maladaptive cardiac hypertrophy mimic the chronic pressure overload commonly 
associated with hypertension. A typical model of pharmacologically induced hypertension is 
the deoxycorticosterone acetate (DOCA) salt-induced model. In this model, the rise in blood 
pressure is mainly brought about by an increased salt and water retention by the kidneys, 
which in turn causes an increase in the circulating blood volume and hence hypertension. In 
addition, neurohumoral compensatory mechanisms such as a disinhibition of the sympathetic 
nervous system play a role (reviewed in (Gomes et al. 2013)). One limitation of this pressure 
overload model is the rather moderate left ventricular hypertrophy while there is a heavy 
burden inflicted onto the kidneys, which may result in deleterious side effects. Another model 
is the transverse aortic constriction (TAC) model, a well-established surgical model in which 
the aortic arch is partially narrowed resulting in an increased resistance in the outflow tract of 
the left ventricle comparable to that of a partially stenosed aortic valve. As a result, the left 
ventricle has to generate significantly more pressure to eject a normal stroke volume, which in 
turn leads to left ventricular hypertrophy and eventually failure. A drawback of this model is its 
low reproducibility, given the variation in time and extent of the ensuing cardiac hypertrophy 
and failure that is dependent upon the level of aortic constriction achieved (reviewed in (Gomes 
et al. 2013). However, when controlled by high-resolution ultrasound imaging of, e.g. blood 
flow and lumen size in the aortic arch, reproducibility of this model can be much improved. 
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The use of catecholamines in model organisms, namely small rodents, revealed a pivotal role 
of neurohumoral signaling in cardiac hypertrophy and progression towards heart failure. In this 
context, the β-adrenoceptor agonist isoprenaline, which has been widely utilized in rats and 
mice, is of particular interest since it induces a pathological concentric cardiac hypertrophy 
when chronically administered, e.g. by osmotic mini-pumps, at a dose of 30 mg * kg-1 * d-1 for 
7 days (reviewed in (Osadchii 2007)). Application for 14 days in susceptible mice, for example, 
may lead to heart failure. The resulting pronounced cardiac hypertrophy in mice after 7 days 
treatment with isoprenaline is commonly analyzed by an increased heart weight to body weight 
(HW/BW) ratio (Saadane et al. 1999, Drews et al. 2010, Lukowski et al. 2010). When analyzed 
by echocardiography, one important parameter is the increased left ventricular posterior wall 
thickness in diastole (LVPWT;d) (Freund et al. 2005, Galindo et al. 2009, Li et al. 2013). 
However, continuous stimulation of β-adrenergic signaling for 7 days typically results in an 
increased systolic function (Drews et al. 2010, Lukowski et al. 2010, Shan et al. 2010) which, 
however, turns into systolic and diastolic dysfunction when continued, presumably due to 
β-adrenoceptor internalization and desensitization (reviewed in (Osadchii 2007)). This 
progression of cardiac hypertrophy towards heart failure likely is associated with changes in 
the extracellular matrix composition as well as myocardial replacement fibrosis due to 
apoptosis or necrosis of the cardiomyocytes (reviewed in (Osadchii 2007)).  
 
1.4 Molecular regulation of cardiac hypertrophy – focus on β-adrenergic signaling 
As mentioned before, pathological cardiac hypertrophy is induced, for instance, due to an 
increased work load for the heart. Hemodynamic overload induces multiple signaling pathways 
in cardiomyocytes such as mechanical stretch-induced signaling as well as that elicited by 
autocrine and paracrine humoral factors such as angiotensin II or transforming growth factor β 
(reviewed in (Heineke et al. 2006)). Moreover, disinhibition of the sympathetic nervous system 
and thus enhanced, namely β-adrenergic signaling serves as a key element in the 
development of cardiac hypertrophy and hear failure (Hunter et al. 1999, Ritter et al. 2003, 
Osadchii 2007). 
Adrenergic signaling is induced and regulated through activation of different subclasses of 
adrenoceptors, including the α1, α2 as well as the β1 and β2-adrenoceptors. The human heart 
predominantly contains β-adrenoceptors (reviewed in (Barki-Harrington et al. 2004)), namely 
β1-adrenoceptors (Rockman et al. 2002). In addition, the human heart contains β2 and 
β3-adrenoceptors, which are largely inactive under physiological conditions (reviewed in 
(Feldman et al. 2005)). In general, cardiac function is attenuated by the parasympathetic 
nervous system and its transmitter acetylcholine which is a direct (atria) or indirect (ventricles) 
antagonist of norepinephrine, the transmitter of the sympathetic nervous system (reviewed in 
(Triposkiadis et al. 2009)).  
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Beta-adrenergic signaling is G-protein coupled and regulates cardiac function via stimulatory 
(Gαs) and inhibitory (Gαi) G-protein signaling. The β1-adrenoceptors signal through Gαs, 
whereas β2-adrenoceptors activate Gαs as well as Gαi proteins albeit to a lesser degree 
(reviewed in (Lohse et al. 2003, Feldman et al. 2005)). Signaling through Gαi inhibits while 
signaling through Gαs stimulates adenylyl cyclase, resulting in formation of the second 
messenger cyclic adenosine monophosphate (cAMP) and subsequent activation of protein 
kinase A (PKA). PKA in turn modulates the activity of several target proteins, which are 
essential for cardiac function (reviewed in (Lohse et al. 2003)). Beta-adrenergic, i.e. 
predominantly β1-adrenergic signaling in the heart of both mice and men increases its 
contractility (positive inotropic effect), elevates heart rate (positive chronotropic effect), 
accelerates relaxation of the myocardium during diastole (lusitropic effect) as well as the rate 
of conduction through the atrioventricular node (positive dromotropic effect) (reviewed in 
(Triposkiadis et al. 2009)). Consequently, cardiac function is markedly enhanced through Gαs 
protein signaling. 
On the contrary, cardiac β3-adrenoceptors seem to be activated during acute β-adrenergic 
stimulation and are supposed to exert a negative ionotropic effect (Gauthier et al. 1998, Rozec 
et al. 2009). In vascular smooth muscle cells, activation of the predominant adrenoceptor 
subclass here, i.e. β2, results in dilation of the coronary arteries and increased coronary blood 
flow (Schutzer et al. 2003). The development of cardiac hypertrophy is thought to be 
associated with activation of Gβ signaling and activation of the extracellular regulated kinase 
pathway upon continuous β-adrenergic stimulation, resulting in the hypertrophic growth of the 
cardiomyocytes (Lorenz et al. 2009a, Lorenz et al. 2009b, Vidal et al. 2012). 
The progression of cardiac hypertrophy towards heart failure (reviewed in (Barki-Harrington et 
al. 2004)) is commonly associated with desensitization of β-adrenoceptors, predominantly 
β1-adrenoceptors. The β-adrenergic receptors are desensitized by phosphorylation or binding 
of β-arrestin impairing Gαs signaling (reviewed in (Ferguson 2001)). A further mechanism is 
up-regulation of Gαi signaling and internalization of the β-adrenergic receptors (reviewed in 
(Ferguson 2001)). Consequently, β-adrenergic signaling is decreased resulting in a decreased 
contractility and relaxation of the heart (systolic and diastolic dysfunction). 
 
1.5 Cardiac function and the UPS – ubiquitin-proteasome system 
Cardiac function is predominantly based on the integrity and functionality of the 
cardiomyocytes. Thus, preservation of cardiomyocytes is essential given the low rate of 
proliferation of these end-differentiated cells in adult mammalians. In adult mice and humans, 
the rate of cardiomyocyte turnover is approximately 1% or less per year (Bergmann et al. 2009, 
Mollova et al. 2013, Senyo et al. 2013). In this context, maintenance of protein homeostasis in 
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cardiomyocytes is crucial due to its pivotal role in the preservation of cellular integrity and 
viability. Predominantly, the ubiquitin-proteasome system (UPS) and autophagy systems 
account for the maintenance of protein homeostasis in the heart (reviewed in (Wang et al. 
2015)). 
However, it seems that the UPS mainly preserves cardiomyocyte structure and function 
through the targeted degradation of structural, functional as well as signaling proteins 
accounting for the control of vital signaling pathways (reviewed in (Drews et al. 2014)). The 
UPS consists of the ubiquitination machinery that encompasses four different enzyme classes 
(E1-E4), the proteasome complexes that degrade the polyubiquitin-tagged substrate proteins 
as well as the deubiquitination machinery comprising various deubiquitinating enzymes 
(DUBs) (Drews et al. 2014). The initial step of substrate poly-ubiquitination is the adenosine 
triphosphate (ATP) dependent activation of ubiquitin by the ubiquitin-activating enzymes 
(E1 class) (Haas et al. 1982). Subsequently, the activated ubiquitin is further transferred to the 
ubiquitin-conjugating enzymes (E2 class) (Pickart et al. 1985). Finally, the ubiquitin is ligated 
to the target protein via ubiquitin ligases (E3 class), which bind the E2 enzymes and their cargo 
(substrate proteins) and transfer the ubiquitin moiety onto the substrate proteins thus marking 
them for proteasomal degradation (Ciechanover et al. 1989, Reiss et al. 1989). In order to 
achieve this, target proteins normally have to be polyubiquitinated via the repetitive transfer of 
ubiquitin molecules to the already attached ubiquitin, and this ubiquitin chain elongation is also 
catalyzed by a concerted interaction of all three enzyme classes. Alternatively, an ubiquitin 
chain is transferred to the initially attached ubiquitin via E4 enzymes (Koegl et al. 1999). 
Currently, two different E1, approximately 30 E2 and more than 600 E3 class enzymes, 
conferring substrate specificity, are known in the human genome (Drews et al. 2014). 
 
1.6 The proteasome – a proteolytic multiprotein complex 
Proteasome complexes are a heterogeneous group of proteolytic multiprotein complexes with 
various functions (Gomes et al. 2006, Drews et al. 2007, Gomes et al. 2009). Notably, they are 
simultaneously present even under normal conditions. The core structure of the proteasome 
complexe is the 20S core complex further referred to as 20S proteasome. The 20S proteasome 
is composed of four heteroheptameric rings, two outer α-rings and two inner β-rings, forming 
a cylindrical particle (Murata et al. 2009). The proteolytic activities are assigned to the subunits 
β1, β2 and β5 and their corresponding inducible subunits β1i, β2i and β5i (Figure 3) (Bochtler 
et al. 1999, Voges et al. 1999). The proteolytic subunits cleave peptide bonds preferably after 
acidic (β1), alkaline (β2 and β2i), or hydrophobic residues (β5, β5i and β1i) and hence their 
activity is referred to as caspase-like (or peptidylglutamyl-peptide hydrolyzing activity), 
trypsin-like or chymotrypsin-like activity, respectively (Figure 3) (Bochtler et al. 1999, Voges et 
al. 1999, Groettrup et al. 2001). 
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Figure 3. Proteasome activity of 
proteolytic β-subunits. 
The β-ring of the 20S core complex is 
formed by 7 distinct β-subunits. The 
proteolytic activity is confined to the 
subunits β1, β2 and β5 and their 
corresponding inducible subunits β1i, 
β2i and β5i. The proteolytic activity is 
referred to as caspase-like, trypsin-
like or chymotrypsin-like activity. 
 
The assembly of the 20S proteasome is a complex process, requiring specific assembly factors 
(reviewed in (Murata et al. 2009)). First the α-ring is formed of seven distinct α-subunits 
(Figure 4) (Hirano et al. 2005, Hirano et al. 2006, Le Tallec et al. 2007). Subsequently, the 
α-ring serves as scaffold for the assembly of the β-ring starting with association of the 
subunit β2 (Figure 4) (Hirano et al. 2008). Then, the remaining six β-subunits are sequentially 
incorporated (Figure 4) (Hirano et al. 2008). Notably, proteolytic subunits and non-proteolytic 
subunits β6 and β7 are synthesized and attached to the α-ring with N-terminal propeptides 
(Figure 4). These propeptides are crucial for dimerization of the two half-proteasomes to form 
the 20S core complex (Figure 4) (Chen et al. 1996, Nandi et al. 1997). Moreover, removal of 
the propeptides at the final step of the assembly via autolysis is essential to expose the 
catalytic threonine residues of the proteolytic β-subunits and hence enable the proteolytic 
activity of the proteasome (Figure 4) (Chen et al. 1996, Schmidtke et al. 1996). Thus, 
undesirable proteolytic activity of synthesized β-subunits is blocked by the propeptides until 
they are incorporated into proteasome complexes. Consequently, proteasome subpopulations, 
containing constitutive or inducible proteolytic β-subunits or even a mixture of both, can only 
be generated through assembly, while subsequent exchange of proteolytic β-subunits within 
the mature 20S proteasome complex is impossible. 
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Figure 4. Model of proteasome assembly. 
Assembly of the 20S core complex is initiated by formation of the α-ring. Subsequently, β-subunits 
are sequentially attached to the α-ring starting with the β2 subunit. The propeptides of the proteolytic 
β-subunits and the subunits β6 and β7 are cleaved via autolysis during maturation of the 20S core 
complex following association of the two half-proteasomes. The 20S core complex may associate 
with the 19S regulatory complex forming the 26S proteasome complex. The base (green) and the lid 
(purple) of the 19S regulatory complex are independently assembled. Subsequently these two 
subcomplexes and the subunit Rpn10 (yellow) are joined. 
Adapted from reference (Murata et al. 2009). 
 
Access to the proteolytic sites of the 20S proteasome is limited due to the conformation of the 
α-rings forming a pore (Groll et al. 2000). However, oxidized proteins, exposing hydrophobic 
patches on their surface, seem to be able to enter the 20S proteasome (reviewed in (Grune et 
al. 2003)). Thus, the 20S proteasome is supposed to be involved in the proteolytic degradation 
of oxidized proteins, which have not been ubiquitinated before (Shringarpure et al. 2001, 
Shringarpure et al. 2003). The entrance of proteins without exposed hydrophobic sites into the 
20S core complex is gated through regulatory complexes, that associate with the 20S core 
complex (Adams et al. 1998). A common regulatory complex is the 19S particle consisting of 
two subcomplexes, designated as base and lid, as well as the regulatory particle 
non-ATPase 10 (Rpn10) (Figure 4). Assembly of the 19S regulatory particle is supposed to be 
associated with the 20S core complex, which potentially acts as an assembly factor (Figure 4) 
(Kusmierczyk et al. 2008). Notably, the proteasome complex consisting of the 20S core 
complex and the associated 19S regulatory complex is referred to as 26S proteasome 
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(Figure 4). The associated 19S regulatory complex enables enhanced substrate access to the 
20S core complex via opening of the α-ring channel (Liu et al. 2006, Smith et al. 2007) and 
substrate unfolding (reviewed in (Bar-Nun et al. 2012)) in an ATP-dependent manner. The 19S 
regulatory particle further contains recognition sites for polyubiquitinated proteins (Deveraux 
et al. 1994, Husnjak et al. 2008). Thus, the 26S proteasome recognizes and degrades 
ubiquitin-tagged target proteins, which are subjected to degradation via the UPS. 
Consequently, the 26S proteasome is implicated in all cellular processes that are regulated 
through the UPS. Proteasomal degradation is further regulated via the association of other 
regulatory complexes, such as the 11S particle (Whitby et al. 2000) and PA200 particle (Ortega 
et al. 2005), which increase proteasomal activity, as well as the proteasome inhibitor 31 (PI31) 
(Zaiss et al. 1999) and the proline/arginine-rich 39-amino-acid peptide (PR39) (Gaczynska et 
al. 2003), which have inhibitory effects. In addition, the proteasomal activity is regulated by 
posttranslational modifications such as phosphorylation of the 20S core complexes (Scruggs 
et al. 2012). 
 
1.7 The UPS and cardiovascular disease 
Over the past decade a crucial role of the UPS in cardiovascular physiology and 
pathophysiology has been elucidated (Powell et al. 2012, Pagan et al. 2013, Drews et al. 
2014). As mentioned before, targeted degradation of structural, functional, as well as signaling 
proteins and thus the control of vital signaling pathways is supposed to be responsible for the 
pivotal role of the UPS in maintaining cardiomyocyte structure and function. 
In experimental mouse models of cardiac hypertrophy, 26S proteasome activity is commonly 
increased in hypertrophied hearts (Depre et al. 2006, Hedhli et al. 2008, Drews et al. 2010). 
Notably, proteasome inhibition results in a reduction of cardiac hypertrophy upon exposure to 
a pro-hypertrophic stimulus (Depre et al. 2006, Hedhli et al. 2008, Stansfield et al. 2008). 
However, the duration of proteasome inhibition as well as the submaximal inhibition of 
increased proteasome activities upon pro-hypertrophic stimulation is thought to be crucial for 
the positive effect of proteasome inhibition in relation to the development of cardiac 
hypertrophy (reviewed in (Drews et al. 2014)). Consequently, interfering with proteasomal 
regulation through utilization of proteasome inhibitors potentially reduces or prevents early 
cardiac remodeling upon exposure to a pro-hypertrophic stimulus. Notably, regulation of the 
proteasomal activity in heart failure is different from that in early cardiac hypertrophy, given the 
association of heart failure in humans with a markedly reduced proteasome function (Drews et 
al. 2014). Thus, a systematic and detailed analysis of proteasomal regulation is critical for 
targeted interventions in cardiac disease (reviewed in (Drews et al. 2014)). However, 
systematic studies concerning the mechanisms of proteasome regulation and their role in 
maladaptive cardiac remodeling are currently limited. 
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Previous research elucidated that at least three mechanisms contribute to proteasome 
regulation during the development of cardiac hypertrophy induced by β-adrenergic 
overstimulation (Drews et al. 2010). In hypertrophic hearts, incorporation of inducible 
β-subunits is increased, 20S core sensitivity to PKA activation is enhanced and the assembly 
of the 26S proteasome is up-regulated (Drews et al. 2010). Inducible β-subunits are 
incorporated into cardiac proteasomes without previous stimulation (Drews et al. 2007). 
However, this increased incorporation is commonly associated with stress responses (Angeles 
et al. 2012). In the context of the development of cardiac hypertrophy, such an enhanced 
incorporation of inducible β-subunits into active cardiac proteasome complexes might be 
adaptive or maladaptive. Ongoing studies in our group revealed an augmentation of cardiac 
hypertrophy in β1i-deficient mice upon continuous β-adrenergic stimulation. 
 
1.8 Proteasome regulation in the heart in the context of aging 
As mentioned before, the prevalence of cardiac hypertrophy dramatically increases with age. 
Moreover, analyses of cardiac function reveal alterations in relation to aging as a consequence 
of structural and functional changes of the cardiomyocytes (reviewed in (Lakatta 2003)). These 
changes in the cardiomyocytes may be associated with alterations of the cardiomyocyte 
proteome with increasing age. Previously, differential abundancies of proteins involved in cell 
signaling, metabolism and immune response as well as structural proteins and proteins 
mediating responses to oxidative stress have been demonstrated in the murine and rat heart 
in young as compared to old animals (Dai et al. 2008, Richardson et al. 2008, Grant et al. 
2009). As the UPS potentially plays a pivotal role in maintaining cardiomyocyte structure and 
function as well as protein homeostasis, its impairment during aging may give rise to the 
accumulation and aggregation of damaged proteins that have been shown to be cytotoxic 
(reviewed in (Kevei et al. 2014)). On the other hand, targeted degradation of crucial regulators 
of aging-related pathways, such as insulin or insulin-like growth factor 1 (IGF-1) signaling, 
through an altered function and/or activity of the UPS may further account for the aging process 
(reviewed in (Kenyon 2010)). Although an essential role of the UPS with regard to aging seems 
self-explanatory, the number of studies on the functional or dysfunctional regulation of 
proteasome function, namely in the heart, in the context of aging are rather limited. 
 
 
 
 
 
 Introduction 
 16 
1.9 Research objectives 
Global β1i knockout mice show an impaired cardiac function upon exposure to a 
pro-hypertrophic stimulus (β-adrenergic overstimulation) as compared to wild type (WT) mice. 
However, the question remains whether it is the absence of β1i incorporation into cardiac 
proteasome complexes in particular or its deficiency per se, which augments cardiac 
hypertrophy in β1i knockout mice upon treatment with isoprenaline. Thus, cardiac-specific 
reintroduction of β1i in β1i-deficient mice may elucidate the essential role of β1i incorporation 
into cardiac proteasome complexes upon exposure to a pro-hypertrophic stimulus. 
Non-viral vector systems are rather inefficient for gene transfer in vivo due to the generally low 
transfection efficiency, lack of cell specificity requiring topical administration routes and 
potential cytotoxicity (reviewed in (Müller et al. 2007)). Moreover, commonly used viral vector 
systems such as retroviruses or adenoviruses lack the necessary tropism for the heart (Lyon 
et al. 2008). Currently, serotype 9 of the adeno-associated virus (AAV) is commonly used for 
the heart-specific reintroduction of transgenes, given that the serotype 9 has the highest 
tropism for the heart (Prasad et al. 2011). In addition, cardiac-specific transgene expression is 
further improved by using a genetically engineered promoter consisting of a fragment of the 
cardiomyocyte-specific myosin light chain promoter (MLC0.26) in combination with parts of the 
viral cytomegalovirus (CMV) immediate-early promoter (Kaya et al. 2011, Pleger et al. 2011, 
Schinkel et al. 2012). The latter acts as an enhancer to ensure constitutive expression in adult 
mice. 
With the aforesaid in mind, three specific aims were pursued in the present work: 
1) To determine through AAV9-based heart-specific reintroduction of the proteasome 
subunit β1i (rescue approach) whether the exaggerated cardiac hypertrophy in 
β1i-deficient mice upon β-adrenergic overstimulation can be abolished or prevented. 
2) To investigate whether the expression and/or organization of sarcomeric proteins in the 
heart of β1i-deficient mice receiving AAV9 harboring β1i is different from that of 
β1i-deficient mice expressing an unrelated transgene following continuous treatment 
with isoprenaline. 
3) To analyze in detail proteasome regulation in the heart of old versus young mice to 
confirm the presumed impairment of proteasome function and to discern on which level 
– proteasome composition, assembly and/or activity – this impairment takes place. 
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2 Materials 
2.1 Chemicals 
Chemicals used in general were obtained from Roth (Karlsruhe), Sigma-Aldirch (Steinheim), 
Roche (Mannheim), Merck (Darmstadt). 
 
2.2 Consumable supplies 
Consumable supplies used in cell culture or for molecular biological analysis were obtained 
from Sarstedt (Nürnbrecht), Eppendorf (Hamburg), TPP (Trasadingen, CH), Greiner 
(Frickenhausen), BD Biosciences (Heidelberg), Nunc (Thermo Scientific) (Dreieich). 
 
2.3 Cell culture 
Devices Distributor Model 
Centrifuge Hettich, Tuttlingen Universal 320 R 
Cell strainer (100µM nylon filter, 
sterile) 
BD Biosciences (Corning), 
Heidelberg 
352360 
Coverslips Marienfeld GmbH, Lauda-
Königshofen 
01 115 00 
Forceps, scissors, tweezers b.i.t. Chirurgiemechanik, 
Bammental 
 
Incubator Thermo Scientific, Dreieich Hera Cell 150 
Laminar flow cabinet Kojair Tech Oy, AD Vught, NL Biowizard 
Microscope Olympus, Hamburg CKX41 
Microscope slides Thermo Scientific, Dreieich J1800AMNZ 
Steritop GP sterilization bottle top 
vacuum filter (150 ml, 22µm) 
Millipore, Schwalbach SCGPS01RE 
Water bath Memmert, Schwabach WNB 7-45 
 
2.3.1 Human embryonic kidney cells (HEK-293) 
Materials Distributor Catalogue number 
DMEM (low glucose, GlutaMAX 
supplement, pyruvate) 
GIBCO (Life Technologies), 
Darmstadt 
21885-025 
Fetal bovine serum (FBS) GIBCO (Life Technologies), 
Darmstadt 
105000064 
Fungizon GIBCO (Life Technologies), 
Darmstadt 
15290026 
Hanks balanced salt solution 
(HBSS) (- calcium, - magnesium) 
GIBCO (Life Technologies), 
Darmstadt 
14175095 
Penicillin/streptomycin GIBCO (Life Technologies), 
Darmstadt 
15070063 
Trypsin/ethylenediaminetetraacetic 
acid (EDTA) 
GIBCO (Life Technologies), 
Darmstadt 
25300054 
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2.3.2 Neonatal rat cardiomyocytes (NRCMs) 
Materials Distributor Catalogue number 
Collagenase type2 Worthington (Cell Systems 
Biotechnologie Vertrieb), 
Troisdorf 
LS004176 
Collagen solution (Collagen A) Biochrom (Millipore), Berlin L7220 
Disodium hydrogenphosphate 
x H2O 
Grüssing, Filsum 12295 
D(+)-glucose Merck, Darmstadt 1.083.371.000 
DMEM medium (high glucose 
4.5g/l, 11g/l sodium pyruvate, no 
glutamine) 
GIBCO (Life Technologies), 
Darmstadt 
21969-035 
Fetal calf serum (FCS) Gold PAA-Laboratories (GE 
Healthcare), Cölbe 
A15-151 
HEPES (> 99.5%) Roth, Karlsruhe 9105.2 
L-glutamine (200 mM) GIBCO (Life Technologies), 
Darmstadt 
25030-024 
Magnesium sulfate heptahydrate  Merck, Darmstadt 1.058.861.000 
New born calf serum (NBCS) GIBCO (Life Technologies) 
Darmstadt 
26010-074 
Pancreatin Sigma-Aldrich, Steinheim P3292 
Penicillin/streptomycin GIBCO (Life Technologies), 
Darmstadt 
15140-122 
Percoll GE Healthcare, Freiburg 17-0891-01 
Potassium chloride Applichem, Darmstadt A3582.1000 
Sodium chloride  Sigma-Aldrich, Steinheim 31424 
Trypan blue solution (0.4%) Sigma-Aldrich, Steinheim T8154 
 
2.4 In vivo studies – OP and echocardiography 
Devices Distributor Model 
Anaesthesia device Groppler, Deggendorf UniVet Prota 
Animal trimmer Braun,Kronberg GT 420 
Echocardiography Visualsonics, Amsterdam, NL Vevo 2100 imaging 
system 
(transducer: 
MS-550D) 
Hot plate Labotect, Rosdorf Hot Plate 062 
Mirco-osmotic pumps Alzet, Cupertino, CA model 1002 
Oxygenizer Respironics (GE Healthcare), 
Freiburg 
EverFlo 
Moscito hemostat, forceps, 
scissors, tweezers 
b.i.t. Chirurgiemechanik, 
Bammental 
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Materials Distributor Catalogue number 
Analgesic (carbostesin luerfit 
ampoule 0.25% / 5 ml) 
AstraZeneca, Wedel PZN: 1177870 
Eye creme (Bepanten) Bayer, Leverkusen PZN: 2182442 
Foliodrape OP-tape Hartmann, Heidenheim 250 5 2418 
Hair removal creme (Snä-Epil 
Sensitive) 
Axisis, Düsseldorf PZN: 2186115 
Isoflurane Baxter, Unterschleißheim HDG9623 
Isoprenaline hydrochloride Sigma-Aldrich, Steinheim I5627-25g 
(Lot #BcBk9694V) 
Iodine ointment (10%) 
(Braunovidon) 
B. Braun, Melsungen PZN: 03188955 
NEG 50 Richard-Allan Scientific 
(Thermo Scientific), Dreieich 
6502 
Sodium metabisulfite Sigma-Aldrich, Steinheim S-1516 
Surgical sutures Ethicon (Johnson & Johnson 
Medical), Norderstedt 
EH 7800 H 
Transpore surgical tape 3M, Neuss S6 1527-1 
 
2.5 Molecular biological methods 
Kits Distributor Catalogue number 
EndoFree plasmid megaprep kit Qiagen, Hilden 12381 
PeqGOLD total RNA kit Peqlab, Erlangen 12-6634-02 
QIAquick gel extraction kit Qiagen, Hilden 28706 
QIAprep spin miniprep kit Qiagen, Hilden 27104 
RNeasy mini kit Qiagen, Hilden 74104 
Transcriptor high fidelity cDNA 
synthesis kit 
Roche, Mannheim 05081955001 
 
Devices Distributor Model 
Agarose gel chamber  
(length 11 cm) 
Peqlab, Erlangen 40-0911 
Centrifuge  
(small volumes: up to 2 ml) 
Thermo Scientific, Dreieich Heraeus Pico 21 
Centrifuge (small volumes: up to 
2 ml; refrigerated) 
Hettich, Tuttlingen Micro 22 R 
Centrifuge (large volumes: 2-50 ml) Hermle, Gosheim Z 323 K 
Gel documentation (RNA, DNA) BioRad, München Gel Doc XR 
Incubator (bacteria) New Brunswick Scientific 
(Eppendorf), Hamburg 
Innova 4230 
pH meter WTW, Weilheim inoLab 
Thermocycler Eppendorf, Hamburg Mastercycler 
Personal 
Scales Sartorius, Göttingen BP 121 S 
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Scales Kern, Balingen EW 820 
Spectrophotometer Thermo Scientific, Dreieich Nanodrop ND-1000 
 
Materials Distributor Catalogue number 
AAV CMV/MLC0.26 EGFP vector provided by Dr. O. Müller  
AAV CMV/MLC0.26 Renilla 
luciferase vector 
provided by Dr. O. Müller  
Agarose Sigma-Aldrich, Steinheim A9539 
Ampicillin Sigma-Aldrich, Steinheim A9518 
100 bp DNA Ladder New England BioLabs, 
Frankfurt/Main 
N3231S 
E. coli DH1 ATTC, Wesel 33849 
E. coli Sure cells Agilent Technologies 
(Stratagene), Santa Clara, 
USA 
200238 
Ethidium bromide (1%=10 mg/ml)) Roth, Karlsruhe 2218 
FastAP thermosensitive alkaline 
phosphatase 
Thermo Scientific, Dreieich #EF0651 
GeneRuler 1 kb DNA Ladder Thermo Scientific, Dreieich # SM0311 
LB medium Roth, Karlsruhe X964.2 
LB agar Roth, Karlsruhe X965.2 
M-MLV reverse transcriptase Promega, Mannheim M170B 
pBlueScript II SK(+)  Agilent Technologies 
(Stratagene), Santa Clara, 
USA 
#212205 
Phusion high fidelity polymerase New England BioLabs, 
Frankfurt/Main 
M0531S 
Proteinase K (20 mg/ml) Thermo Scientific, Dreieich EO-0491 
pSP72 Promega, Mannheim P2191 
Restriction enzymes 
AgeI 
BamHI 
BsrGI 
HindIII 
SmaI 
New England BioLabs, 
Frankfurt/Main 
 
R0552S 
R0104S 
R0575S 
R0136S 
R0141S 
T4 polynucleotide kinase Thermo Scientific, Dreieich #EK0031 
T4 DNA ligase New England BioLabs, 
Frankfurt/Main 
M0202S 
 
2.6 Protein biochemical methods 
Kits Distributor Catalogue number 
Renilla-Glo luciferase assay 
system 
Promega, Mannheim E2710 
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Devices Distributor Model 
Fluorescence reader Thermo Scientific, Dreieich Fluoroskan Ascent 
Luminescence reader Berthold, Bad Wildbad MicroLumat  
LB 96 P 
Microplate spectrophotometer BioTek; Bad Friedrichshall Powerwave Xs 
Molecular imager Bio-Rad; München Pharos FXTM Plus 
Isoelectric focusing 2D GE Pharmacia Biotech (GE 
Healthcare), Freiburg 
IPGphor 
Power supply (Western blot) Bio-Rad; München PowerPac basic 
Power supply (2D GE) Consort, Turnhout, BE E833 
Semidry blotting Bio-Rad; München TransBlot turbo 
transfer system 
Hand-held homogenizer for 1.5 ml 
tubes 
Sigma-Aldrich, Steinheim Z359947 
Tenbroeck hand-held homogenizer VWR, Bruchsal 432-1276 
Ultracentrifuge Beckmann Coulter, Krefeld TL-100 
ultracentrifuge 
Western blot documentation system GE Healthcare, Freiburg QuantLAS 4000 
mini 
Westen blot gel chamber Bio-Rad; München Mini Protean 
2D GE chamber GE Healthcare, Freiburg Ettan Daltsix 
 
Materials Distributor Catalogue number 
7-Amino-4-methylcoumarin (AMC) Sigma-Aldrich, Steinheim 257370 
Bradford assay solution BioRad, München 500-0006 
ECL prime (Western blot detection 
reagent) 
GE Healthcare, Freiburg RPN2232 
IPG strips GE Healthcare, Freiburg 17-6002-45 
Microfluor black plate, flat bottom Fisher Scientific, Schwerte 1058-8885 
Milk powder Roth, Karlsruhe T145.2 
Ponceau S solution Sigma-Aldrich, Steinheim P7170 
Phosphatase inhibitor cocktail II Sigma-Aldrich, Steinheim P5726 
Phosphatase inhibitor cocktail III Sigma-Aldrich, Steinheim P0044 
Protease inhibitor cocktail Roche, Mannheim 04 693 132 001 
Precision plus protein dual color 
standard 
BioRad, München 161-0374 
Ruthenium(II)-tris 
(bathophenanthroline-disulphonate) 
(RuBP) [Fluo-R] 
Serva Electrophoresis, 
Heidelberg 
35091.01 
Sea sand Grüssing, Filsum 13137 
Transfer membrane (nitrocellulose) VWR(BioTrace), Bruchsal 732-3031 
Ultracentrifuge tubes Beranek, Weinheim 343778 
Unstained protein marker  
(2-212 kDa) 
New England BioLabs, 
Frankfurt/Main 
P7702S 
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2.7 Immunochemical methods 
Devices Distributor Model 
Fluorescence 
microscope 
(Xcellence RT 
software) 
Olympus, 
Hamburg 
IX 81 
filters (FITC/TRITC/DAPI)  
FITC λex 460-480nm, λem 495-540nm, 484 beamfilter 
TRITC λex  535-550nm, λem 610-675nm, 565 LP beamfilter  
DAPI λex 360-370 nm, λem 420-485nm, 400 beamfilter  
Microscope Olympus, 
Hamburg 
CX31 
Microtome 
cryostat 
Thermo 
Scientific, 
Dreieich 
HM 500 O 
 
Materials Distributor Catalogue number 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim A2153 
Casein Sigma-Aldrich, Steinheim C5890 
1,4-Diazabicyclo[2.2.2]octane 
solution (DABCO) 
Sigma-Aldrich, Steinheim 290734 
4′,6-Diamidin-2-phenylindol (DAPI) Life Technologies, Darmstadt D1306 
Eukitt O. Kindler (Sigma-Aldrich), 
Steinheim 
03989 
Mayer’s hematoxylin solution Roth, Karlsruhe T865.2 
Mowiol 4-88 Calbiochem (Millipore), 
Schwalbach 
475904 
 
2.8 Buffers and solutions 
Buffer/solution Ingredients 
PBS (pH 7.4) 140 mM sodium chloride 
2.7 mM potassium chloride 
8 mM disodium hydrogenphosphate 
1.5 mM potassium dihydrogenphosphate 
TBE (pH 7.5) 90 mM TRIS 
73 mM boric acid 
3 mM EDTA 
TBS (pH 7.4) 20 mM TRIS 
0.9% (w/v) sodium chloride 
TBST 0.1% (w/v) Tween-20 
in TBS buffer 
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2.8.1 HEK-293 cells 
Buffer/solution Ingredients 
DMEM medium (HEK-293) 10% FBS 
1% penicillin/streptomycin 
1% fungizon 
 
2.8.2 NRCMs 
Buffer/solution Ingredients 
10x ADS (pH 7.4) 
(sterile) 
1163.6 mM sodium chloride 
197.2 mM HEPES 
94.2 mM disodium hydrogenphosphate x H2O 
55.5 mM glucose 
53.6 mM potassium chloride 
8.3 mM magnesium sulfate heptahydrate 
Digestion solution (NRCMs) 
(sterile) 
0.6 mg/ml pancreatin 
0.5 mg/ml collagenase type 2 
in ADS buffer 
DMEM medium including FCS 
(NRCMs) 
10% FCS Gold 
1% penicillin/streptomycin 
2 mM L-glutamine 
DMEM medium without FCS 
(NRCMs) 
1% penicillin/streptomycin 
2 mM L-glutamine 
Percoll gradient 7 ml bottom-layer 
3 ml top-layer 
Percoll stock solution 90% (v/v) Percoll 
in 10x ADS buffer 
Bottom-layer Percoll gradient 65% (v/v) Percoll stock solution 
35% (v/v) 1x ADS buffer 
Top-layer Percoll gradient 45% (v/v) Percoll stock solution 
55% (v/v) 1x ADS buffer with phenol red 
 
2.8.3 Molecular biological methods 
Extraction of genomic DNA from mice tail biopsies 
Buffer/solution Ingredients 
Tail biopsy digestion buffer  
(pH 8.8) 
 
67 mM TRIS 
16.6 mM ammonium sulfate 
6.5 mM magnesium chloride 
1% (v/v) 2-mercaptoethanol 
0.5% (w/v) TritonX-100 
1 µg/µl proteinase K 
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Agarose gel electrophoresis 
Buffer/solution Ingredients 
Agarose gel 1% (w/v) agarose 
0.3 pg/ml ethidium bromide 
in TBE buffer 
5x RNA/DNA loading buffer 75% (w/v) glycerine 
180 mM TRIS 
146 mM boric acid 
6 mM EDTA 
0.01% (w/v) xylene cyanol 
0.01% (w/v) bromphenol blue 
 
Preparation of plasmid DNA by alkaline lysis 
Buffer/solution Ingredients 
Alkaline lysis solution I (pH 8.0) 
 
50 mM glucose 
25 mM TRIS 
10 mM EDTA 
Alkaline lysis solution II 0.2 M sodium hydroxide 
1% (w/v) SDS 
Alkaline lysis solution III 5 M potassium acetate 
4.3% (v/v) acetic acid 
TE 10 mM TRIS 
1 mM EDTA 
 
2.8.4 Protein biochemical methods 
Proteasome activity assay and active site labeling 
Buffer/solution Ingredients 
Homogenization buffer  
(pH 7.5) 
 
20 mM HEPES (500 mM stock solution) 
150 mM sodium chloride (5 M stock solution) 
1 mM magnesium chloride (100 mM stock solution) 
0.5 mM EDTA (50 mM stock solution) 
10x Caspase- and trypsin-like 
activity buffer (pH 7.5) 
250 mM HEPES 
5 mM EDTA 
0.5% (w/v) NP-40 
0.01% (w/v) SDS 
10x Chymotrypsin-like activity 
buffer (pH 7.5) 
250 mM HEPES  
5 mM EDTA 
0.3% (w/v) SDS 
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Western blot analysis and total protein staining 
Buffer/solution Ingredients 
Acrylamide gel 
Stacking gel  
(6% acrylamide) 
 
 
 
 
 
1.25 ml stacking gel buffer 
0.75 ml 40% (w/v) acrylamide (37.5:1) 
0.32 g glycerin 
2.75 ml water 
100 µl 10% (w/v) ammonium persulfate 
100 µl N, N, N', N'-tetramethylethylenediamine 
Resolving gel 
(13% acrylamide) 
2.5 ml resolving gel buffer 
3.25 ml 40% (w/v) acrylamide (37.5:1) 
0.63 g glycerin 
3.78 ml water 
50 µl 10% (w/v) ammonium persulfate 
50 µl N, N, N', N'-tetramethylethylenediamine 
Fixation solution 40% (w/v) ethanol 
10% (w/v) acetic acid 
5x Protein loading buffer  
(pH 6.8) 
310 mM TRIS 
50% (v/v) glycerin 
170 mM SDS 
5% (v/v) 2-mercaptoethanol 
Resolving gel buffer (pH 8.8) 1.5 M TRIS 
0.4% (w/v) SDS 
10x Running buffer 240 mM TRIS 
2 M glycin 
1% (w/v) SDS 
Ruthenium staining solution 1 µM RuBP 
Semi-dry transfer buffer 48 mM TRIS 
39 mM glycin 
0.02% (w/v) SDS 
20% (v/v) methanol 
Stacking gel buffer (pH 6.8) 
 
0.5 M TRIS 
0.4% (w/v) SDS 
 
2.8.5 Immunochemical methods 
Buffer/solution Ingredients 
Aniline blue solution 2.5% (w/v) aniline blue 
2% (v/v) acetic acid 
Biebrich Scarlet acid fuchsin 
solution 
90 ml 1% Biebrich scarlet solution 
10 ml 1% acid fuchsin solution 
1 ml 37% acetic acid 
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Isofix (pH 7.3) 
 
0.3% (w/v) paraformaldehyde 
1% (w/v) glutaraldehyde 
0.07 M cacodylate 
Phosphotungstic-
phosphomolybic acid solution 
25 ml 5% phosphotungstic acid solution 
25 ml 5% phosphomolybic acid solution 
Weigert’s hematoxylin solution 0.5% (w/v) hematoxylin 
50% (v/v) ethnol 
0.6% (v/v) iron trichloride 
0.2% (v/v) hydrochloride acid 
Mowiol (pH 8.5) 10% (w/v) mowiol 4-88 
25% (v/v) glycerine 
0.1 M TRIS  
2.5% (v/v) DABCO 
 
2.9 Primer 
Primer Sequence Reference 
AAV ITR forward 5’ GCG ACT CTA GAT CAT AAT CAG CC 3’  
AAV ITR reverse 5’ GGC TAT GAA CTA ATG ACC CCG 3’  
AAV sequencing forward 5’ AGG CTA GCC TCG ACG GTA CC  3’  
AAV sequencing reverse 5’ GGC TGA TTA TGA TCT AGA GTC GC 3’  
β1i_2 forward 5’ CCCGTGTCCCTCCGAGATAC 3’ (Van Kaer et al. 1994) 
β1i_4 reverse 5’ GGGATCCAGGACCAGGAAAG 3’ (Van Kaer et al. 1994) 
β1i_3 forward 5’ AGGGTGTCAGCTCCCCTGGA 3’ (Van Kaer et al. 1994) 
neo_A reverse 5’ CTTGGGTGGAGAGGCTATTC 3’ (Van Kaer et al. 1994) 
β1i direct forward 5’ ATG CTG CGG GCA GGA GCA C  3’  
β1i direct reverse 5’ TCA CTC ATC GTA GAA TTT TGG CAG C 
3’ 
 
β1i overhang forward 5’ TT ACC GGT GCC ACC ATG CTG CGG 
GCA GGA GCA C  3’ 
 
β1i overhang reverse 5’  GGG CCC  TGT ACA TCA CTC ATC GTA 
GAA TTT TGG CAG C 3’ 
 
 
2.10 Fluorescently tagged substrates 
Substrate Distributor Catalogue number 
Z-LLE-AMC Calbiochem (Millipore), Schwalbach 53914 
Boc-LSTR-AMC Bachem, Bubendorf, CH I-1940 
Suc-LLVY-AMC Bachem, Bubendorf, CH I-1395 
 
2.11 Proteasome inhibitors 
Inhibitor Distributor Catalogue number 
Z-Pro-Nle-Asp-H Enzo Life Sciences, Lörrach BML-ZW9490 
Epoxomicin Boston Biochem, Cambridge, USA I-112 
Bortezomib LC Laboratories, Woburn, USA B-1408 
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2.12 Antibodies 
WB: Western blot; IHC: Immunohistochemistry 
2.12.1 Primary antibodies 
Antibody Distributor  
(Catalogue number) 
Dilution Application 
Mouse anti-α7 Enzo Life Sciences, Lörrach 
(PW8110) 
1:2500 WB 
Mouse anti-β1 Abcam, Cambridge, UK 
(ab58081) 
1:1666 
1:400 
WB 
IHC 
Mouse anti-β1i Enzo Life Sciences, Lörrach 
(PW8840) 
1:800 
1:200 
WB 
IHC 
Mouse anti-β2 Enzo Life Sciences, Lörrach 
(PW9300) 
1:2500 WB 
Rabbit anti-β5 Enzo Life Sciences, Lörrach 
(PW88959 
1:1666 WB 
Mouse anti-β5i Enzo Life Sciences, Lörrach 
(PW8845) 
1:1666 WB 
Rabbit anti-actin Sigma-Aldrich, Steinheim 
(A2066) 
1:3000 WB 
Mouse anti-α-actinin Sigma-Aldrich, Steinheim 
(A7811) 
1:2000 
1:1500 
WB 
IHC 
Rabbit anti-desmin Dianova, Hamburg 
(DLN-13734) 
1:4000 
1:400 
WB 
IHC 
Rabbit anit-MLC2v 
(cardiac) 
Abcam, Cambridge, UK 
(ab79935) 
1:4000 WB 
Mouse anti-β-MHC Millipore, Schwalbach 
(MAB1628) 
1:1500 WB 
Mouse anti-troponin I 
(cardiac)  
Abcam, Cambridge, UK 
(ab19615) 
1:4000 WB 
Mouse anti-α-tubulin Sigma-Aldrich, Steinheim 
(T5168) 
1:6000 WB 
 
2.12.2 Secondary antibodies 
Antibody Distributor  
(Catalogue number) 
Dilution Application 
Goat anti-mouse IgG  
(Fab fragment) 
Dianova, Hamburg 
(115-007-003) 
1:13 IHC 
Rat anti-mouse IgG HRP Rockland (Biomol), Hamburg 
(18-8817-33) 
1:5000-1:10000 WB 
Goat anti-rabbit IgG HRP Sigma-Aldrich, Steinheim 
(A-6154) 
1:10000 WB 
 
 Materials 
 28 
Goat anti-mouse IgG  
biotin-SP-conjugated 
Dianova, Hamburg 
(115-067-003) 
1:500 IHC 
Donkey anti-mouse IgG 
Cy3 
Dianova, Hamburg 
(715-166-150) 
1:1000 IHC 
Goat anti-rabbit IgG Alexa 
Fluor 647 
Dianova, Hamburg 
(111-495-006) 
1:1000 IHC 
Streptavidin Cy3 Dianova, Hamburg 
(016-160-084 ) 
1:500 IHC 
 
2.13 AAVs 
AAV Concentration 
AAV2-β1i 3.9 * 1010 vg/ml 
AAV6-β1i 1.87 * 1011 vg/ml 
AAV6-EGFP 2.56 * 1011 vg/ml 
AAV9-β1i 1.2 * 1012 vg/ml 
AAV9-Renilla Luciferase 1.0 * 1012 vg/ml 
 
The packaging of DNA in different serotypes of AAV for this project was kindly performed by 
the research group of Dr. O. Müller (Dept. of Internal Medicine III, University Clinic Heidelberg). 
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3 Methods 
3.1 Cell culture 
In general, sterile materials and solutions were used, all solutions were pre-warmed to 37°C in 
a water bath. All cell culture related work was carried out under a laminar flow cabinet. The 
cells were cultured in the incubator at 37°C and 5% carbon dioxide. 
 
3.1.1 HEK-293 cells 
Thawing of HEK-293 cells 
The cells (passage 15) stored in cryotubes in liquid nitrogen were quickly thawed in 37°C  water 
bath and transferred to DMEM medium . The cell suspension was carefully mixed by inverting, 
pelleted by centrifugation for 5 min at 500 x g and the supernatant fraction removed by 
aspiration. The cells were resuspended in 5 ml of DMEM medium and transferred in a 
T25 filter flask. 
 
Maintenance of HEK-293 cells 
The cells were periodically checked under the microscope. The medium was changed every 
second day or earlier in cases where the cell confluence was lower than 80% and/or upon a 
noticeable color change of the media from red to orange as indicative of a pH shift and nutrient 
deficiency. For this purpose, the medium was aspirated and 5 ml of fresh DMEM medium was 
added after washing the cells with 2 ml of HBSS. 
 
Passaging of HEK-293 cells 
The cells were passaged at approximately 80% confluency. For this purpose, the cells were 
detached from the culture vessel by adding 1 ml of 0.05% trypsin EDTA solution per T25 flask 
and incubated for 1-3 min at room temperature (RT) after washing the cells with 2 ml of HBSS. 
The detachment was microscopically monitored and stopped by the addition of 2 ml of DMEM 
medium. The cells were pelleted by centrifugation for 5 min at 500 x g to remove all traces of 
the trypsin EDTA solution. Finally, the cell suspension was passaged at a ratio of 1:3 to 1:5 
and was transferred in a new T25 filter flask after gently resuspending the cell pellet in DMEM 
medium. 
 
Sub-culturing of HEK-293 cells  
HEK-293 cells were sub-cultured for 12 to 16 hours before starting the AAV2 infection. After 
detachment, the cells were counted using a Neubauer chamber (Harrison et al. 1997). For this 
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purpose, the cells were 1:100 diluted in HBSS and 20 µl of this suspension was transferred in 
the prepared Neubauer chamber. The cells within the corner squares were counted and the 
number was divided by four to get the mean cell number of one corner square. Then, the cell 
number was calculated according to the formula outlined below. 
410 dilution
squarecorner
cells
ml
cells
 
The cell suspension was diluted according to the necessary cell amount and total volume.  
 
 cells / well medium / well 
6-well plate 5 x 105 2 ml 
 
3.1.2 Preparation of NRCMs 
The preparation of neonatal rat cardiomyocytes (NRCMs) was performed with the approval 
(T-05/13) of the sanctioning authority (Regierungspräsidium Karlsruhe) and according to the 
German animal protection code. 
Primary NRCMs were prepared from the hearts of neonatal rats on the postnatal day one to 
three according to previously published protocol (Frank et al. 2008). The preparation of NRCMs 
was established with support of Susann Werkmeister (Dept. of Internal Medicine III, University 
Clinic Heidelberg). One day before preparation of NRCMs (at least 2 h before plating the cells), 
the cell culture dishes and plates were coated using collagen stock solution diluted 1:10 in 
ADS buffer. In addition, sterile coverslips were placed into 48-well plates prior to coating for 
the immunofluorescence analysis. 
The neonatal rats were decapitated using sterile large scissors. Then, the heart was excised 
and transferred to the ice-cold ADS buffer. After removing the atria and other remaining tissue 
pieces, the ventricles were transferred to the fresh, ice-cold ADS solution. Subsequently, the 
tissue was digested under sterile conditions using a digestion solution containing pancreatin 
and collagenase type 2 to isolate the cells. For this purpose, the ADS buffer was carefully 
removed by pipetting and the ventricles were cut into small pieces. The tissue pieces were 
then transferred to a T75 flask containing the digestion solution and shaken for 20 min at 37°C 
in a water bath.  
- standard volumes of digestion solution:  
  24 neonatal rats = 18-20 ml digestion solution = 1x T75 
  36 neonatal rats = 27-30 ml digestion solution = 1x T75 
The supernatant solution from the first digestion step was discarded. On the contrary, cell 
suspensions from the following digestion steps were collected and stored in 50 ml tubes at 
37°C with loosened cap. The collected solution was passed through a cell strainer in a 50 ml 
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tube containing 5 ml of NBCS and the cell strainer was washed with additional 2-3ml of NBCS. 
After adding new digestion solution to the tissue pieces, the cell suspension was centrifuged 
for 5 min at ~500 x g in the meantime. The cell pellet was resuspended in 5 ml of NBCS after 
aspiration of the supernatant. The digestion was repeated up to 6 times until the tissue was 
almost entirely digested. Next, the cell suspensions, stored at 37°C, were pooled and pelleted 
by centrifugation for 5 min at ~500 x g. The cell pellet was then carefully resuspended in 
1x ADS buffer. Then, the cell suspension was added drop-wise onto the Percoll gradient 
(7 ml bottom-layer + 3 ml top-layer) in 2 ml increments.  
- standard: 2 pregnant rats = 4 Percoll gradients 
 3 pregnant rats = 6 Percoll gradients 
 4 pregnant rats = 8 Percoll gradients 
The cardiomyocytes were separated from fibroblasts using a Percoll gradient centrifugation 
step for 30 min at 1000 x g at 4°C (turn off brake). After centrifugation, the upper, colorless 
phase and the interphase containing fibroblasts as well as the first half of the top, red layer 
phase was removed and discarded. The second half of the top-layer phase and the colorless 
bottom-layer phase containing cardiomyocytes were pooled in 2x 50 ml tubes. Next, ice-cold 
1x ADS buffer was added up to 50 ml to each cell suspension. After centrifugation for 5 min at 
~500 x g, the supernatant was discarded and the cells were pooled and resuspended in 50 ml 
of ice-cold 1x ADS buffer, centrifuged as before and carefully resuspended in 40 ml of medium 
containing 10% FCS. The cell suspension was 1:2 diluted in 0.4% trypan blue solution to 
determine the cell concentration using a Neubauer chamber as described previously 
(see 3.1.1) (Harrison et al. 1997). Living, unstained cells within all corner squares were counted 
(dead cells = blue). Following this, the cell suspension was diluted according to the necessary 
cell amount and total volume and plated onto the previously prepared, collagen-coated culture 
vessels.  
 cells / well medium / well 
60mm dish 3 x 106 4 ml 
6-well plate 1.5 x 106 2 ml 
12-well plate 500.000 1 ml 
24-well plate 150.000  0.5 ml 
48-well plate 90.000 0.3 ml 
 
Two days after preparation, the cardiomyocytes were starved by changing the medium 
(0% FCS). The AAV6 infection was initiated three days after the preparation. 
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3.1.3 Infection of cells 
The AAV CMV/MLC0.26 β1i or EGFP vector was packaged into AAV2 particles for HEK-293 
or AAV6 particles for NRCMs infection. In HEK-293 cells, the infection was carried out 12 to 
16 hours after sub-culturing. In contrast, the primary NRCMs were infected three days after 
preparation and one day after starvation. After the application of the virus, the medium was not 
changed in both in vitro systems. The infected cells were incubated at 37°C for 48 hour to 
72 hours before they were harvested or fixed on coverslips for immunofluorescence staining. 
The virus titer of each virus batch used was determined by quantitative real time PCR by our 
collaborators (O. Müller, Dept. of Internal Medicine III, University Clinic Heidelberg). Thus, a 
defined number of vector genomes instead of infectious virus particles per cell was used for 
infection of NRCMs or HEK-293 cells. In accordance, the number of infectious virus particles 
is assumed to be lower than the number of vector genomes. The number of vector genomes 
per cell is hereafter referred to as multiplicity of infection (MOI). 
The infection experiment was started by the addition of fresh medium containing the 
appropriate vector amount after aspiration of the old medium. The vector amount, needed for 
a defined MOI, was calculated according to the formula outlined below. 
- example:  AAV6 CMV/MLC0.25 β1i 
o virus stock concentration  = 
ml
vg111087.1   (vg = vector genomes) 
    = 
8109.1   vg in 1 µl 
 
o the MOI should be 104 using
4107  cells, thus 
8107 vg are needed: 
      
xµl
vg
µl
vg 88 107
1
109.1 


   
      µl
vg
vgµl
x 7.3
109.1
1071
8
8



 virus stock solution 
 
3.1.4 Harvesting cells 
mRNA and protein analysis 
The cells were harvested directly in the cell media using a cell scraper. After centrifugation for 
5 min at ~500 x g, the supernatant was discarded and the cell pellet was resuspended in 
1 ml of PBS to remove all traces of the medium. Then, the cells were pelleted again by 
centrifugation and were quick-frozen in liquid nitrogen and stored at -20°C after aspiration of 
the supernatant.  
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Immunfluorescence analysis 
The cells, grown on coverslips, were fixed according to the scheme outlined below. 
 
 fixative incubation time 
HEK-293 cells isofix 30 min on ice 
NRCMs 4% paraformaledhyde and 
4% sucrose in PBS 
10 min at RT on shaker 
   
 
3.2 In vivo studies 
3.2.1 In vivo hypertrophy model 
The animal experiments were performed with the approval (35-9185.81/G-194/11) of the 
sanctioning authority (Regierungspräsidium Karlsruhe) and according to the German animal 
protection code. 
The experimental setup used to investigate the influence of the reintroduction of β1i in 
β1i-deficient mice upon induction of hypertrophy is shown in figure 5.  
 
 
Figure 5. β1i-deficient mice received 1011 vector genome equivalents of the cardio-tropic serotype 9 
of adeno-associated virus harboring β1i (AAV β1i) or Renilla luciferase (AAV Luci) 4 weeks prior to 
induction of hypertrophy via 7-day treatment using an infusion rate of 30 mg * kg-1 * day-1 of 
isoprenaline 
 
Male β1i knockout mice were intravenously injected using 1011 vector genome equivalents of 
the cardio-tropic AAV9 CMV/MLC0.26 β1i at the age of 8 weeks. The Renilla luciferase gene 
packaged into AAV9 served as a control in β1i-deficient mice. The tail vein injection was kindly 
performed by Bianca Heil (Interfacultary Biomedical Faculty, University Heidelberg). After 
4 weeks, cardiac function was analyzed by echocardiography prior to and post pharmacologic 
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induction of hypertrophy by isoprenaline treatment (Figure 5). Subsequently, the proteasome 
regulation was investigated in hypertrophic hearts. 
 
Hypertrophy induction by treatment with isoprenaline 
In accordance with previously utilized animal model, cardiac hypertrophy was induced by 
7 days of isoprenaline treatment using micro-osmotic pumps, which release isoprenaline at a 
rate of 30 mg * kg-1 * day-1 (Drews et al. 2010). 
The following parameters of the micro-osmotic pump (alzet, model 1002) and the experimental 
setup were used to calculate the necessary isoprenaline concentration. 
- micro-osmotic pump = alzet model 1002 (length: 1.5 cm; diameter: 0.6 cm; 
weight: 400 mg): 
 pumping rate:  0.22 µl/h ( 0.05 µl/h) 
 duration:  14 d 
 reservoir volume: 100 µl 
- experimental setup: 
 infusion rate isoprenaline:  30 mg/kg/d = 1.25 mg/kg/h 
 maximum body weight mouse: 35 g 
𝑐 (𝑖𝑠𝑜𝑝𝑟𝑒𝑛𝑎𝑙𝑖𝑛𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛) =  
1.25
𝑚𝑔
ℎ × 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡[𝑘𝑔]
0.00022
𝑚𝑙
ℎ
 
𝑐 (𝑖𝑠𝑜𝑝𝑟𝑒𝑛𝑎𝑙𝑖𝑛𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛) =  
1.25
𝑚𝑔
ℎ × 0.035 [𝑘𝑔]
0.00022
𝑚𝑙
ℎ
 
 
𝑐 (𝑖𝑠𝑜𝑝𝑟𝑒𝑛𝑎𝑙𝑖𝑛𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛) =  198.86 
𝑚𝑔
𝑚𝑙
 
 
Accordingly, 20 ml solution was calculated to contain 3.977 g of isoprenaline. Thus, 4.663 g of 
isoprenaline hydrochloride was diluted in 20 ml of sterile PBS. Aliquots of the isoprenaline 
stock solution were prepared and stored at -20°C. 
The loading of the micro-osmotic pumps with isoprenaline solution was kindly performed by 
Dr. O. Drews (Dept. of Cardiovascular Physiology, University Heidelberg) according to the 
manufacturer’s instructions (Alzet, Cat. no. 0004317). The isoprenaline stock solution was 
diluted with PBS depending on the actual weight of the mice. The loaded pumps were primed 
overnight in sterile PBS. 
Subsequently, the micro-osmotic pump was implanted under 1-3% isoflurane anesthesia. 
Initially, the fur was completely removed on the implant site on the back using an animal fur 
shaver and a hair removal creme. After disinfection with iodine ointment (braunovidion), the 
skin on the back was incised and a paravertebral pocket was created towards the head 
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between the subcutis and the fasciae of the back muscles. Next, the pump was washed 
thoroughly in sterile water and inserted in the paravertebral pocket. Finally, the wound was 
sutured using surgeon’s knots and disinfected with iodine ointment. On the first two days the 
mice were monitored at least twice a day and thereafter at least once. The pump implantation 
was kindly performed by Felix Trogisch (Dept. of Cardiovascular Physiology, University 
Heidelberg). 
 
Echocardiography 
Cardiac function was investigated by echocardiography using the transducer MS-550D and 
the Vevo 2100 imaging system (Visualsonics) prior to and post induction of hypertrophy by 
7 days treatment with isoprenaline (Gao et al. 2011).  
The echocardiography was done under 1-3% isoflurane anesthesia. The morphology and the 
systolic function of the heart were analyzed in the parasternal long axis view (PLAX) 
(Figure 6A) as well as in the parasternal short axis view (PSAX) (Figure 6B). Anatomical 
structures are identified in the brightness mode (B-mode) (Figure 6A, B) displaying 
two-dimensional images of an area of interest. In the motion mode (M-mode) the movement 
of the sample volume (vertical line in B-mode) over time is displayed (Figure 6C). In the PLAX 
view, the aorta and the apex are on a horizontal line and only the left ventricle is displayed 
(Figure 6A). In the PSAX view, the cross section of the middle of the heart is shown, indicated 
by the presence of both papillary muscles (Figure 6B). Morphological parameter, such as left 
ventricular internal diameter (LVID) and left ventricular posterior wall thickness (LWPWT) in 
systole and diastole, are analyzed in M-mode in the PLAX and PSAX view (Figure 6C). 
Moreover, the left ventricular internal dimensions (LVID;d and LVID;s) are used to calculate 
the ejection fraction (EF) and the fractional shortening (FS), which are utilized to evaluate the 
contractility of the ventricle. In addition, parameters reflecting the systolic function of the heart 
are analyzed, such as stroke volume (SV) and cardiac output (CO). The former is defined as 
the ejected blood volume during systole while the latter is the ejected blood volume per minute. 
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Figure 6. Representative echocardiographic images in mice. 
Cardiac morphology and systolic function is analyzed in the parasternal long axis (PLAX) (A) and in 
the parasternal short axis (PSAX) (B) view in B-mode as well as in M-mode (C). The movement of 
the line in B-mode is displayed over time in M-mode. The corresponding electrocardiogram (ECG) 
(green) and the respiration rate (yellow) is displayed below the M-mode image. In M-mode (C), the 
left ventricular internal diameter (LVID) and left ventricular posterior wall thickness (LVPW) in diastole 
and systole were measured. 
 
The diastolic function of the heart is analyzed in the apical four chamber view (Figure 7A) 
utilizing color and pulse wave (PW) Doppler mode (Figure 7B, C). Doppler mode imaging is 
utilized to analyze the velocity of the movement of blood or tissue. In color Doppler mode, the 
direction and the velocity of blood flow is visualized. Accordingly, blood flow towards and away 
from the transducer is gradually colored in blue to white and red to white, respectively. In PW 
Doppler mode, the values such as the velocity of blood flow, which is visualized in color 
Doppler mode imaging, are measured. For this purpose, the sample volume (square) is placed 
above the mitral valves and the blood flow is visualized using the color Doppler mode 
(Figure 7B). In the apical four chamber view, both ventricles and atria are visible (Figure 7A). 
Using the PW Doppler mode, the passive filling of the ventricle (E value) and the active filling 
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of ventricle (A value) is analyzed (Figure 7C). In addition, the E/A ratio, a common indicator of 
diastolic dysfunction is calculated. 
 
 
Figure 7. Representative echocardiographic images in mice. 
Diastolic function is investigated in the apical four chamber view of the heart (A). For this purpose, 
the sample volume (square) is placed above the mitral valves in color Doppler mode (B). The E and 
A value is measured in the pulse wave (PW) Doppler mode (C). The corresponding ECG (green) and 
the respiration rate (yellow) is displayed below the PW mode image. 
 
The Vevo 2100 software (Visualsonics) was used for the analysis of the echocardiographic 
data. The analyzed morphological, systolic and diastolic parameter, as well as the formula 
used for calculations are outlined below. 
- morphological parameter (PLAX, M-Mode): 
 LVID;s / LVID;d 
 LVPWT;s / LVPWT;d 
 
- systolic function (PLAX, M-Mode): 
 𝑆𝑉 = (
7.0
2.4+𝐿𝑉𝐼𝐷;𝑑
∗ 𝐿𝑉𝐼𝐷; 𝑑3) − (
7.0
2.4+𝐿𝑉𝐼𝐷;𝑠
∗ 𝐿𝑉𝐼𝐷; 𝑠3) 
 𝐶𝑂 = 𝑆𝑉 ∗
ℎ𝑒𝑎𝑟𝑡 𝑟𝑎𝑡𝑒
1000
 
 𝐸𝐹 = 100 ∗ [
(
7.0
2.4+𝐿𝑉𝐼𝐷;𝑑
∗𝐿𝑉𝐼𝐷;𝑑3)−(
7.0
2.4+𝐿𝑉𝐼𝐷;𝑠
∗𝐿𝑉𝐼𝐷;𝑠3)
7.0
2.4+𝐿𝑉𝐼𝐷;𝑑
∗𝐿𝑉𝐼𝐷;𝑑3
] 
 𝐹𝑆 = 100 ∗
𝐿𝑉𝐼𝐷;𝑑−𝐿𝑉𝐼𝐷;𝑠
𝐿𝑉𝐼𝐷;𝑑
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- diastolic function (apical four chamber, PW Doppler): 
 E value 
 A value 
 E/A 
 
Euthanasia and organ removal 
The mice were euthanized by cervical dislocation under 1-3% isoflurane anesthesia. The 
organs were removed in following order: heart, lungs and liver. All organs were washed in ice-
cold PBS and dried on tissue wrap to remove all traces of liquid. In addition, the heart was 
carefully and manually pumped in PBS on ice to remove blood from the ventricles. This step 
is important given that the blood contamination would interfere with the downstream analysis. 
Then, the organ weight was measured prior to quick-freezing in liquid nitrogen and long-term 
storage at -80°C.  
In addition, the basis of the heart of animals utilized for histological analyses were embedded 
in NEG 50 to enable the preparation of cryosections (Bancroft et al. 2008c). For this purpose, 
the heart was horizontally cut using a scalpel and the apex was quick-frozen in liquid nitrogen 
and stored at -80°C for biochemical analysis. The basis was transferred in 30mM 
2,3-butanedionemonoxime in PBS to relax the cardiac muscle. After incubation for 3 min on 
ice, the basis was washed in ice-cold PBS and dried on tissue wrap to remove all traces of 
liquid. Subsequently, the basis was transferred in a cup made of aluminum foil covered with 
NEG 50 (cross section down). After ensuring that the heart basis was covered completely in 
NEG 50 and the samples were frozen in liquid nitrogen using pre-cooled isopentane as a 
freezing agent and stored at -80°C. 
 
3.2.2 In vivo aging model 
In collaboration with Dr. Kleinbongard (Dept. of Pathophysiology, University Hospital Essen), 
the proteasome regulation in cardiac aging was investigated in two blinded studies using 
4 versus 26 months old male mice and 3, 9 and 30 months old male mice (Figure 8). It should 
be noted that animals of the former study (4 versus 26 months old mice) were sacrificed due 
to visible signs of distress, suggesting a very poor overall health condition, thus accounting for 
the variability in their age upon analysis (communicated by Dr. Kleinbongard, Dept. of 
Pathophysiology, University Hospital Essen). Analysis of the cardiac function of 3, 9 and 
30 months old mice via echocardiography by our collaborators (data not shown) did not show 
pathological abnormalities. Thus, these mice appeared healthy. 
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Figure 8. Scheme of different age 
groups compared in two blinded 
studies. 
 
3.3 Molecular biological methods 
3.3.1 Extraction of nucleic acids 
RNA extraction from mouse tissue 
Total RNA was purified from the tissues of C57BL/6J WT mice utilizing the RNeasy mini kit 
according to manufacturer’s recommendations. Notably, the excised tissue was stabilized in 
RNAlater RNA stabilization reagent before disruption in 2 ml of RLT buffer utilizing a handheld 
homogenizer on ice. In addition, the integrity of total RNA was assessed via agarose gel 
electrophoresis (see 3.3.5.) with intact total RNA resulting in clear 28S and 18S rRNA bands. 
 
RNA extraction from cell pellets 
The total RNA was purified from cell pellets using the peqGOLD total RNA kit according to 
manufacturer’s instructions. 
 
Extraction of genomic DNA from mice tail biopsies 
The genomic DNA was extracted from mice tail biopsies stored at -20°C (Malumbres et al. 
1997, Wang et al. 2006). For this purpose, the tail biopsy (~1 cm) was digested in 150 µl of tail 
biopsy digestion buffer at 55°C overnight. On the next day, the proteinase K was heat 
inactivated for 10 min at 95°C. Next, cell debris were removed by centrifugation for 10 min at 
~20.000 x g. Subsequently, the genomic DNA in the supernatant was precipitated to remove 
components which inhibit the PCR reaction (Malumbres et al. 1997, Wang et al. 2006). For 
this purpose, 5 µl of 3 M actetate solution (pH 5.2) and 125 µl of ice-cold 100% ethanol were 
added to 50 µl of the supernatant. After incubation at -20°C overnight, the DNA was pelleted 
by centrifugation for 15 min at ~20.000 x g at 4°C. Then, the DNA pellet was washed with 1 ml 
of 70% ethanol. After centrifugation for 5 min at ~20.000 x g at 4°C, the supernatant was 
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carefully decanted and the DNA pellet was air-dried for 5-10 min at room temperature (RT). 
Finally, the DNA was dissolved in 50 µl of 10 mM TRIS buffer (pH 8.5). 
The genomic DNA was used to analyze the genotype of the mice via PCR (see 3.3.4) and 
subsequent agarose gel electrophoresis (see 3.3.5).  
 
3.3.2 Determination of RNA and DNA concentration 
The RNA, cDNA or DNA concentration was determined using the Nanodrop ND-1000 
spectrophotometer. According to Lambert-Beer law, the RNA, cDNA or DNA concentration 
was calculated by measuring the ultraviolet light absorption (OD260nm = 1 corresponds to a 
concentration of 40 ng of RNA, 33 ng of cDNA or 50 ng of DNA per µl solution) (Buckingham 
2011). In addition, the purity of the RNA or DNA solution was assessed using the ratio of the 
absorption at 260 nm to 280 nm. An A260/A280 ratio of 2.0 indicated a highly purified RNA. 
Values below 2.0 may indicate DNA contamination, whereas values above 2.0 suggest 
potential protein or other aromatic compound contamination. In contrast, an A260/A280 ratio 
of 1.8 is indicative of highly purified DNA. Values above 1.8 may indicate RNA, protein or 
contamination with aromatic compounds (Buckingham 2011). 
 
3.3.3 Reverse transcription 
Reverse transcription using total RNA extracted from mouse tissue 
The cDNA was synthesized from total RNA via reverse transcriptase reaction using the 
Transcriptor high fidelity cDNA synthesis kit according to manufacturer’s instructions. First, the 
pre-annealing mixture was prepared according to the scheme outlined below. After 10 min 
denaturation at 65°C and cooling on ice, the components of the reaction mixture were added 
to the pre-annealing mixture and the reverse transcription was performed for 30 min at 55°C. 
Finally, the reverse transcriptase was heat inactivated by incubation at 85°C for 5 min.  
pre-annealing mixture (1x): reaction mixture (1x): 
water (PCR-grade) 10.4 µl - x 
µl 
anchored-oligo(dT)18 
primer [50 pmol/µl] 
1 µl 
total RNA (5 µg in total) x µl 
total volume 11.4 µl 
 
5x reaction buffer  4 µl 
desoxynucleotide mix [10 mM each] 2 µl 
DTT [100 nM] 1 µl 
pre-annealing mix 11.4 µl 
protector RNase inhibitor [40 U/µl] 0.5 µl 
reverse transcriptase [180 U/µl] 1.1 µl 
total volume 20 µl 
 
 
Notably, the Transcriptor high fidelity cDNA synthesis kit provides a markedly higher fidelity 
than the M-MLV reverse transcriptase used for the reverse transcription of total RNA from cell 
pellets. Thus, the cDNA, which was synthesized via reverse transcriptase reaction using the 
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Transcriptor high fidelity cDNA synthesis kit, was used for plasmid construction due to the 
higher accuracy of the reaction. 
 
Reverse transcription using total RNA isolated from cell pellets 
The cDNA was synthesized from total RNA, isolated from cell pellets, via reverse transcriptase 
reaction using the moloney murine leukemia virus (M-MLV) reverse transcriptase according to 
manufacturer’s recommendations. First, the pre-annealing mixture was prepared according to 
the scheme outlined below and denatured for 5 min at 70°C. After cooling on ice, the 
components of the reaction mixture were added and the reverse transcription was performed 
for 60 min at 42°C. Then, the reaction mix was incubated for 5 min at 85°C to heat inactivate 
the reverse transcriptase. 
pre-annealing mixture (1x): reaction mixture (1x): 
water (PCR-grade) 13 µl - x µl 
anchored-oligo(dT)15 
primer [0.5 µg/µl] 
2 µl 
total RNA (2 µg in total) x µl 
total volume 15 µl 
 
water (PCR-grade) 17.75 µl 
5x M-MLV reaction buffer  5 µl 
desoxynucleotide mix [10 mM each] 1.25 µl 
pre-annealing mix 15 µl 
reverse transcriptase [200 U/µl] 1 µl 
total volume 40 µl 
 
 
3.3.4 Polymerase chain reaction (PCR) 
PCR – amplification of gene of interest for cloning 
The gene of interest was amplified via polymerase chain reaction (PCR) using Phusion high 
fidelity polymerase according to manufacture’s recommendations. The ‘β1i direct primers’ or 
‘β1i overhang primers’ were used for the amplification of the β1i gene or the insertion of the 
Kozak consensus sequence, as well as the restriction sites, needed for subcloning, 
respectively. 
- PCR master mix (1x): 
nuclease-free water  21 µl – x µl 
forward primer [10 µM] 2 µl 
reverse primer [10 µM] 2 µl 
template cDNA (200 ng per reaction) x µl 
2x phusion master mix 25 µl 
total volume 50 µl 
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- thermocycler protocol: 
step time temperature 
preheat cycler  98°C 
initial denaturation 2min 98°C 
35 cycles:   
denaturation 1min 98°C 
annealing 1min 60°C 
extension 1min 72°C 
final extension 10min 72°C 
store  4°C 
 
Semiquantitative PCR 
The β1i mRNA expression was analyzed after AAV2 CMV/MLC0.26 β1i infection in HEK-293 
cells. 
First, total RNA was purified from cell pellets (6-well; 5 x 105 cell / well sub-cultured; 48 hours 
after AAV infection) using the peqGOLD total RNA kit (see 3.3.1.). Subsequently, cDNA was 
synthesized from 2µg of total RNA via reverse transcriptase reaction using the M-MLV reverse 
transcriptase (see 3.3.3). Then, the β1i gene was amplified using 250 ng of cDNA via 
polymerase chain reaction (PCR) utilizing Phusion high fidelity polymerase according to 
manufacture’s recommendations. Finally, the mRNA expression of β1i (660 bp) in HEK-293 
cells was analyzed by agarose gel electrophoresis (see 3.3.5). 
- PCR master mix (1x): 
nuclease-free water  8.4 µl – x µl 
β1i direct primer forward [10 µM] 0.8 µl 
β1i direct primer reverse [10 µM] 0.8 µl 
template cDNA (250 ng per reaction) x µl 
2x phusion master mix 10 µl 
total volume 20 µl 
 
- thermocycler protocol: 
step time temperature 
preheat cycler  98°C 
initial denaturation 2min 98°C 
35 cycles:   
denaturation 1min 98°C 
annealing 1min 60°C 
extension 1min 72°C 
final extension 10min 72°C 
store  4°C 
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PCR - genotyping 
Heterozygous β1i-deficient mice were mated and genotyped. Male homozygous β1i knockout 
mice were then subsequently used for the in vivo hypertrophy model. 
The DNA was assessed for the presence of the β1i gene (primer pair: β1i-2 and β1i-4; 550 bp) 
and the neomycin cassette (primer pair: β1i-3 and neoA; 1500 bp) via PCR using the Phusion 
high-fidelity DNA polymerase according to manufacturer’s recommendations. Subsequently, 
the PCR products were analyzed by agarose gel electrophoresis (see 3.3.5) using a 1.5% (w/v) 
agarose gel, which was commonly run at 80 V for approximately 90 min. Accordingly, 
homozygous β1i-deficient mice were negative for the β1i gene (550 bp) and positive for the 
neomycin cassette (1500 bp) PCR product. 
- PCR master mix (1x):  
nuclease-free water  18.8 µl 
5x phusion HF buffer 4 µl 
dNTPs [each 10mM] 0.2 µl 
forward primer [10 µM] = β1i-2 or β1i-3 0.2 µl 
reverse primer [10 µM] = β1i-4 or neoA 0.2 µl 
Phusion polymerase [2 U/µl] 0.2 µl 
precipitated genomic DNA 1.2 µl 
total volume 20 µl 
 
- thermocycler protocol: 
primer pair  β1i-2 & β1i-4 β1i-3 & neoA 
    
step time temperature 
preheat cycler  94°C 94°C 
initial denaturation 2min 94°C 94°C 
35 cycles:    
denaturation 1min 94°C 94°C 
annealing 1min 55°C 65°C 
extension 3min 72°C 72°C 
final extension 10min 72°C 72°C 
store  4°C 4°C 
 
3.3.5 Agarose gel electrophoresis 
In general, agarose gel electrophoresis of PCR products was used to analyze the mRNA 
expression of a gene of interest or for genotype determination. Moreover, the electrophoretic 
separation of digested plasmids or PCR products was used to purify the products or to assess 
the digestion or the successful gene of interest insertion into a plasmid (Sambrook et al. 1989). 
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After adding 5x loading buffer, the DNA fragments were commonly separated using a 1% (w/v) 
agarose gel. The gel was run at 100 V for approximately 90 min. Finally, the DNA fragments 
were visualized by ultraviolet light due to the intercalated ethidium bromide and recorded using 
the Gel Doc XR gel documentation system. The DNA fragment sizes were verified by utilizing 
DNA ladders. In addition, DNA bands were excised to purify the DNA utilized in subsequent 
procedures (e.g. construction of plasmid). 
 
3.3.6 Purification of DNA after enzymatic reactions and agarose gel electrophoresis 
Following enzymatic reactions such as PCR, dephosphorylation and restriction digestion, the 
DNA fragments used for cloning were purified due to presence of ions or other ingredients 
which would otherwise interfere with downstream reactions. The DNA fragments that were 
separated by agarose gel electrophoresis were thus purified using the QIAquick gel extraction 
kit according to manufacturer’s instruction. 
 
3.3.7 Cloning 
Restriction digestion of cloning vectors 
Restriction digestion of cloning vectors was used to insert specific DNA fragments as well as 
to verify the successful insertion of the gene of interest. The restriction digestion using different 
restriction enzymes was performed according to manufacturer’s instructions regarding specific 
buffer conditions, incubation temperature and time. Subsequently, 1500-2000ng of plasmid 
were used for the preparative restriction digestions, subjected to gel electrophoresis 
(see 3.3.5) and later purified using the QIAquick gel extraction kit (see 3.3.6). The successful 
insertion of the specific DNA fragment (100 ng starting amount) was verified by agarose gel 
electrophoresis and visualization by ultraviolet light (see 3.3.5). 
 
Dephosphorylation of blunt end digested cloning vectors 
Blunt end digested cloning vectors (e. g. via restriction enzyme SmaI) were dephosphorylated 
using FastAP thermosensitive alkaline phosphatase according to manufacturer’s 
recommendations to avoid re-ligation. One phosphatase unit was added per 1 µg of template. 
After incubation for 20 min at 37°C, the phosphatase was inactivated by incubation for 5 min 
at 75°C. Then, the digested and dephosphorylated cloning vector was purified using the 
QIAquick gel extraction kit (see 3.3.6) after agarose gel electrophoresis (see 3.3.5). 
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Phosphorylation of PCR products 
At least one of the templates had to be phosphorylated to ligate a vector and an insert 
(Sambrook et al. 1989). Since the blunt end digested vectors were dephosphorylated to avoid 
re-ligation, the PCR products were thus phosphorylated using the T4 polynucleotide kinase. 
According to manufacturer’s recommendations, the T4 DNA ligase buffer was used to optimize 
the reaction conditions for the subsequent ligation. First, the molarity of 5’-termini, which were 
phosphorylated in the reaction, was calculated using the following formula. 
  endsDpairsbase
µl
µg
template
l
mol
M 2650 










  
Accordingly, one T4 polynucleotide kinase unit was added per 1 nmol 5’-termini. The 
phosphorylation mix was incubated for 20 min at 37°C. After heat inactivation (10 min at 75°C) 
of the T4 polynucleotide kinase the phosphorylated PCR products were used for ligation of 
double-stranded DNA (dsDNA). 
 
Ligation of dsDNA 
Phosphorylated PCR products were ligated with dephosphorylated blunt end digested cloning 
vectors using the T4 DNA ligase according to manufacturer’s instructions. In addition, the T4 
DNA ligase was further utilized to ligate AgeI and BsrGI digested β1i insert and AAV 
CMV/MLC0.26 vector. The amount of insert, needed for specific vector to insert ratio, was 
calculated and the ligation mix was prepared and incubated at RT overnight using the formula 
and scheme outline below. 
ratioaforneededinsertofngvectorofng
kbinvectoroflength
kbininsertoflength
1:1  
 inserts: β1i direct PCR product = 660 bp 
  β1i overhang PCR product = 686 bp 
  AgeI and BsrGI restricted β1i insert = 666 bp 
 vectors: pBlueScript II SK(+) = 2961 bp 
  pSP72 = 2462 bp 
  AAV CMV/MLC0.26 = 5312 bp 
 
- ligation mix (1x):  
water (PCR-grade) 10 µl - x µl - y µl 
10x T4 DNA ligase buffer 1 µl 
linear vector x µl 
insert  y µl 
50% PEG 4000 solution 1 µl 
T4 DNA ligase [400 CEU / µl] 1.25 µl 
total volume 10 µl 
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3.3.8 Transformation 
Preparation of competent E.coli 
Competent E.coli (DH1 or Sure cells) derived from a chemical induction were prepared 
according to the published protocol by Joe Sambrook (Sambrook et al. 1989). Sterile materials 
were used, the working place was disinfected using 70% ethanol and procedures were 
performed next to the flame of a Bunsen burner in order to generate semi-sterile working 
conditions. First, an overnight culture was prepared. For this purpose, 10 µl of E. coli 
suspension of a glycerin stock was used to inoculate 10 ml of sterile LB medium in 13 ml round 
bottom tubes with push caps and the bacterial suspension was incubated at 37°C with vigorous 
shaking (150 rpm) over night. The next day, 100 µl of overnight culture were used to inoculate 
100 ml of sterile LB medium in a 250 ml Erlenmeyer flask. The bacterial culture was incubated 
at 37°C with vigorous shaking (110 rpm) and the growth was monitored by measuring the 
absorbance at 600 nm (OD600). When the OD600 reached 0.4-0.6, the bacterial culture was 
chilled for 10 min on ice in order to stop the growth of the culture in its exponential phase. The 
bacterial cells were then harvested by centrifugation for 10 min at 2700 x g at 4°C. The cell 
pellet was resuspended in 60 ml of ice-cold solution containing 80 mM MgCl2 and 
20 mM CaCl2. After centrifugation for 10 min at 2700 x g at 4°C, the supernatant was decanted 
and the tube was inverted to remove all traces of the liquid. In a subsequent step, the cell pellet 
was resuspended in 4 ml of ice-cold 100 mM CaCl2 solution. After adding 140 µl of sterile 
DMSO, the solution was immediately mixed by inverting and was placed for 15 min on ice. 
Finally, the suspension was dispensed in single-use aliquots and quick-frozen in liquid 
nitrogen. The chemically competent cells were placed at -80°C for long-term storage. 
 
Transformation of competent E. coli  
Competent E. coli were transformed using a ligation mix (see 3.3.7.) or plasmid DNA 
(Sambrook et al. 1989). Accordingly, 1 µl of ligation mix or approximately 20 ng of plasmid 
DNA was added to 50 µl of competent E.coli, which were thawed on ice. Notably, E.coli DH1 
were utilized for the transformation with the ligation mix due to the higher transformation 
efficiency as compared to E.coli Sure cells which lack endonuclease. The latter cells were used 
for transformation of AAV CMV/MLC0.26 vectors to avoid recombination processes by the 
inverted terminal repeats (ITRs). After incubation of E.coli for 45 min on ice, the cells were 
subject to heat shock for exactly 2 min at 42°C and chilled on ice followed by the addition of 
200 µl of pre-warmed sterile LB medium. Next, the solution was shaken (350 rpm) for 90 min 
at 37°C before plating on LB agar plates containing the selective antibiotic ampicillin (0.1 
mg/ml). The cultures were incubated up-side down over night at 37°C  
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Propagation of positively transformed colonies 
Distinct colonies which formed on agar plates (positively transformed bacteria containing 
ampicillin resistance gene) were singly selected to inoculate 9 ml of sterile LB medium 
containing 0.1 mg/ml ampicillin in 13 ml round bottom tubes with push caps. The cell 
suspension was incubated at 37°C with vigorous shaking (150 rpm) over night to propagate 
potentially positively transformed colonies (Sambrook et al. 1989). 
 
Preparation of plasmid DNA by alkaline lysis according to Birnboim and Doly (1979)  
The plasmid DNA, prepared according to the protocol of Birnboim and Doly (1979), was used 
for the verification of the insertion by restriction digestion (Birnboim et al. 1979). In contrast, 
the plasmid DNA was prepared utilizing specific kits for all other applications e.g. sequencing 
or subcloning. 
For the purpose of preparing plasmid DNA by alkaline lysis, 1.5 ml of the overnight bacterial 
culture were harvested by centrifugation for 20 s at ~20.000 x g at 4°C. After decanting the 
supernatant, the cell pellet was resuspended in 100 µl of ice-cold alkaline lysis solution I. Then, 
200 µl of alkaline lysis solution II and 150 µl of alkaline lysis solution III were added. The 
suspension was inverted after the addition of each solution and was incubated for 5 min on 
ice. After centrifugation for 5 min at ~20.000 x g at 4°C, the supernatant was transferred to a 
new 1.5 ml tube and the DNA was precipitated by the addition of 2 volumes of 100% ethanol 
followed by 2 min incubation on ice. The solution was then centrifuged for 5 min at ~20.000 x g. 
The DNA pellet was washed by adding 1 ml of 70% ethanol and centrifugation for 2 min at 
~20.000 x g. After decanting the supernatant, the DNA pellet was air-dried for 5-10 min at RT 
and was dissolved in 30 µl of buffer TE.  
 
Preparation of purified plasmid DNA 
Purified plasmid DNA, subsequently used for sequencing and subcloning, was prepared using 
the QIAprep spin miniprep kit. For this purpose, 8 ml of overnight bacterial culture was 
harvested by centrifugation for 10 min at 6800 x g at 4°C. Subsequently, the plasmid DNA was 
purified according to manufacturer’s instructions. 
 
Preparation of glycerol stocks for long-term storage 
Glycerol stocks of colonies harboring the desired insert were prepared for long-term storage. 
For this purpose, 520 µl of sterile 87% glycerol solution were added to 420 µl of overnight 
bacterial culture and carefully mixed by inverting. The glycerol stocks were stored at -80°C. 
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3.3.9 Sequencing  
Sequencing was used to verify the inserted sequence (‘AAV sequencing primers’) as well as 
the integrity of the ITR’s (‘AAV ITR primers’) of the AAV CMV/MLC0.26 vectors and was carried 
out by Seqlab - sequence laboratories Göttingen GmbH. 
 
3.3.10 Preparation of AAV CMV/MLC0.26 β1i vector for packaging into AAV particles 
AAV CMV/MLC0.26 β1i or Renilla Luciferase (provided by Dr. O. Müller, Dept. of Internal 
Medicine III, University Clinic Heidelberg) vector, used for packaging into AAV particles, were 
purified utilizing the EndoFree plasmid megaprep kit according to manufacturer’s instructions. 
Large culture volumes were used due to the low copy number of the plasmid. 
Initially, 2 ml of overnight culture of E. coli harboring AAV CMV/MLC0.26 β1i or Renilla 
Luciferase were used to inoculate pre-warmed 2 L of sterile LB medium containing the 
selective antibiotics ampicillin (0.1 mg/ml). The bacterial culture was incubated at 37°C with 
vigorous shaking (110 rpm) and the growth was monitored by measuring the absorbance at 
600 nm. After approximately six to seven hours, the OD600 of 0.8-0.9 was reached revealing 
the end of the exponential phase of growth. Then, the bacterial culture was chilled on ice prior 
to harvesting by centrifugation at 12.000 x g for 10 min at 4°C. The procedure was repeated 
4 times to harvest a sufficient amount of bacterial cells (= 11-12 g wet cell pellet) prior to 
plasmid DNA preparation using EndoFree plasmid megaprep kit in conjunction with the  
plasmid DNA isolation procedure according to the protocol of Birnboim and Doly (Birnboim et 
al. 1979). 
Briefly, the plasmid DNA was isolated according to the protocol of Birnboim and Doly (Birnboim 
et al. 1979). For this purpose, the cell pellets were resuspended in 180 ml of ice-cold alkaline 
lysis solution I and were transferred to a 1 L bottle. In subsequent steps, 180 ml of alkaline 
lysis solution II and 180 ml of alkaline lysis solution III were added. The suspension was 
inverted after the addition of each solution and was incubated for 10 min on ice. The bacterial 
lysate was then centrifuged for 5 min at 9.000 x g at 4°C. After pooling the supernatant in a 2 L 
bottle, the DNA was precipitated by adding 2 volumes of 100% ethanol and incubated for 
20 min on ice. Next, the precipitated DNA was pooled into one 50 ml tube by centrifugation for 
5 min at 10.000 x g at 4°C. The DNA pellet was washed by adding 40 ml of 70% ethanol, 
centrifuged for 5 min at ~15.000 x g at 4 °C and air-dried overnight at RT. Finally, plasmid DNA 
was purified using the EndoFree plasmid megaprep kit according to manufacturer’s 
recommendations. 
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The presence of the gene of interest as well as the integrity of the ITR’s of the AAV 
CMV/MLC0.26 β1i or Renilla Luciferase vector, used for packaging in AAV particles, was 
checked by restriction digestion and sequencing prior to packaging in AAV particles. 
 
3.4 Protein biochemical methods 
3.4.1 Protein extraction 
Protein extraction from cell pellets 
The total protein extraction from cells was performed using a modified protocol for protein 
extraction from heart tissue (Drews et al. 2010). For this purpose, cell pellets (6-well; 5 x 105 
cell / well sub-cultured; 48 hours after AAV infection) were thawed on ice and homogenized in 
100 µl of freshly prepared homogenization buffer containing 1 mM DTT and a spatula tip of  
sea sand (higher shear force) using a hand-held homogenizer (1.5 ml tube specificity) by 
turning the pestle 20 times. The cell homogenate was then centrifuged for 30 min at 
~20.000 x g at 4°C. The supernatant fraction containing the proteins was transferred to a new 
tube and stored at -20°C and the cell debris pellet was discarded.  
 
Protein extraction from hearts 
The total protein was extracted from mouse hearts in accordance with previously published 
protocols (Drews et al. 2010). Notably, all solutions and equipment were pre-cooled to 4°C. 
First, the frozen heart was homogenized in 1.5 ml of freshly prepared homogenization buffer 
(containing 1mM DTT, 1% (v/v) phosphatase inhibitor cocktail II, 1% (v/v) phosphatase 
inhibitor cocktail III) using a Tenbroeck hand-held homogenizer by turning the pestle 20 times. 
The supernatant (= crude extract) was carefully removed after centrifugation for 1 min at 
500 x g at 4°C to remove the cell debris. Following this, the crude extract was ultracentrifuged 
for 1 h at 100.000 x g at 4°C. Finally, the supernatant (= heart homogenate) was transferred 
to a new 1.5 ml tube. The solution amount necessary for 26S activity assays and active site 
labeling was kept on ice. Aliquots of the remaining homogenate were quick-frozen in liquid 
nitrogen and stored at -20°C. Notably, 1% (w/v) protease inhibitor cocktail was added to the 
homogenates which were not used for proteasome activity assays or active site labeling prior 
to freezing. 
 
3.4.2 Determination of protein concentration – Bradford assay 
The protein concentration was determined utilizing the Bradford reagent according to 
manufacturer’s recommendations. This assay is based on the shift in the absorbance 
maximum to 595 nm when the Coomassie dye reacts with basic or aromatic amino acid 
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residues (solution turns blue). Moreover, the absorbance at 595 nm is proportional to the 
protein concentration over a broad dynamic range. A standard curve using 0, 20, 40, 60, 80, 
100, 120, 140, 160,180 and 200 µg of BSA per ml was utilized to determine the protein 
concentration of the samples. The Bradford assay was performed in a 96-well plate. For this 
purpose, 100 µl of Bradford reagent was added to 10 µl of protein solution. After 5 min 
incubation at RT, the optical density (OD) was measured at 595 nm using the Powerwave Xs 
microplate spectrophotometer. 
 
3.4.3 Proteasome activity assays 
Proteasome activity was analyzed according to previously published protocols (Drews et al. 
2010). The 26S proteasome activities were measured on the day of heart homogenization, 
given the remarkable decline of 26S proteasome activities due to freezing. In addition, the 20S 
proteasome activities were commonly analyzed up to one day following heart homogenization 
due to the decline of 20S proteasome activity with increasing storage time of the homogenate. 
The 26S or 20S caspase-, trypsin- or chymotrypsin-like activities were analyzed using 0.1mM 
fluorescently tagged substrates Z-LLE-AMC, Boc-LSTR-AMC or Suc-LLVY-AMC, 
respectively, for 25 µg of total protein homogenate. All samples were measured in triplicates 
and the total reaction volume was 100 µl. In addition, all activities were analyzed in the absence 
and presence of a specific proteasome inhibitor. In accordance with the analyzed proteasome 
activity, 10 µM epoxomicin, 20 µM epoxomicin or 30 µM Z-Pro-Nle-Asp-H inhibitor was used 
to inhibit chymotrypsin-, trypsin- or caspase-like activity, respectively. The ATP-dependent 26S 
activities were analyzed in homogenization buffer after the addition of 50 µM ATP. In contrast, 
the 20S activity assays were performed in specific buffers containing low amounts of 
detergents. For this purpose, the 20S caspase- and trypsin-like activity buffer and the 20S 
chymotrypsin-like activity buffer were prepared as 10x stock solutions (stored at -20°C) in order 
to adjust the buffer conditions in the 20S activity assays. Moreover, a standard curve using 
100, 275, 600, 1250 and 2500 nM free AMC was prepared to calculate the substrate turnover 
rate. 
First, the required buffer conditions were created by applying 80 µl of buffer per well in a black 
96-well plate. Then, 10 µl of 2.5µg/µl heart homogenate solution was added and incubated for 
30 min at RT in the dark to facilitate inhibition of the specific proteasome activity in sample 
mixtures containing proteasome inhibitors for measuring non-proteasomal background activity. 
After pre-equilibration for 15 min on ice, 10µl of 1mM fluorescently tagged substrate was added 
using a multistep pipette. Finally, the release of AMC was measured at 37°C using the 
fluorometer Fluoroskan Ascent at an excitation wavelength of 390 nm and an emission 
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wavelength of 460 nm for up to 90 min using a measurement interval of 5 min. The measured 
signal was integrated over 20 ms. 
The time was plotted against the emission values to evaluate the proteasomal activity. The 
substrate turnover rate (pmol/[mg*min]) was calculated from the linear phase of the curve for 
each sample using the AMC standard curve. Non-proteasomal activities measured in the 
presence of specific proteasome inhibitors were subtracted. 
3.4.4 Active site labeling of proteolytic proteasome subunits 
The incorporation of proteolytic β-subunits into active proteasome complexes was investigated 
using the activity based probes MV151 (Verdoes et al. 2006) or MVB003 (Florea et al. 2010). 
These proteasome-specific and fluorescently-tagged inhibitors label proteolytic β-subunits in 
native 26S and 20S proteasomes and were kindly provided by Dr. B. Florea and 
Prof. H. Overkleeft (Institute of Chemistry, University of Leiden, NL). Notably, the active site 
labeling was performed on the day of heart homogenization given the remarkable decrease of 
the 26S proteasome activity due to freezing. Proteolytic proteasome subunits were labeled 
using 25 µg of total protein and 1µM activity based probe MV151 or MVB003, respectively for 
the total reaction volume was 20 µl. The active site labeling was performed in homogenization 
buffer after the addition of 1 mM DTT and 50 µM ATP. In addition, the active site labeling was 
performed in the presence and absence of the specific proteasome inhibitor bortezomib to 
ensure that the detected bands correspond to the proteolytic β-subunits. For this purpose, 
0.1 µM bortezomib was used to inhibit proteasomal activity. First, the required buffer conditions 
were established in a total volume of 6 µl. Then, 10 µl of 2.5 µg/µl heart homogenate solution 
was added and incubated for 1 h on ice to inhibit the specific proteasome activity. Finally, the 
proteolytic β-subunits were labeled by adding 2 µl of 10 µM MV151 or MVB003 solution and 
incubated for 1 h at 37°C. After polyacrylamide gel electrophoresis (PAGE) (see 3.4.4.), the 
β-subunits were visualized and documented using the Pharos FXTM Plus Molecular Imager at 
an excitation wavelength of 532 nm and an emission wavelength of 605 nm. The band 
intensities were analyzed using the QuantityOne software and normalized to the total protein 
staining using ruthenium. 
 
3.4.5 Luciferase activity assay 
The enzymatic activity of the Renilla luciferase in the β1i knockout mice injected with AAV9 
CMV/MLC0.26 luciferase was analyzed in triplicates utilizing the Renilla-Glo luciferase assay 
system according to manufacturer’s recommendations. For this purpose, the crude extracts of 
the hearts (without ultracentrifugation) were used, stabilized by the addition of 1% (w/v) 
protease inhibitor cocktail. In addition, all samples were diluted in homogenization buffer 
(1:20), incubated for 15 min on ice as well as pre-equilibrated for 15 min at RT before the 
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Renilla luciferase assay reagent was added. These additional steps were performed given that 
isoflurane, used for the anesthesia of the mice, inhibits the Renilla luciferase activity (Keyaerts 
et al. 2012). Accordingly, preliminary experiments revealed the increase in the Renilla 
luciferase activity due to the reduced effect of the inhibitor when the crude extracts were diluted 
and incubated for a prolonged time period. The luminescence was measured using the 
MicroLumat LB 96 P after the addition of 100 µl of Renilla luciferase assay reagent per 
100 µl of 1:20 diluted sample in black 96-well plates and 10 min incubation at RT. The 
measured signal was integrated over 10 s. The AAV β1i treated samples were utilized for 
background correction of the AAV Luci treated samples. In addition, the Renilla luciferase 
activity was normalized to the total protein utilized in the assay. 
 
3.4.6 Western blot analysis 
The Western blot analysis is a routine technique to analyze the abundance of a protein in a 
sample (Hames 1998). First, the proteins are separated by their size using polyacrylamide gel 
electrophoresis (PAGE). For this purpose, 25 µg of total protein were denatured by adding 
5x protein loading buffer and incubation for 5 min at 95°C. The lysates were loaded onto a 
polyacrylamide gel (in general 13% resolving and 6% stacking gel) that was subject to 100 V 
for 2-2.5 h. Notably, the precision plus protein dual color standard was used to estimate the 
molecular weight of the separated proteins. After electrophoresis, the proteins were blotted 
onto a nitrocellulose membrane using the semi dry TransBlot turbo transfer system for 1 h at 
25V and 400 mA according to manufacturer’s recommendations. Following this, the membrane 
was air-dried for 30 min. The membrane was then stained with Ponceau S solution for 5 min 
after rehydration to visualize the proteins. Subsequently, the membrane was scanned and 
documented. After destaining in water or TBST, the unspecific binding sites were blocked using 
5% (w/v) milk solution for 1 h at RT or overnight at 4°C. Finally, the protein of interest was 
detected using a specific primary antibody (see 2.12.1.) in combination with a horseradish 
peroxidase (HRP) -conjugated secondary antibody (see 2.12.2.) according to manufacturer’s 
recommendations. The primary and secondary antibodies were diluted in 5% (w/v) milk 
solution and applied for 4 h at RT or overnight at 4°C (primary antibody) or 1 h at RT (secondary 
antibody). After the application of ECL prime chemiluminescent substrate for 5 min at RT the 
emitted light was detected using the Image QuantLAS 4000 mini system. The band intensities 
were analyzed using the Image QuantLAS 4000 mini software and normalized to total protein 
staining using Ponceau S. 
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3.4.7 Proteome analysis 
2D gel electrophoresis 
The 2D gel electrophoresis (2D GE) was performed according to published protocols (Drews 
et al. 2007). First, the samples were isoelectric focused using the IPGphor. This was performed 
according to a modified protocol of Gorg et al. using 18 cm, pH 3-10 IPG strips (Gorg 2004). 
Accordingly, 200 µg of precipitated protein was resuspended in 350 µl buffer containing 
8 M (w/v) urea, 0.1% (w/v) CHAPS, 0.2% (w/v) DTT and 0.5% (v/v) Pharmalytes 3-10 for in 
gel rehydration at 30 V for 11 h. The voltage was gradually increased from 150 V, 300 V to 
600 V every 60 min. Subsequently, the voltage was increased to 3500 V within 30 min. The 
steady state of the isoelectric focusing was reached after 18 kV-h at 3500 V. The second 
dimension was facilitated on 12% acryl amide gels. Prior to loading, the samples were 
equilibrated according to previously published protocols (Gorg et al. 1988). Finally, the 
separated proteins were visualized by ruthenium staining. Precipitation, 2D GE, staining and 
laser densitometry were kindly performed by Dr. O. Drews, Anita Kühner and Mathilde Lorenz 
(Dept. of Cardiovascular Physiology, University Heidelberg). Spot volumes were quantified 
using the QuantityOne analysis software. 
Proteins were compared to published reference gels of a cardiac proteome database 
(HP-2DPAGE: http://web.mpiib-berlin.mpg.de/hp-2dpage/heart1.html). 
 
Total protein staining using ruthenium 
After one or two-dimensional gel electrophoresis, proteins were stained using a ruthenium 
complex. First, the gels were fixed using fixation solution containing 40% (v/v) ethanol and 
10% (v/v) acetic acid on a shaker for 6 h or overnight. Following this, the gels were washed 
two times in 20% ethanol on a shaker for 30 min. After complete removing of the washing 
solution, the proteins were stained using 1 µM ruthenium(II)-tris-(bathophenanthroline-
disulphonate) (RuBP) in deionized water on a shaker in the dark for 6 h or overnight. The gels 
were then washed two times in deionized water in the dark for 15 min. Finally, the gels were 
destained in fixation solution on a shaker in the dark for 6 h or overnight. The Proteins were 
visualized and documented using Pharos FXTM Plus Molecular Imager at an excitation 
wavelength of 488 nm and an emission wavelength of 605 nm. The band intensities were 
analyzed utilizing the QuantityOne analysis software and normalized to total protein staining. 
The molecular weight of the separated bands or spots were estimated by the utilization of the 
protein standard from the same gel.  
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3.5 Immunochemical methods 
3.5.1 Immunofluorescence analysis 
The localization as well as the abundance of various proteins was analyzed using 
immunofluorescence staining of cells or heart tissue cryosections (7 µm), which were prepared 
on glass slides using the microtome HM 500 O microtome cryostat and air-dried for 30 min at 
RT (Bancroft et al. 2008c). The preparation of the cryosections was kindly performed by Anita 
Kühner (Dept. of Cardiovascular Physiology, University Heidelberg). Endogenous mouse IgG 
were blocked using anti mouse Fab fragments when primary mouse antibodies were used in 
NRCMs or mouse heart tissue to prevent unspecific staining of the fluorescent-labeled 
secondary antibodies.  
First, the cells or 7µm heart tissue cryosections were fixed according to the scheme outlined 
below. 
 fixative incubation time 
HEK-293 cells isofix 30 min on ice 
NRCMs 4% paraformaledhyde and 4% 
sucrose in PBS 
10 min at RT on shaker 
heart tissue cryosections 4% paraformaldehyde in PBS 30 min at RT 
 
After washing the samples three times for 5 min in 1x PBS, the cells were permeabilized by 
adding 0.2% (w/v) TritionX-100 in PBS for 10 min at RT. Then, the unspecific binding sites 
and, if necessary, the endogenous moue IgG were blocked using the solutions listed below. 
- unspecific binding sites: 
 blocking solution incubation time 
cells 5% (w/v) BSA in PBS 30 min at RT on shaker 
heart tissue cryosections 2% (v/v) goat serum in 0.1% (w/v) 
TritonX-100 in PBS 
2h at RT 
 
- endogenous mouse IgG: 
 blocking solution incubation time 
cells 1:13 diluted Fab goat anti-mouse 
in 0.1% (w/v) BSA / 0.25% (w/v) 
casein in PBS 
1h at RT  
heart tissue cryosections 1:13 diluted Fab goat anti-mouse 
in 1% (v/v) goat serum in 0.05% 
(w/v) TritonX-100 in PBS 
overnight at 4°C 
 
Following this, the protein of interest was detected using a specific primary antibody 
(see 2.12.1.) in combination with a fluorescently tagged secondary antibody (see 2.12.2.) 
according to manufacturer’s recommendations. In contrast, β1i and β1 was detected in cells 
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using a cascade of the β1i specific primary antibody, a biotin conjugated secondary antibody 
and Cy3 conjugated streptavidin binding to the biotin molecules to amplify the signal. The 
antibodies as well as the Cy3 conjugated streptavidin were diluted in the same solutions listed 
in the scheme above for blocking the endogenous mouse IgG and were applied for 20 min to 
2h at RT in the dark. The samples were washed three times for 5 min in PBS after each 
incubation step. Next, the nuclei were stained by the application of 2 mg/ml DAPI stock solution 
diluted 1:5000 in PBS for 10 min at RT. Finally, the samples were mounted in mowiol and a 
coverslip was applied. The Olympus IX81 microscope and Exellence RT software was used 
for the analysis. Notably, EGFP expression and localization in NRCMs upon AAV6 CMV/MLC 
EGFP infection was analyzed on the Olympus IX81 microscope using the FITC filters (λex 460-
480nm, λem 495-540nm, 484 beamfilter).  
 
3.5.2 Histological staining of heart cryosections 
Apart from immunofluorescence staining, histological staining of heart cryosections was used 
for the analysis of the cardiomyocyte size (HE staining) (Bancroft et al. 2008a) or fibrosis 
(Masson’s trichrome staining) (Bancroft et al. 2008b). 
 
Hematoxylin and eosin (HE) staining 
For this purpose, 7 µm heart cryosections were prepared using the microtome HM 500 O 
microtome cryostat on glass slides and were air-dried for 30 min at RT. In the next step, the 
nuclei were stained by incubation in Mayer’s hematoxylin solution for 8 min and rinsed in 
running tap water (= bluing) for 10 min. After rinsing in deionized water, the counterstaining 
was performed by applying 0.1% (w/v) eosin solution for 5 min. Subsequently, the cryosections 
were washed 3 times in deionized water for 1 min. Finally, the tissue was dehydrated through 
one-minute incubation in 70%, 85%, 96% ethanol and isopropanol respectively and two times 
incubation in xylol for 2 min. Following this, the cryosections were mounted in Eukitt and a 
coverslip was applied. The HE staining was kindly performed by Anita Kühner (Dept. of 
Cardiovascular Physiology, University Heidelberg). 
The HE staining results in a dark blue stained nuclei and non-nuclear structures which are 
colored in various shades of red. The cross-sectional area was quantified using the ImageJ 
software. 
 
Masson’s trichrome staining 
Similarly to the HE staining described previously, 7 µm heart cryosections were prepared using 
the microme HM 500 O microtome cryostat and were air-dried for 30 min at RT on glass slides. 
Then, the tissue was fixed via incubating in 4% paraformaldehyde in PBS for 1 h. After washing 
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3 times in deionized water for 1 min, the cryosections were incubated in Bouin’s mordant 
overnight. On the next day, the tissue was rinsed in running tap water until the yellow color 
was removed. Following this, the cryosections were stained in Weigert’s hematoxylin solution 
and Biebrich Scarlet acid fuchsin solution for 10min each. The tissue was then stained in 
aniline blue solution for 5 min after acidification in freshly prepared phosphotungstic-
phosphomolybic acid solution for 10 min. Finally, the cryosections were transferred in 1% 
acetic acid solution for 2 to 5 min. In addition, the samples were washed in deionized water 
after each staining step. Next, the tissue was dehydrated in a one-minute incubation in 70%, 
85%, 96% ethanol and isopropanol respectively and two times incubation in xylol for 2 min. 
Finally, the cryosections were mounted in Eukitt and a coverslip was applied. The Masson’s 
trichrome staining was kindly performed by Anita Kühner (Dept. of Cardiovascular Physiology, 
University Heidelberg). 
Following the Masson’s trichrome staining the nuclei are stained in black, the collagen is 
stained in blue, the muscle fibers and the cytoplasm are dyed in red. The ImageJ software was 
used to measure the area of collagen. 
 
3.6 Statistical analysis 
A two-tailed student’s t-test with unequal variance was used for the statistical analysis (Bonner 
et al. 2011). In this test, the probability of the occurrence of the null hypothesis is calculated. 
The null hypothesis implies the comparability of the data sets. A high p value (p > 0.1) confirms 
the null hypothesis. In contrast, a low p value (p < 0.05) refutes the null hypothesis. Thus, the 
data sets are considered to be significantly different (p < 0.05 = significant; p < 0.01 = highly 
significant). 
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4 Results 
4.1 Cardiac-specific β1i reintroduction via adeno-associated virus 
A cardiac tissue-specific expression vector harboring the β1i gene was constructed to 
reintroduce β1i into the heart of β1i knockout mice via serotype 9 of adeno-associated virus 
(Figure 9). 
 
 
Figure 9. Scheme of AAV CMV/MLC0.26 β1i vector.  
Schematic illustration of the β1i vector construct containing a genetically engineered promoter 
consisting of parts of the viral cytomegalovirus (CMVenh) immediate-early gene promoter and a 
fragment of the tissue-specific myosin light chain promotor (MLC0.26) as well as the β1i gene within 
the inverted terminal repeats (ITR). 
 
Given the absence of a commercially available β1i clone which exhibits perfect 
complementarity to the β1i gene of C57BL/6J wild type mice, the initial task within this project 
was to isolate and clone the β1i gene (660 bp) from Mus musculus (strain C57BL/6J). For this 
purpose, the total RNA was extracted from the liver of C57BL/6J mice and the β1i gene was 
amplified via PCR using the ‘β1i direct primers’ after reverse transcription (Figure 10A). 
Subsequently, the β1i gene was introduced into the pBlueScript II SK(+) vector after restriction 
digestion using SmaI via blunt end ligation (Figure 10B) in order to use one clone with verified 
β1i sequence for further processing. In a subsequent step, an AgeI restriction site as well as 
the Kozak sequence were inserted upstream and a BsrGI restriction site downstream of the 
β1i gene by PCR using ‘β1i overhang primers’ (Figure 10C).  
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Figure 10. AAV CMV/MLC0.26 β1i vector construction. 
(A) The β1i gene (660 bp) from C57BL/6J wild type mice was amplified via PCR after isolation of total 
RNA from the liver and cDNA synthesis. (B) The insertion of β1i in the pBlueScript II SK(+) vector via 
blunt end ligation was verified by HindIII (5’ end) and BamHI (3’ end) digestion indicating two distinct 
bands corresponding to β1i (684 bp) and the pBlueScript II SK(+) backbone (2925 bp) in lane 1 as 
compared to the empty vector (lane C). (C) Subsequently, the Kozak sequence and an AgeI and 
BsrGI restriction site was introduced by PCR using ‘β1i overhang primers’ (lane 2). (D) The successful 
insertion of the extended β1i sequence in the pSP72 vector via blunt end ligation was verified by AgeI 
(5’ end) and BsrGI (3’ end) digestion indicating two distinct bands corresponding to β1i (666 bp) and 
the pSP72 backbone (2462 bp) in lane 3. (E) In the last step, the β1i gene was subcloned into the 
AAV CMV/MLC0.26 vector via the AgeI and BsrGI restriction sites. Using these restriction enzymes, 
two distinct bands were revealed, corresponding to β1i (666 bp) and the AAV CMV/MLC0.26 
backbone (5312 bp) in lane 4. (R = β1i direct PCR product) 
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The extended β1i gene was further introduced into a vector after restriction digestion using 
SmaI via blunt end ligation for sequence verification. For this purpose, the pSP72 vector was 
used in parallel to the pBlueScript II SK(+) vector, given the low transformation efficiency using 
the pBlueScript II SK(+) vector in the previous blunt end ligation. In accordance with this 
previous result, a clone containing the correct extended β1i sequence was obtained using the 
pSP72 vector. Initially, the insertion of the extended β1i sequence in the pSP72 vector was 
analyzed via BamHI digestion (Figure 11). The successful introduction of the insert resulted in 
an increase in size of the linearized vector (Figure 11). Subsequently, the insertion of the 
extended β1i sequence in the pSP72 vector was verified by AgeI (5’ end) and BsrGI (3’ end) 
digestion indicating two distinct bands corresponding to β1i and the pSP72 backbone 
(Figure 10D). Finally, the β1i gene was subcloned into the AAV CMV/MLC0.26 vector through 
the AgeI and BsrGI restriction sites (Figure 10E). 
 
 
Figure 11. Representative image of BamHI digested clones. 
The insertion of the extended β1i sequence in the pSP72 vector via blunt end ligation resulted in an 
increase in size of the linearized vector after BamHI digestion (R = empty pSP72 vector [2462 bp]). 
In accordance, clones 2 and 3 contained no insert, whereas clones 1, 4-7 and 9-17 contained the 
extended β1i sequence. In contrast, clone 8 potentially contained two inserts. After AgeI and BsrGI 
digestion, clone 13 was used for subcloning into the AAV CMV/MLC0.26 vector (Figure 10E). 
 
4.2 Infection of HEK-293 cells using the AAV CMV/MLC0.26 β1i vector construct led 
to correct expression of β1i at an elevated level 
The initial task was to verify the correct expression of β1i using the AAV CMVenh/MLC0.26 β1i 
vector construct. For this purpose, the abundance of β1i was analyzed on the mRNA and 
protein levels in HEK-293 cells after AAV2 CMV/MLC0.26 β1i infection. The 
AAV CMV/MLC0.26 β1i vector was packaged into AAV2 instead of AAV9 virus particles due 
to the higher infection efficiency of the former (O. Müller, personal communication). 
The mRNA and protein abundance of β1i was increased 2.6-fold and 1.6-fold, respectively, 
48 hours after infection of the HEK-293 cells using AAV2 CMV/MLC0.26 β1i at a MOI of 103 
(Figure 12A, C). The infection efficiency of AAV2 virus particles was not analyzed at this stage. 
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Figure 12. Analysis of β1i expression 48 hours post 
AAV2 CMV/MLC0.26 β1i infection of HEK-293 cells. 
(A) Analysis of β1i mRNA expression 48 hours post 
infection of HEK-293 cells at a MOI of 103 as 
analyzed by semi-quantitative PCR. n=3. 
(B) Ponceau S staining of the nitrocellulose 
membrane before Western blot shown in C. 
(C) Analysis of β1i protein abundance 48 hours post 
infection of HEK-293 cells at a MOI of 103 as 
analyzed by β1i Western blot analysis. n=3. 
 
4.3 Immunofluorescence analysis revealed increased β1i abundance in 
cardiomyocytes after AAV6 CMV/MLC0.26 β1i infection 
Primary neonatal rat cardiomyocytes (NRCMs) were chosen to analyze β1i abundance in 
cardiomyocytes via immunofluorescence staining after AAV6 CMV/MLC0.26 β1i infection. The 
advantage of NRCMs as compared to HEK-293 cells was the higher degree of similarity to the 
in vivo conditions. The primary cells isolated from the hearts of neonatal rats were composed 
of cardiomyocytes and other cells (e.g. fibroblasts). Thus, the initial task was to identify the 
cardiomyocytes. Close to 80% of the cells were identified as cardiomyocytes according to 
α-actinin staining (Figure 13A). Infection efficiency was approximately 50% using 
AAV6 CMV/MLC0.26 EGFP at a MOI of 105 for 48 hours (Figure 13B). Moreover, the α-actinin 
staining of AAV6 CMV/MLC0.26 EGFP infected NRCMs revealed a rather specific infection of 
the cardiomyocytes using AAV6 virus particles (Figure 13B).  
Due to the lower titer of vector genomes in the AAV6 CMV/MLC0.26 β1i batch, the MOI was 
lowered while the exposure time was simultaneously extended to 72 hours. Thus, β1i gene 
transfer was investigated by immunofluorescence analysis after infection of the NRCMs with 
AAV6 CMV/MLC0.26 β1i at a MOI of 104 for 72 hours. The number of β1i-positive cells was 
increased in AAV6 CMV/MLC0.26 β1i infected cells in relation to untreated cells. In the virus 
control, the number of β1i-positive cells was found to be increased after 
AAV6 CMV/MLC0.26 EGFP infection as compared to the untreated control cells 
(Figure 13C, E). This increase in β1i may be attributed to cellular stress due to strong EGFP 
overexpression suggesting that EGFP is an unsuitable control for in vivo gene transfer. 
AAV6 CMV/MLC0.26 β1i or EGFP infection did not influence expression of the proteasomal 
β1 subunit, the constitutive counterpart of β1i, in relation to the untreated cells (Figure 13D, E). 
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Figure 13. Increased β1i 
abundance in isolated 
cardiomyocytes after AAV6 
CMV/MLC0.26 β1i infection of 
NRCMs. 
(A) Representative image of 
NRCMs. Cardiomyocytes were 
stained by α-actinin staining. 
Other cells (e.g. fibroblast) are 
indicated by the arrow. 
 
(B) Infection efficiency of the 
construct in cultured NRCMs was 
analyzed by using AAV6 
CMV/MLC0.26 EGFP at a MOI of 
105 for 48 hours. Cardiomyocytes 
were stained for α-actinin. n=3. 
 
(C) Analysis of the number of β1i 
positive cells 72 hours after 
infection of NRCMs using AAV6 
CMV/MLC0.26 β1i or EGFP at a 
MOI of 104. n=3. 
 
(D) The number of β1-positive 
cells was analyzed 72 hours after 
infection of NRCMs using AAV6 
CMV/MLC0.26 β1i or EGFP at a 
MOI of 104. n=3. 
 
(E) Statistical analysis of the 
number of β1i (C) or β1 (D) 
positive cells 72 hours after  
infection of NRCMs using AAV6 
CMV/MLC0.26 β1i or EGFP at a 
MOI of 104. MeanSD. 
** p<0.01 vs. control cells. n=3. 
 Results 
 62 
4.4 Reintroduction of β1i into β1i-deficient mice reduced cardiac remodeling and 
improved cardiac function following isoprenaline treatment 
Initially, the correct expression of β1i after AAV9 CMV/MLC0.26 β1i (AAV β1i) injection (i.v.) 
into β1i knockout mice was analyzed in heart homogenates by Western blot analysis. 
The proteasome subunit β1i was not detected in hearts of untreated β1i knockout mice 
(Figure 14). On the contrary, AAV9-based reintroduction of β1i into β1i-deficient animals was 
revealed by detection of β1i via Western blot analysis (Figure 14). In addition, two bands 
corresponding to β1i were observed in β1i knockout mice upon AAV β1i injection (Figure 14). 
The abundance of β1i in AAV β1i-injected β1i-deficient mice was similar as in untreated wild 
type animals (Figure 14). In contrast, abundance of β1i was increased following 7 days of 
isoprenaline treatment in AAV β1i-injected β1i knockout mice as compared to AAV β1i-treated 
β1i-deficient animals without exposure to a pro-hypertrophic stimulus (Figure 14). 
 
 
Figure 14. Successful β1i reintroduction into 
β1i knockout mice after AAV β1i injection. 
The abundance of β1i (highlighted in blue and red) 
was analyzed by Western blot analysis in heart 
homogenates of untreated wild type (WT) or β1i 
knockout (KO) mice as well as in AAV β1i-injected 
β1i-deficient mice without (β1i) or with exposure to 
isoprenaline for 7 days (β1i Iso). 
 
After demonstrating the functional expression of β1i using the AAV CMVenh/MLC0.26 β1i vector 
construct, the effect of β1i reintroduction on the development of isoprenaline-induced cardiac 
hypertrophy was investigated in β1i-deficient mice. For this purpose, cardiac morphology and 
function was analyzed by echocardiography prior to and post induction of hypertrophy by 
isoprenaline treatment in AAV9 CMV/MLC0.26 β1i (AAV β1i) or AAV9 CMV/MLC0.26 
luciferase (AAV Luci) injected β1i knockout mice. 
Echocardiographic analysis of the cardiac morphology in the parasternal long axis view in 
M-mode indicated no significant differences between AAV β1i or AAV Luci-injected 
β1i-deficient mice prior to treatment with isoprenaline (Figure 15, 16; Table 1).  
In contrast, echocardiographic analysis revealed an increase in left ventricular posterior wall 
thickness in diastole in AAV Luci and AAV β1i-injected mice indicating the development of 
cardiac hypertrophy in both groups after 7 days of isoprenaline treatment (Figure 16A). 
Notably, the increase in left ventricular posterior thickness in diastole was higher in AAV Luci 
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as compared to AAV β1i-injected β1i-deficient mice upon exposure to isoprenaline 
(Figure 16A).  
 
 
Figure 15. Representative echocardiographic images of the parasternal long axis (PLAX) view. 
Beta1i knockout mice treated with AAV β1i or AAV Luci were analyzed by echocardiography prior to 
(day 1) and post (day 8) induction of hypertrophy by isoprenaline treatment. Cardiac morphology and 
systolic function were investigated in B-mode and M-mode in the PLAX of the heart. Image in M-mode 
corresponds to the movement of the line displayed in B-mode over time. The corresponding ECG 
(green) and the respiration rate (yellow) is displayed below the M-mode images. The left ventricular 
internal diameter (LVID) and left ventricular posterior wall thickness (LVPW) in diastole and systole 
were measured in M-mode. 
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In addition, following treatment with isoprenaline left ventricular posterior wall thickness in 
systole was increased in AAV Luci as well as AAV β1i-injected β1i-deficient mice (Figure 16B). 
Similarly, the elevation of left ventricular posterior wall thickness in systole was higher in 
AAV Luci-treated control mice as compared to AAV β1i-injected β1i-deficient animals 
(Figure 16B). The analysis of left ventricular internal diameter in diastole upon exposure to 
isoprenaline revealed an increase in AAV Luci-injected control mice as well as in β1i-deficient 
mice into which β1i had been reintroduced (Figure 16C). In addition, following 7 days of 
isoprenaline treatment left ventricular internal diameter in systole was increased in AAV Luci 
and AAV β1i-injected β1i-deficient mice (Figure 16D). Notably, this increase was higher in the 
former (Figure 16D). 
 
 
Figure 16. AAV9-based reintroduction of β1i in β1i-deficient mice attenuated the increase in 
left ventricular posterior wall thickness (LVPWT;d) following induction of hypertrophy.  
Cardiac morphology (left ventricular posterior wall thickness (LVPWT) in diastole (LVPWT;d) (A) or 
systole (LVPWT;s) (B), left ventricular internal diameter (LVID) in diastole (LVID;d) (C) or systole 
(LVID;s) (D)) was analyzed in parasternal long axis (PLAX) view in M-mode in AAV Luci or 
AAV β1i-injected β1i knockout mice prior to and post exposure to isoprenaline. * p<0.05, ** p<0.01. 
n=6. 
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The systolic function of the heart was analyzed in the parasternal long axis view in M-mode 
(Figure 17; Table 1). In accordance with the cardiac morphology, systolic function of AAV β1i 
and AAV Luci-injected β1i knockout mice was comparable prior to the initiation of isoprenaline 
treatment (Figure 17).  
 
 
Figure 17. Systolic dysfunction was prevented by β1i reintroduction via 
AAV9 CMV/MLC0.26 β1i in β1i-deficient mice upon induction of hypertrophy. 
Systolic function of the heart (ejection fraction (EF) (A), fractional shortening (FS) (B)), cardiac output 
(CO) (D), stroke volume (SV) (E)) was analyzed in parasternal long axis (PLAX) view in M-mode. In 
addition, the heart rate of AAV β1i or AAV Luci-injected β1i-deficient mice prior to and post 
isoprenaline treatment is indicated in (C). * p<0.05, ** p<0.01. n=6. 
 
Following isoprenaline treatment the analysis of the systolic function revealed a decrease of 
ejection fraction (Figure 17A) and fractional shortening (Figure 17B) in AAV Luci-injected mice 
indicating systolic dysfunction. On the contrary, systolic function upon exposure to isoprenaline 
was not altered after the reintroduction of β1i in β1i-deficient mice (Figure 17A, B). Due to the 
isoprenaline-dependent elevation of heart rate in AAV Luci as well as AAV β1i-treated mice 
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(Figure 17C), the ejected blood volume per minute (cardiac output) was increased in both 
groups albeit less in AAV Luci-treated mice (Figure 17D). The ejected blood volume during 
systole (stroke volume) was unchanged in AAV Luci-injected mice upon experimental 
hypertrophy (Figure 17E). In contrast, the stroke volume was increased following isoprenaline 
treatment in β1i-deficient mice into which β1i had been reintroduced (Figure 17E). 
Furthermore, diastolic function was analyzed in the apical four chamber view using color and 
pulse wave Doppler mode (Figure 18, 19; Table 1). 
 
 
Figure 18. Representative echocardiographic images of the apical four chamber view.  
Echocardiographic analysis of AAV β1i as well as AAV Luci-injected β1i-deficient mice was performed 
prior to (day 1) and post (day 8) exposure to isoprenaline. Diastolic function (E and A value) was 
analyzed using pulse wave (PW) Doppler mode in the apical four chamber view of the heart. For this 
purpose, the sample volume (square) was placed above the mitral valves. The corresponding ECG 
(green) and the respiration rate (yellow) is displayed in the M-mode images below. 
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Analysis of diastolic function indicated no significant differences between AAV β1i and 
AAV Luci-injected β1i-deficient mice prior to exposure to isoprenaline (Figure 18, 19). 
 
 
Figure 19. AAV9 based reintroduction of β1i in β1i knockout mice attenuated changes in the 
E/A ratio following exposure to a pro-hypertrophic stimulus. 
Diastolic function (E value (A), A value (B), E/A ratio (C)) was analyzed in the apical four chamber 
view using pulse wave (PW) and color Doppler mode in AAV β1i or AAV Luci-injected β1i-deficient 
mice prior to and post exposure to isoprenaline. * p<0.05, ** p<0.01. n=6. 
 
After induction of hypertrophy, the passive filling (E value) of the left ventricle was increased 
in both groups (Figure 19A). In contrast, upon isoprenaline treatment the active filling of the 
left ventricle during atrial systole (A value) was elevated in β1i-deficient mice into which β1i 
had been reintroduced, whereas this parameter was unchanged in AAV Luci-injected 
β1i knockout animals (Figure 19B). In consequence, the E/A ratio, commonly used as an 
indicator of diastolic function of the heart, was increased upon exposure to isoprenaline in 
AAV Luci-treated control mice (Figure 19C). In contrast, following induction of hypertrophy the 
E/A ratio remained at a level comparable to pretreatment values in β1i-deficient mice into which 
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β1i had been reintroduced (Figure 19C). Thus, after 7 days exposure to isoprenaline the 
increase in the E/A ratio was higher in AAV Luci-injected as compared to AAV β1i-treated 
β1i knockout mice (Figure 19C).  
 
Table 1. Cardiac remodeling and function was improved by β1i reintroduction in β1i-deficient 
mice upon isoprenaline treatment. 
 view parameter 
AAV β1i 
prior vs. post  
AAV Luci 
prior vs. post  
cardiac  
morphology 
PLAX 
M-mode 
LVPWT;d 
[mm] 
  
LVPWT;s 
[mm] 
  
LVID;d 
[mm] 
  
LVID;s 
[mm] 
  
systolic 
function 
PLAX 
M-mode 
EF 
[%] 
  
FS 
[%] 
  
heart rate 
[bpm] 
  
CO 
[ml/min] 
  
SV 
[µl] 
  
diastolic  
function 
apical four 
chamber 
pulse wave 
E 
[mm/s] 
  
A 
[mm/s] 
  
E/A  
ratio 
  
Cardiac morphology and function of AAV β1i or AAV Luci-injected β1i knockout mice was analyzed 
prior to and post isoprenaline treatment. In the parasternal long axis (PLAX) view in M-mode, the 
cardiac morphology (left ventricular posterior wall thickness in diastole (LVPWT;d) or systole 
(LVPWT;s), left ventricular internal diameter (LVID) in diastole (LVID;d) or systole (LVID;s)) as well as 
the systolic function (ejection fraction (EF), fractional shortening (FS), cardiac output (CO), stroke 
volume (SV)) was analyzed. Moreover, the diastolic function (E value, A value, E/A ratio) was analyzed 
in the apical four chamber view using pulse wave and color Doppler mode. 
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4.5 Increased HW/BW ratio and cardiomyocyte cross-sectional area after isoprenaline 
treatment  
The increase in left ventricular posterior wall thickness in diastole upon isoprenaline treatment 
was determined by echocardiographic analysis. Thus, the heart weight to body weight ratio 
(HW/BW ratio), an indicator of cardiac hypertrophy, was analyzed in AAV β1i or 
AAV Luci-injected and isoprenaline-treated β1i knockout mice. In addition, the cross-sectional 
area of cardiomyocytes was quantified in heart cryosections to determine cardiomyocyte size 
in these mice. 
Notably, the HW/BW ratio was increased following 7 days of isoprenaline treatment in 
AAV Luci-injected mice as compared to AAV β1i-treated β1i-deficient animals (Figure 20).  
 
 
Figure 20. Attenuated isoprenaline-induced increase of the HW/BW ratio after β1i 
reintroduction.  
The heart weight to body weight ratio (HW/BW ratio), lung weight to body weight ratio (LW/BW ratio) 
and liver weight to body weight ratio (LiW/BW ratio) was analyzed in AAV β1i or AAV Luci-injected 
β1i-deficient mice 7 days after starting the isoprenaline treatment. In addition, HW/BW ratios of the 
present study were compared to those in wild type (WT) and β1i knockout mice (β1i KO) performed 
by Lidia Gaal and Felix Trogisch, respectively. In these studies, the HW/BW ratio was analyzed 
following exposure to isoprenaline for 7 days or sham treatment in WT or β1i-deficient mice. 
MeanSD. # p=0.05, ** p<0.01. n=6. 
 
In order to evaluate the difference in the HW/BW ratio observed in the present study, present 
results were compared to those of parallel studies by our group performed by Lidia Gaal and 
Felix Trogisch. Following induction of hypertrophy by exposure to isoprenaline for 7 days the 
HW/BW ratio was increased in wild type mice as well as β1i knockout mice as compared to 
sham treated control animals (Figure 20). Moreover, the increase in HW/BW ratio was higher 
in β1i-deficient as compared to wild type mice following exposure to a pro-hypertrophic 
stimulus (Figure 20). Thus, the increase in the HW/BW ratio due to the reintroduction of β1i in 
β1i-deficient mice in the present study was comparable with the difference of the HW/BW ratio 
between wild type and β1i-deficient mice in parallel studies (Figure 20). 
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Moreover, the lung weight to body weight ratio (LW/BW ratio) and the liver weight to body 
weight ratio (LiW/BW ratio) was analyzed in the present study. The LW/BW ratio was greater 
after 7 days of isoprenaline treatment in AAV Luci as compared to AAV β1i-injected β1i 
knockout mice (Figure 20). In contrast, the LiW/BW ratio was not changed following induction 
of hypertrophy after the reintroduction of β1i in β1i-deficient mice as compared to 
AAV Luci-treated control mice (Figure 20). 
The level of increase in HW/BW ratio matched those of the left ventricular posterior wall 
thickness in diastole in AAV Luci as well as AAV β1i-injected β1i-deficient mice (Figure 21). 
 
 
Figure 21. Association between heart 
weight to body weight ratio (HW/BW 
ratio) and left ventricular posterior wall 
thickness in diastole (LVPWT;d) after 7 
days of isoprenaline treatment in 
AAV Luci-injected control mice as well 
as β1i-deficient animals into which β1i 
had been reintroduced. 
 
The cross-sectional area of cardiomyocytes was quantified in hematoxylin and eosin (HE) 
stained heart cryosections.  
According to analyses of a limited number of samples (n=1-2), the AAV9-based reintroduction 
of β1i into β1i knockout mice had no effect on cardiomyocyte size as compared to untreated 
β1i-deficient mice (Figure 22). On the contrary, cross-sectional area seemed to be increased 
after 7 days exposure to isoprenaline in AAV β1i-injected β1i knockout mice (Figure 22). 
Similarly, analysis of the cross-sectional area seemed to reveal an increase upon induction of 
hypertrophy in AAV Luci-injected β1i-deficient mice (Figure 22). 
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Figure 22. Isoprenaline treatment potentially induced an increase in the cardiomyocyte size in 
AAV β1i and AAV Luci-injected β1i knockout (β1i KO) mice. 
Heart cryosections (base of the heart) of untreated β1i knockout mice (A, n=1), AAV β1i-injected 
β1i-deficient mice (B, n=2) as well as AAV β1i (C, n=2) or AAV Luci-injected (D, n=1) and 
isoprenaline-treated (7 days) β1i knockout mice were hematoxylin and eosin (HE) stained. The 
cross-sectional area was measured using ImageJ software in 15 areas of 3 cryosections per heart 
(E). Statistical analysis was not performed due to limited number of samples. MeanSD. 
 
4.6 Areas with an increased myocardial collagen content were not observed after β1i 
reintroduction prior to hypertrophy induction in β1i knockout mice 
Heart cryosections were stained with Masson’s trichrome to analyze the myocardial collagen 
content after AAV injection and induction of hypertrophy in β1i knockout mice. 
According to analyses of a limited number of samples (n=1-2), areas with an increased 
myocardial collagen content were neither observed in hearts of untreated or AAV β1i-injected 
β1i-deficient mice (Figure 23E, F) nor identified in hearts of β1i-deficient mice into which β1i 
had been reintroduced following exposure to isoprenaline (Figure 23G). In contrast, 
approximately one quarter of the tissue showed intrafibrillar blue staining indicating collagen 
following exposure to a pro-hypertrophic stimulus in AAV Luci-injected control mice 
(Figure 23H). 
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Figure 23. Reintroduction of β1i in β1i-deficient mice potentially prevents the formation of 
areas with an increased myocardial collagen content upon induction of hypertrophy 
Hematoxylin and eosin (HE) stained heart cryosections (base of the heart) of untreated β1i-deficient 
mice (A, n=1), AAV β1i injected β1i knockout mice (B, n=2) as well as AAV β1i (C, n=2) or AAV 
Luci-injected (D, n=1) and 7 days to isoprenaline exposed β1i-deficient mice. Sections of the same 
samples were stained with Masson’s Trichrome (E-H). Collagen is stained in blue. Areas with an 
increased myocardial collagen content are indicated by arrows (approximately 25% in H). 
 
4.7 Beta1i or Renilla luciferase was expressed in the hearts after AAV injection 
Cardiac function and left ventricular posterior wall thickness was modified after 7 days of 
isoprenaline treatment by reintroduction of β1i into β1i-deficient mice as compared to 
AAV Luci-injected control mice. In a subsequent step, potential regulation on the proteasomal 
level was investigated in this context. Initially, successful cardiac gene delivery via serotype 9 
of adeno-associated viruses was analyzed on the protein level by Western blot analysis. 
Renilla luciferase was not detected in untreated wild type or AAV β1i-injected and 
isoprenaline-treated β1i knockout mice (Figure 24A). In contrast, Renilla luciferase abundance 
was demonstrated after injection of AAV Luci in hypertrophic hearts of β1i-deficient mice 
(Figure 24A). 
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Figure 24. Beta1i and Renilla luciferase was detected after AAV β1i and AAV Luci injection, 
respectively, in hypertrophic hearts of β1i-deficient mice. 
Heart homogenates (soluble fraction) of untreated wild type mice (WT) as well as AAV β1i (β1i) or 
AAV Luci-injected (Luci) and isoprenaline-treated (7 days) β1i knockout mice were analyzed for the 
abundance of Renilla luciferase (highlighted in green) (A) or β1i (highlighted in blue, red) (B). 
 
In addition, β1i was detected in untreated wild type mice. In contrast, detection of β1i in 
AAV Luci and isoprenaline-treated β1i knockout mice was negative (Figure 24B). In 
accordance with previous results (Figure 14), β1i abundance was demonstrated in 
hypertrophic hearts of β1i-deficient mice upon AAV9-based reintroduction of β1i (Figure 24B). 
Moreover, two bands corresponding to β1i were detected in AAV β1i-injected β1i-deficient 
mice following 7 days of isoprenaline treatment while one band was observed in untreated wild 
type mice (Figure 24B). Notably, Western blot analysis indicated an inhomogeneous 
abundance of Renilla luciferase and β1i in hypertrophic hearts of AAV Luci and 
AAV β1i- injected β1i-deficient mice, respectively (Figure 24A, B). 
In addition to the analysis of protein abundance, luciferase activity was analyzed using a 
Renilla luciferase activity assay to demonstrate the correct formation of the three dimensional 
structure of the protein. 
Renilla luciferase activity was detected in all hypertrophic hearts of AAV Luci-injected 
β1i-deficient mice (Figure 25). Thus, the three dimensional structure of the protein was 
correctly formed. Notably, Renilla luciferase activity was inhomogeneous among the different 
samples of AAV Luci and isoprenaline-treated β1i knockout mice (Figure 25). 
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Figure 25. Detected Renilla luciferase activity revealed the expression of a correctly folded 
protein upon AAV9-based introduction of Renilla luciferase in β1i-deficient mice. 
Following continuous exposure to isoprenaline (7 days) Renilla luciferase activity (indicated in white) 
in heart crude extracts of AAV Luci-injected β1i knockout mice was measured in triplicates. MeanSD. 
The Renilla luciferase abundance (indicated in black) in heart homogenates (soluble fraction) of the 
same samples analyzed by Western blot analysis was normalized to Ponceau staining. 
 
4.8 Neither 26S nor 20S proteasome activities were significantly changed by β1i 
reintroduction into β1i-deficient mice prior to induction of hypertrophy 
The abundance of β1i in hypertrophic hearts was verified in AAV β1i-injected β1i knockout 
mice by Western blot analysis. In a subsequent step, the incorporation of the reintroduced β1i 
into active proteasome complexes was investigated using the activity based probe MVB003. 
Moreover, the effect of β1i incorporation into active proteasome complexes on proteasomal 
activity was analyzed using proteasome activity assays. 
Active site labeling of heart homogenates using MVB003 revealed the incorporation of 
constitutive (β1, β2, β5) as well as inducible (β2i, β5i) proteolytic β subunits in proteasome 
complexes of hypertrophic hearts (Figure 26A). Moreover, an additional band presumably 
corresponding to β1i was detected in AAV β1i-injected as compared to AAV Luci-treated 
β1i-deficient mice following 7 days of isoprenaline treatment (Figure 26A). 
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Figure 26. Beta1i was incorporated into active proteasome complexes. 
(A) Proteasome active sites were labeled by MVB003 in heart homogenates of AAV β1i or 
AAV Luci-injected and isoprenaline-treated (7 days) β1i-deficient mice. The proteasome was inhibited 
using bortezomib prior to active site labeling in one of the samples to identify proteolytic β-subunits 
via a competitive assay. Proteasome subunits were designated according to previous publication 
(Florea et al. 2010). (B) The active site labeling was quantified and normalized by total protein staining 
using ruthenium (C). MeanSD. ** p<0.01. n=5. 
 
In addition, the active site labeling was quantified and normalized by total protein staining using 
ruthenium (Figure 26B, C). The analysis indicated an increase in the incorporation of β1 
subunits into proteasome complexes in AAV Luci as compared to AAV β1i-injected 
β1i-deficient mice upon exposure to isoprenaline (Figure 26B). Moreover, the incorporation of 
β5 subunits into proteasome complexes seemed elevated in AAV Luci as compared to 
AAV β1i-injected β1i knockout mice (Figure 26B). Notably, this elevation as well as the 
increase in the total incorporation of proteolytic subunits into proteasome complexes was not 
significant in AAV Luci as compared to AAV β1i-injected β1i-deficient mice following exposure 
to a pro-hypertrophic stimulus (Figure 26B). 
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In a subsequent step, the effect of β1i incorporation into proteasome complexes on 
proteasomal activity of hypertrophic hearts was analyzed by proteasome activity assays using 
heart homogenates. 
None of the 26S or 20S proteasome activities were significantly changed in AAV β1i as 
compared to AAV Luci-injected β1i knockout mice following continuous exposure to 
isoprenaline (7 days) (Figure 27). Still, the 26S caspase-like activity and the 20S caspase-like 
activity seemed increased in AAV Luci-injected control mice as compared to β1i-deficient mice 
into which β1i had been reintroduced upon treatment with isoprenaline (Figure 27). 
 
 
Figure 27. Beta1i reintroduction did not significantly change 26S and 20S proteasome 
activities in hypertrophic hearts of β1i-deficient mice. 
Following exposure to isoprenaline for 7 days the proteasome activities were analyzed in heart 
homogenates of AAV β1i or AAV Luci-injected β1i knockout mice. Non-proteasomal activities, 
measured in the presence of specific proteasome inhibitors, were excluded from the figure. MeanSD. 
n=5. 
 
4.9 The abundance of other proteasome subunits than β1i was not significantly 
changed by reintroduction of β1i into hearts of β1i-deficient mice prior to induction 
of hypertrophy 
The abundance of proteasome subunits was analyzed in heart homogenates of AAV β1i or 
AAV Luci-injected and isoprenaline-treated (7 days) β1i knockout mice to investigate the 
potential influence of reintroduction of β1i on the abundance of other proteolytic and structural 
proteasome subunits. 
The abundance of structural subunits α7 and Rpt4 was not changed in hypertrophic hearts 
upon reintroduction of β1i in β1i-deficient mice as compared to AAV Luci-injected control 
animals (Figure 28). In contrast, the abundance of proteolytic subunits β1, β2, β5 and β5i 
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seemed higher in AAV Luci as compared to AAV β1i-injected β1i-deficient mice upon exposure 
to isoprenaline (Figure 28). This increase was not significant given the large SD (Figure 28). 
 
 
 Figure 28. The abundance of other proteolytic and structural proteasome subunits than β1i 
was not significantly altered in hypertrophic hearts of β1i-deficient mice with prior 
reintroduction of β1i as compared to AAV Luci-injected control mice.  
The abundance of structural subunits (α7, Rpt4) as well as proteolytic β-subunits (β1, β1i, β2, β5, β5i) 
normalized to Ponceau S staining was analyzed in heart homogenates by Western blot analysis in 
AAV β1i or AAV Luci-injected and isoprenaline-treated (7 days) β1i-deficient mice (n=5) and untreated 
wild type mice (n=3). MeanSD. 
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The abundance of Renilla luciferase in AAV Luci-injected and isoprenaline-treated β1i 
knockout mice seemed not to be associated with the abundance of proteolytic (β1, β2, β5, β5i) 
or structural (Rpt4) proteasome subunits. In contrast, the abundance of α7 seemed to be 
increasing with increasing abundance of Renilla luciferase in AAV Luci-treated control mice 
following exposure to isoprenaline. In addition, the abundance of reintroduced β1i in 
AAV β1i-injected β1i knockout mice seemed to be associated with the abundance of β1 and 
β2. Following induction of hypertrophy, β1 and β2 abundance was lowest when abundance of 
β1i was highest in AAV β1i-injected β1i-deficient mice.  
In addition, the abundance of proteasome subunits in hypertrophic hearts of AAV β1i or 
AAV Luci-injected β1i knockout mice was compared to untreated hearts of wild type mice to 
initially evaluate the potential effects of AAV β1i or AAV Luci injection and exposure to 
isoprenaline on proteasome subunit abundance.  
The abundance of the structural subunit α7 was not changed in untreated wild type mice as 
compared to AAV-injected and isoprenaline-treated β1i knockout animals (Figure 28). Due to 
the large SD, the abundance of β1, β2, β5, β5i and Rpt4 was not significantly modified in hearts 
of untreated wild type mice as compared to hypertrophic hearts of AAV-injected β1i-deficient 
animals (Figure 28). The abundance of β1, β2, β5i and Rpt4 was higher while the abundance 
of β5 was lower in AAV Luci-injected and 7 days to isoprenaline exposed β1i knockout mice 
as compared to untreated wild type animals (Figure 28). Moreover, the abundance of β1, β5i 
and Rpt4 was elevated to a lower extent while the abundance of β2 and β5i was reduced to a 
higher extent in hypertrophic hearts of AAV β1i injected β1i-deficient mice as compared to 
hearts of untreated wild type mice (Figure 28).  
 
4.10 The abundance of sarcomeric proteins was not significantly altered in 
hypertrophic hearts of β1i-defcient mice with prior β1i reintroduction 
In a subsequent step, the influence of reintroduction of β1i on the abundance of sarcomeric 
proteins, which are reported targets of proteasomal degradation, was investigated. For this 
purpose, the abundance of sarcomeric proteins was analyzed in heart crude extracts or heart 
homogenates of AAV β1i or AAV Luci-injected and isoprenaline-treated β1i knockout mice. 
The abundance of sarcomeric proteins actin, β-myosin heavy chain (β-MHC), ventricular 
myosin light chain 2 (MLC2v), α-tubulin, α-actinin and desmin were not altered in hypertrophic 
hearts of β1i-deficient mice into which β1i was reintroduced as compared to AAV Luci-injected 
β1i control animals (Figure 29). In contrast, the abundance of troponin I seemed lower in 
AAV Luci as compared to AAV β1i-injected β1i knockout mice following 7 days of isoprenaline 
treatment (Figure 29). 
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Figure 29. The abundance of sarcomeric proteins was not significantly altered in β1i knockout 
mice with β1i reintroduction prior to isoprenaline treatment. 
The abundance of sarcomeric proteins β-myosin heavy chain (β-MHC) and α-actinin as well as 
desmin, α-tubulin, actin, troponin I and ventricular myosin light chain 2 (MLC2v=) normalized to 
Ponceau S staining was analyzed in AAV β1i or AAV Luci-injected and 7 days to isoprenaline exposed 
β1i-deficient mice (n=5) and in untreated wild type mice (n=3) by Western blot analysis. The former 
was investigated in heart crude extracts while the latter was analyzed in heart homogenates (soluble 
fraction). MeanSD. # p=0.08, * p<0.05, ** p<0.01. 
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Moreover, the potential influence of isoprenaline treatment and AAV infection on the 
abundance of sarcomeric proteins was initially investigated by the analysis of these proteins 
in hypertrophic hearts of AAV-injected β1i-deficient mice as compared to untreated wild type 
mice. 
The abundance of MLC2v and α-tubulin was not altered in untreated wild type mice as 
compared to AAV β1i or AAV Luci-injected and isoprenaline-treated β1i knockout mice 
(Figure 29). In contrast, the abundance of β-MHC, α-actinin and desmin was decreased in 
untreated wild type mice as compared to AAV β1i-injected β1i-deficient mice following 
exposure to isoprenaline (Figure 29). However, this decrease, with the exception of desmin, 
was not significant due to the large SD. Moreover, the analysis revealed an increase of the 
abundance of actin and troponin I in untreated wild type mice as compared to AAV β1i and 
isoprenaline-treated β1i knockout mice (Figure 29). 
 
4.11 Desmin localization was not modified by induction of hypertrophy in hearts of 
β1i-deficient mice receiving gene transfer 
Desmin was analyzed in heart cryosections of untreated, AAV β1i-treated as well as AAV β1i 
or AAV Luci-injected and 7 days to isoprenaline exposed β1i knockout mice by 
immunofluorescence staining to investigate whether the localization of desmin within 
cardiomyocytes was altered in a disease-dependent manner. 
According to analyses of a limited number of samples (n=1-2), desmin seemed to be located 
in Z-disks and intercalated disks in hearts of untreated or AAV β1i-injected β1i knockout mice 
(Figure 30A, B). Moreover, the localization seemed not to be modified upon induction of 
hypertrophy in AAV β1i or AAV Luci-treated β1i-deficient mice (Figure 30C, D). However, the 
analysis suggested a higher increase of the desmin fluorescence intensity in AAV β1i versus 
AAV Luci-injected β1i knockout mice following 7 days of isoprenaline treatment as compared 
to untreated animals (Figure 30E). 
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Figure 30. Desmin localization seemed to be unchanged by induction of hypertrophy in hearts 
of β1i knockout mice receiving gene transfer.  
Heart cryosections (base of the heart) of untreated β1i knockout mice (A, n=1), AAV β1i-injected 
β1i-deficient mice (B, n=2) as well as AAV β1i (C, n=2) or AAV Luci-injected (D, n=1) and 
isoprenaline-treated (7 days) β1i knockout mice were analyzed for desmin abundance and 
localization by immunofluorescence analysis. Localization of desmin in Z-disks and intercalated disks 
is visualized by rectangles and arrows, respectively. The desmin fluorescence intensity per cell was 
analyzed in 15 areas of 3 cryosections per sample using Olympus Xcellence software (E). Statistical 
analysis was not performed due to limited number of samples. MeanSD. 
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4.12 Heart weight to body weight ratio was not significantly altered in aged as 
compared to young mice 
In collaboration with Dr. Kleinbongard (Dept. of Pathophysiology, University Hospital Essen), 
age-related alterations of the cardiac proteome and proteasome system were analyzed in 
4 versus 26 months old mice as well as in 3, 9 and 30 months old animals. Notably, the health 
status of the old (26 and 30 months old) mice was different (communicated by 
Dr. Kleinbongard, Dept. of Pathophysiology, University Hospital Essen). The 26 months old 
mice were sacrificed due to visible signs of distress, suggesting a poor health condition. In 
contrast, the 30 month group showed no visible signs of distress. Furthermore, cardiac function 
of the 3, 9 and 30 months old mice was analyzed by echocardiography through our 
collaborators (data not shown). Accordingly to this data, hearts of the 30 months old animals 
did not show pathological abnormalities. 
Initially, the heart weight (HW) and the heart weight to body weight ratio (HW/BW ratio) of 
differentially aged mice were analyzed by our collaborators. 
The HW and HW/BW ratio were not significantly altered in old (26 and 30 months old) mice as 
compared to young (4 and 3 months old) animals (Figure 31A, B). 
 
 
Figure 31. The heart weight (HW) and heart weight to body weight ratio (HW/BW ratio) were 
not different in aged as compared to young wild type mice.  
The HW and HW/BW ratio was analyzed in 4 and 26 months old mice (n=5) (A) as well as in 3, 9 and 
30 months old animals (n=5-6) (B). MeanSD. ** p<0.01 versus 3 months old animals. 
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In contrast, the HW and HW/BW ratio were decreased in 9 versus 3 months old mice 
(Figure 31B). The HW as well as BW data were kindly provided by our collaborators 
(Dr. Kleinbongard, Dept. of Pathophysiology, University Hospital Essen). 
 
4.13 Increased 26S proteasome activities in aged hearts 
Cardiac 20S and 26S proteasome activities were analyzed in heart homogenates from 
4 versus 26 months old mice and 3, 9 and 30 months old animals. 
Cardiac 20S proteasome activities were not significantly increased in 4 as compared to 
26 months old mice (Figure 32). Comparing the heart homogenates from 3, 9 and 30 months 
old mice, the caspase-, trypsin- and chymotrypsin-like 20S proteasome activities were likewise 
unaltered (Figure 33). 
 
 
Figure 32. The 26S proteasome activities were increased in hearts of aged mice. 
Proteasome activities were analyzed in heart homogenates from 4 and 26 months old mice. 
Non-proteasomal activities measured in the presence of a specific proteasome inhibitor have been 
subtracted from the values shown. Activities in 26 months old mice are indicated as percentage of 
those in 4 months old animals. MeanSD. ** p<0.01 versus 4 months old animals. n=5. 
 
In contrast, the caspase-, trypsin- and chymotrypsin-like 26S proteasome activities were 
increased in hearts from 26 as compared to 4 months old mice. (Figure 32). These activities 
were elevated to a lesser extend in 30 months old as compared to the 3 months old mice 
(Figure 33). Moreover, the 26S proteasome activities seemed to increase successively with 
age in the latter study (Figure 33). 
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Figure 33. The 26S proteasome activities were elevated with age. 
26S and 20S proteasome activities were analyzed in heart homogenates from 3, 9 and 30 months 
old wild type mice. Non-proteasomal activities have been subtracted from the values shown (see 
figure 32). MeanSD. ** p<0.01 versus 3 months old animals. n=5-6. 
 
4.14 Differential alteration of the proteasome assembly in aged mice 
Proteasome assembly in differentially aged wild type mice was investigated in heart 
homogenates by active site labeling using the activity based probe MV151 given that 
26S proteasome activities were significantly increased in aged as compared to young hearts. 
The active site labeling of heart homogenates revealed the incorporation of constitutive 
proteolytic subunits β1, β2 and β5 into proteasome complexes of differentially aged mice 
(Figure 34A; 35A). In addition, the active site labeling was quantified and normalized to total 
protein staining using ruthenium (Figure 34B, C; 35B, C). Comparing 4 versus 26 months or 
3 versus 9 or 30 months old mice with regard to total protein abundance showed no differences 
with statistical significance (Figure 34B; 35B). Still, incorporation of β1, β2 and β5 into 
proteasome complexes seemed to be increased in 26 months old as compared to 4 months 
old mice (Figure 34C). This increase was not significant due to the large SD. Incorporation of 
constitutive proteolytic subunits into proteasome complexes was unchanged in 30 as 
compared to 3 or 9 months old mice (Figure 35C).  
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Figure 34. The incorporation of proteolytic β-subunits in proteasome complexes was not 
significantly increased in 26 as compared to 4 months old mice.  
(A) Proteasome active sites were labeled by MV151 in heart homogenates from 4 versus 26 months 
old mice. In addition, proteasome active site labeling (in particular β1 and β5) was inhibited by using 
bortezomib prior to labeling to identify proteolytic β-subunits through a competitive assay. Designation 
of proteasome subunits was performed according to previous publication (Verdoes et al. 2010). (C) 
The active site labeling was quantified and normalized to total protein staining using ruthenium (B). 
MeanSD. # p=0.06. n=5. 
 
Accordingly, total incorporation of proteolytic subunits into proteasome complexes seemed 
elevated in 26 versus 4 months old mice (Figure 34C) while this was not altered in 30 versus 3 
or 9 months old animals (Figure 35C). 
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Figure 35. The incorporation of proteolytic β-subunits into cardiac proteasome complexes was 
unchanged in the context of aging.  
(A) Active sites of proteasome complexes were labeled by MV151 in heart homogenates from 3, 9 
and 30 months old mice. Proteasome subunits were designated according to previous publication 
(Verdoes et al. 2010). (C) The active site labeling was quantified and normalized to total protein 
staining using ruthenium (B). MeanSD. n=5-6. 
 
In addition, the abundance of proteasomal subunits was analyzed in heart homogenates from 
3, 9 as well as 30 months old mice by Western blot analysis. 
Comparing 9 versus 3 months old mice, the abundance of the structural subunits Rpt4 and α7 
as well as the proteolytic subunits β1, β2, β5, β5i and β1i was not altered with statistical 
significance (Figure 36). The abundance of all analyzed structural and proteolytic proteasome 
subunits seemed elevated in the hearts of 30 months old mice as compared to 3 months old 
animals (Figure 36). This increase was statistically significant for the abundance of β5 and β5i 
(Figure 36). 
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Figure 36. Proteasome subunits with altered abundance in cardiac aging. 
The abundance of proteolytic β-subunits as well as structural subunits (α7, Rpt4) normalized to 
Ponceau S staining was investigated in heart homogenates from 3, 9 as well as 30 months old mice 
by Western blot analysis. MeanSD. ** p<0.01. n=5-6. 
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4.15 Differentially altered cardiac proteome in aged as compared to young mice 
In addition to the alteration of cardiac proteasome complexes in the context of aging, 
age-related alteration of cardiac proteomes was analyzed by total protein staining after 1D and 
2D gel electrophoresis using heart homogenates from differentially aged wild type mice. 
Using 1D gel electrophoresis, 30 bands were quantified in 4 versus 26 months old mice of 
which 15 bands were unchanged (Figure 37). When comparing 3, 9 and 30 months old 
animals, a total of 26 bands was quantified of which 17 remained unaltered (Figure 38). 
 
 
Figure 37. More than 10 abundant protein bands were increased in aged hearts of wild type 
mice. 
Total protein staining using ruthenium of heart homogenates from 4 and 26 months old mice was 
analyzed after 1D gel electrophoresis. Significantly elevated age induced protein bands (AIP) (green) 
or decreased age reduced protein bands (ARP) (red) were highlighted. Protein bands were named 
according to their molecular weight (kDa). MeanSD. * p<0.05, ** p<0.01. n=5. 
 
Quantified protein bands were named according to their molecular weight (kDa) and indicated 
as age reduced proteins (ARP) or age induced proteins (AIP) depending on whether their 
abundance in old animals was significantly decreased or increased as compared to young 
mice. Comparing 26 versus 4 months old mice, 2 protein bands were decreased and 13 protein 
bands increased (Figure 37). On the contrary, when comparing the 3, 9 and 30 months old 
animals by 1D gel electrophoresis only 3 protein bands were significantly affected (Figure 38). 
The intensity of protein band ARP 64 was decreased in 9 versus 3 months old mice while that 
of protein band ARP 18 was decreased in 30 as compared to 3 months old animals. Moreover, 
the intensity of protein band AIP 25 was increased in 9 and 30 months old mice as compared 
to 3 months old animals (Figure 38). 
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Figure 38. The abundance of eight protein bands was changed in cardiac aging. 
Total protein of heart homogenates from 3, 9 as well as 30 months old mice was stained after 1D gel 
electrophoresis using ruthenium. Increased age induced protein bands (AIP) (green) or decreased 
age reduced protein bands (ARP) (red) were highlighted and named according to their molecular 
weight (kDa). MeanSD. # p0.1, * p<0.05, ** p<0.01. n=5-6. 
 
The comparison of the total protein staining after 1D gel electrophoresis of heart homogenates 
revealed a similar band pattern in 4 or 26 months old mice as compared to 3, 9 or 30 months 
old animals (Figure 39). However, bands altered with statistical significance were quite 
different between the two studies (Figure 39). 
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Figure 39. Marked difference in 
significantly altered protein bands in 26 
as compared to 30 months old mice. 
After 1D gel electrophoresis total protein 
staining using ruthenium of heart 
homogenates from 4 and 26 months old 
mice was compared to this of 3, 9 and 30 
months old animals. Increased age 
induced protein bands (AIP) were 
highlighted in green and decreased age 
reduced protein bands (ARP) were 
highlighted in red. 
 
The heart homogenates from 4 and 26 months old mice were further analyzed by 2D gel 
electrophoresis to separate bands into individual proteins and facilitate protein identification. 
Spots, which potentially corresponded to the ARPs or AIPs identified via 1D gel 
electrophoresis, were compared to 2D gels of published reference gels of a cardiac proteome 
database (HP-2DPAGE: http://web.mpiib-berlin.mpg.de/hp-2dpage/heart1.html). According to 
this, four of these spots seemed to correspond to essential structural (myosin light chain 3, 
ventricular myosin light chain 2) and functional proteins (transferrin, myoglobin) (Figure 40). 
AIP 75 potentially corresponds to transferrin, AIP 24 to myosin light chain 3 (MLC3), AIP 19 to 
ventricular myosin light chain 2 (MLC2v) and AIP 16 to myoglobin. Quantification of the spots 
on representative 2D gel electrophoresis gels supports the notion that MLC3 and myoglobin 
were increased in 26 months old mice as compared to 4 months old animals (Figure 40). 
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Figure 40. Proteins with putative changes in cardiac aging. 
2D gel electrophoresis of heart homogenates from 4 as well as 26 months old mice and proteins were 
stained using ruthenium complex (performed by M. Lorenz and Dr. O. Drews). Spot volume 
(CNT*mm² = counts*mm²) was analyzed using Quantity One software. Marked proteins correspond 
to the following proteins of published reference gels from a cardiac proteome database (HP-2DPAGE: 
http://web.mpiib-berlin.mpg.de/hp-2dpage/heart1.html): transferrin, myosin light chain 3 (MLC3), 
ventricular myosin light chain 2 (MLC2v) and myoglobin. 
 
4.16 Altered abundance of sarcomeric proteins in context of aging 
The abundance of sarcomeric proteins, which are reported targets of proteasomal degradation, 
were analyzed in heart homogenates of 3, 9 and 30 months old wild type mice by Western blot 
analysis due to the published alteration of the contractility in aged hearts. 
Comparing 9 versus 3 months old mice, the abundance of ventricular myosin light chain 2 
(MLC2v), β-myosin heavy chain (β-MHC), α-tubulin, actin and troponin I was not altered. 
Moreover, an increase in α-actinin and desmin abundance in 9 as compared to 3 months old 
mice was not statistically significant (Figure 41). The abundance of α-tubulin and MLC2v was 
unchanged while the abundance of β-MHC, actin, α-actinin and desmin was increased in 
30 months old mice as compared to 3 month old animals (Figure 41). However, this increase 
was not statistically significant. The abundance of troponin I was decreased in 30 months old 
mice (Figure 41). 
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Figure 41. Abundance of sarcomeric proteins in the context of aging. 
The abundance of the sarcomeric proteins β-myosin heavy chain (β-MHC), α-actinin, desmin, 
α-tubulin, actin, troponin I and ventricular myosin light chain 2 (MLC2v) normalized to Ponceau S 
staining was analyzed in heart homogenates from 3, 9 and 30 months old mice by Western blot 
analysis. MeanSD. * p<0.05. n=5-6.  
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5 Discussion 
Cardiovascular diseases result in the highest mortality worldwide. Moreover, the prevalence 
of cardiac hypertrophy and heart failure dramatically increases with age (Lakatta et al. 2003). 
Proteasomal degradation accounts for the regulation of multiple pathways involved in heart 
disease (Willis et al. 2010). However, systematic studies regarding the mechanisms of 
proteasomal regulation and their role in the pathogenesis of heart disease are currently limited. 
The present study demonstrated for the first time that following induction of hypertrophy the 
heart-specific incorporation of β1i into proteasome complexes of β1i-deficient mice attenuates 
hypertrophy development and prevents manifestation of systolic and diastolic dysfunction. 
Thus, the previously reported increase in the incorporation of inducible β-subunits into cardiac 
proteasomes complexes in wild type mice following isoprenaline exposure (Drews et al. 2010) 
seems to be an important protective mechanism in cardiac remodeling. A first analysis of the 
sarcomer structure in the cardiomyocytes following continuous β-adrenergic stimulation 
indicated that the observed phenotype of the β1i-deficient animals is not related to a 
disturbance of this structure or a deregulated degradation of contractile proteins. However, 
increased levels of troponin I upon treatment with isoprenaline and reintroduction of β1i in 
β1i-deficient mice potentially contributed to the maintenance of cardiac function in these 
animals. In the context of aging, marked alterations of the cardiac proteome were associated 
with significantly increased 26S proteasome activities. Moreover, this increase seemed to be 
adaptive with respect to the extent of the alterations in the cardiac proteome, and may be 
generally associated with a poor health status and serve to maintain protein homeostasis and 
cardiac function in the aging animal. 
 
5.1 NRCMs – the preferable in vitro system to verify correct transgene expression 
using AAV CMV/MLC0.26 vectors  
A standard cloning approach is the direct cloning of PCR products into target vectors (Scharf 
et al. 1986). For this purpose, two different restriction sites at the 5’ and 3’ end of the gene of 
interest are inserted via PCR using overhang primers. Subsequently, the gene of interest is 
inserted into the target vector via cohesive-end ligation after restriction digestion of the PCR 
product and the vector (Kaufman et al. 1990). A drawback of this approach is that it is not 
possible to figure out, which (intermediate) step fails in a failing cloning procedure. 
Alternatively, the PCR product containing the restriction sites is inserted into a standard vector 
via blunt-end ligation (Innis et al. 2012). This procedure has the advantage to verify the inserted 
sequence before its insertion into the target vector and to restart the cloning procedure at a 
higher level if the cohesive-end ligation into the target has failed. 
 Discussion 
 94 
Using the AAV CMV/MLC0.26 target vector, it is particularly recommended to use this 
intermediate step due to low transformation efficiency, which was also observed in the present 
study. Moreover, an additional intermediate step was necessary due to the small yield by PCR 
using reverse transcribed cDNA from the liver of C57BL/6J wild type mice as a template and 
‘β1i overhang primers’ in this study. Thus, the β1i gene was initially amplified from reverse 
transcribed cDNA using ‘β1i direct primers’ and inserted via blunt-end ligation into a standard 
cloning vector. This standard vector containing β1i was subsequently used as a template for 
PCR using ‘β1i overhang primers’. 
HEK-293 cells are commonly used to verify the correct expression of a transgene encoded by 
adeno-associated viral vectors containing a CMV promoter and packaged into AAV2 particles 
(Hagstrom et al. 2000, Kaspar et al. 2002, Shimpo et al. 2002). In previous studies using AAV 
vectors containing a transgene under the control of a combined CMV/MLC promoter, NRCMs 
were used to analyze correct expression of the transgene following infection by AAV6 particles 
(Geisler et al. 2011, Friedrich et al. 2014, Weber et al. 2014). In the present study, correct 
expression of β1i was verified in HEK-293 cells and NRCMs using the AAV CMV/MLC0.26 β1i 
vector packaged into appropriate AAV particles. Thus, both approaches are applicable for 
verifying functionality of the adeno-associated viral vector system used. However, rodent 
cardiac cells (NRCMs) seem preferable due to the higher degree of similarity to the in vivo 
conditions (rodent hypertrophy model). 
 
5.2 Effective reintroduction of β1i in hearts of β1i knockout mice via 
AAV9 CMV/MLC0.26 β1i 
To my knowledge, the proteasome subunit β1i has not been reintroduced into a β1i-deficient 
model organism, e.g. by way of viral gene transfer, so far. Using AAV9 harboring expression 
constructs under the control of a CMV-enhanced myosin light chain promoter, transgene 
expression in the heart was demonstrated in different disease models (Kaya et al. 2011, Pleger 
et al. 2011, Schinkel et al. 2012). In a porcine model of myocardial infarction, myocardial 
expression of S100A1, a positive regulator of myocardial contractility, was moderately 
increased through AAV9 CMV/MLC0.26 S100A1 gene transfer using 1.5 ×  1013 vector 
genomes per animal (Pleger et al. 2011). Serum levels of interleukin-10 (IL-10), a potent 
anti-inflammatory cytokine, were markedly elevated by AAV9 CMV/MLC0.26 IL-10 gene 
transfer using 1012 vector genomes per animal in a mouse model of autoimmune myocarditis 
(Kaya et al. 2011). In the present study, the expression of β1i in β1i-deficient mice was similar 
to that of wild type animals after AAV9 CMV/MLC0.26 β1i gene transfer using 1011 vector 
genomes, demonstrating sufficient transgene expression using an even lower number of 
vector genomes per animal. 
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The proteasome subunit β1i is synthesized in a precursor form consisting of a N-terminal 
propeptide (18 AA) and a C-terminal tail (201 AA), and lacks proteolytic activity (Murata et al. 
2009). The N-terminal propeptide is cleaved off during the dimerization of the two 
half-proteasomes to the 20S core complex via autolysis to expose the catalytic threonine 
residue of the C-terminal tail hence enabling proteolytic activity (Murata et al. 2009). Thus, the 
observed two β1i bands likely correspond to the β1i precursor form (23.4 kDa) and the 
processed form of β1i (21.3 kDa) (Figure 14, 24). Detection of the processed form of β1i can 
be interpreted as an indication for incorporation of the reintroduced β1i into proteasome 
complexes in AAV β1i-injected β1i-deficient mice. 
The incorporation of all constitutive and inducible proteasome subunits in proteasome 
complexes has previously been reported for thymus homogenates of wild type mice by active 
site labeling using the activity based probe MVB003 (BODIPY-epoxomicin) (Florea et al. 2010). 
The labeling pattern of the proteasome subunits, observed in the present study, was slightly 
modified as compared to the aforementioned labeling pattern (Florea et al. 2010). Thus, distinct 
β5 and β5i bands were observed in the mouse heart but only one band corresponded to the 
β5 and β5i subunit in the labeling pattern from the mouse thymus (Florea et al. 2010). The 
presence of distinct β5 and β5i bands in the present study might be due to differential 
posttranslational modifications of these β-subunits in the mouse thymus and the mouse heart, 
respectively, namely in view of the reported cardiac-specific phosphorylation sites of the 
β5 subunit (Cui et al. 2014). The lowest band, observed in the MVB003 labeling pattern in 
heart homogenates of AAV β1i-injected β1i knockout mice, most likely corresponds to β1i 
when considering that the processed form of β1i is the smallest proteasome subunit. 
Accordingly, the lowest band of the active site labeling in the mouse thymus has been 
designated β1i, too (Florea et al. 2010). This β1i-like band was detected in AAV β1i-injected 
but not AAV Luci-injected β1i knockout mice. This may point to the incorporation of β1i in 
proteolytically active proteasome complexes in AAV β1i-injected β1i knockout mice following 
isoprenaline treatment.  
 
5.3 Beta1i reintroduction in β1i knockout mice attenuates cardiac hypertrophy 
development upon isoprenaline exposure 
Continuous stimulation of the β-adrenergic pathway through isoprenaline infusion is a 
well-established model of cardiac hypertrophy in various model organisms (reviewed in 
(Osadchii 2007)). In previous studies, 7-day treatment using an infusion rate of 
30 mg * kg-1 * d-1 of isoprenaline has been commonly used to induce cardiac hypertrophy in 
mice (Saadane et al. 1999, Drews et al. 2010, Lukowski et al. 2010). In these studies, the heart 
weight to body weight ratio (HW/BW ratio) was used as a marker for cardiac hypertrophy. In 
C57BL/6J wild type mice and β1i knockout mice, the HW/BW ratio was strongly increased 
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following isoprenaline exposure pointing to the development of cardiac hypertrophy (ongoing 
studies) (Liem D 2012). In this context, the HW/BW ratio of AAV Luci-injected β1i-deficient 
mice was similar to that of untreated β1i knockout mice while the HW/BW ratio of 
AAV β1i-treated β1i-deficient mice was equivalent when compared to wild type animals. 
Moreover, the HW/BW ratio was markedly increased after isoprenaline treatment in 
AAV Luci-injected control mice as compared to AAV β1i-treated β1i knockout mice. Thus, the 
reintroduction of β1i reduced the development of cardiac hypertrophy in the β1i-deficient mice 
to the level of the isoprenaline-treated wild type mice. 
Echocardiography is a well-established non-invasive method to analyze cardiovascular 
structure and function in mice (Rottman et al. 2007, Stypmann 2007, Scherrer-Crosbie et al. 
2008). In addition to the HW/BW ratio, the left ventricular posterior wall thickness in diastole 
(LVPWT;d) is an established hypertrophy indicator (Freund et al. 2005, Galindo et al. 2009, Li 
et al. 2013). One advantage of the non-invasive monitioring of this parameter is its 
determination prior to and post induction of cardiac hypertrophy. In the present study, changes 
in LVPWT;d in the different experimental groups mirrored those of the HW/BW ratio, again 
suggesting that the AAV9-based reintroduction of β1i into β1i-deficient mice normalized the 
hypertrophy-associated increase in wall thickness to the level of wild type mice that had been 
exposed to isoprenaline for 7 days. 
Cardiac hypertrophy is commonly classified to be concentric (symmetrical) or eccentric 
(asymmetrical) based on an alteration of the distribution of the muscle mass resulting in a 
modification of the heart’s shape and ventricular volume (reviewed in (Heineke et al. 2006, 
Maillet et al. 2013)). Besides remodeling of the extracellular matrix and coordinated 
angiogenesis, an increase in cardiomyocyte size due to the addition of sarcomeres in parallel 
or in series is the pivotal element of hypertrophic growth of the heart. In concentric hypertrophy, 
the thickness of the ventricular wall and septum is irregularly increased in proportion to the 
ventricular volume, which is maintained or even reduced, due to the predominant addition of 
sarcomeres in parallel. In the isoprenaline hypertrophy model, a concentric hypertrophy 
ensues evidenced by the fact that the cross-sectional area of the cardiomyocytes is 
significantly increased (Galindo et al. 2009, Lukowski et al. 2010). Accordingly, the 
cardiomyocyte cell width to cell length ratio, represented by the cross-sectional area, was 
strongly increased following isoprenaline treatment both in AAV Luci and AAV β1i-injected 
β1i-deficient mice, suggesting that the missing incorporation of β1i into cardiac proteasome 
complexes does not have a major effect on the structural changes in the heart following 
exposure to a pro-hypertrophic stimulus. Nonetheless, concentric hypertrophy seemed to be 
more pronounced in AAV Luci as compared to AAV β1i-injected β1i-deficient animals 
(preliminary results). Thus, the less severe cardiac hypertrophy upon reintroduction of β1i in 
β1i-deficient mice, as indicated by the HW/BW ratio and the left ventricular posterior wall 
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thickness in diastole, might be due to a somewhat different remodeling process that requires 
further investigation. 
After 7 days of isoprenaline treatment, the systolic function of the heart is increased in wild 
type mice (Drews et al. 2010, Lukowski et al. 2010, Shan et al. 2010). In contrast, ejection 
fraction (EF) and fractional shortening (FS) – two parameters indicative of systolic function – 
are reduced upon isoprenaline treatment in β1i knockout mice (ongoing studies) (Liem D 
2012). Herein, the same was true for the isoprenaline-treated AAV Luci-injected β1i-deficient 
animals. Thus, the presumed loss of β1i incorporation into cardiac proteasome complexes 
resulted in an accelerated systolic dysfunction following continuous exposure to isoprenaline. 
EF and FS were not altered in isoprenaline-treated AAV β1i-injected β1i-deficient mice pointing 
to an effective prevention of systolic dysfunction. There was, however, no increase in systolic 
function in these animals as it normally occurs in wild type mice (Drews et al. 2010, Lukowski 
et al. 2010, Shan et al. 2010). This lack of an increased systolic function following 7 days of 
isoprenaline treatment might be a different adaptive response of the heart to β-adrenergic 
overstimulation in the absence of β1i or a negative effect of the systemic loss of β1i that was 
not recovered by the heart-specific reintroduction of β1i. 
Assessment of left ventricular diastolic function by echocardiography is a part of the standard 
procedure for the diagnosis of heart diseases in humans (reviewed in (Nagueh et al. 2009)). 
In this context, the transmitral filling patterns, and in particular the so-called E/A ratio, are used 
as parameters indicative of diastolic dysfunction (Nagueh et al. 2009). Currently, the number 
of studies using echocardiography in mice is limited, due to the lack of appropriate 
echocardiography instruments for small laboratory animals such as mice with adequate spatial 
and temporal resolution. With the introduction of high-resolution digital ultrasound imaging this 
situation has recently been significantly improved, especially for the analysis of small rodents 
such as mice. In previous studies, diastolic dysfunction characterized by a significant alteration 
of the E/A ratio, has been reported for the transverse aortic constriction (TAC) model of 
pressure overload-induced concentric hypertrophy and heart failure in mice (Dirkx et al. 2013, 
Wang et al. 2014, Carley et al. 2015). In the present study, diastolic function of the heart was 
altered due to the lusitropic effect of isoprenaline. Thus, the accelerated relaxation in diastole 
results in an increased passive filling of the ventricle (E value). Similarly, its positive ionotropic 
effect results in an increased active filling of the ventricle (A value) due to the enhanced 
contractility. Thus, the E/A ratio was not changed in response to isoprenaline in wild type mice 
in previous studies from our laboratory (ongoing studies) (Drews et al. 2010).  
In the present study, diastolic function deteriorated (increased E/A ratio) in the presence of 
isoprenaline in AAV Luci but not AAV β1i-injected β1i-deficient mice, suggesting that the 
reintroduction of β1i prevents the development of diastolic dysfunction. The E value increased 
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following treatment with isoprenaline both in AAV Luci and AAV β1i-injected β1i-deficient 
animals but this effect was more pronounced in the reconstituted β1i knockout mice. Upon 
isoprenaline treatment, the A value was increased in the AAV β1i-injected but not in the AAV 
Luci-treated β1i-deficient mice indicating that diastolic dysfunction in these animals is caused 
by a decreased contractility of the atria. In addition, the present study confirmed the 
applicability of the E/A ratio as an indicator of diastolic dysfunction in the isoprenaline model 
of cardiac hypertrophy in mice. 
The progression of normal diastolic function towards severe dysfunction is represented by four 
different transmitral inflow patterns in humans (Nagueh et al. 2009) and in mice (Du et al. 
2008). These patterns include normal filling (E>A), impaired left ventricular relaxation (E<A), 
pseudonormal filling (E>A) and restrictive filling (E>>A) (Du et al. 2008, Nagueh et al. 2009). 
Analysis of cardiac function at an intermediate step might enable a better judgement of the 
rapid progression of diastolic dysfunction (Gao et al. 2011). Thus, cardiac function should be 
investigated after 3 or 4 days of isoprenaline exposure (Saadane et al. 1999) when the E value 
is likely to be elevated already. This seems less clear for the A value, reflecting the contractility 
of the atria, which may in fact be increased earlier and more transiently in AAV Luci-injected 
β1i knockout mice. Along these lines it would also be interesting to analyze whether systolic 
function in these animals is increased at such an earlier time point. In summary, investigating 
the aforementioned parameters after 3-4 days isoprenaline exposure may provide a better 
insight into the mechanisms underlying the deteriorating cardiac function associated with the 
loss of β1i in these animals, which could be restored by the AAV9-based reintroduction of β1i 
into (the active proteasomes of) the heart. 
Myocardial fibrosis is closely associated with cardiac remodeling in various cardiovascular 
diseases (Lorell et al. 2000, Kitamura et al. 2001, Moreo et al. 2009). In previous studies using 
the isoprenaline hypertrophy model, myocardial collagen content was analyzed by Masson’s 
trichrome staining (Saadane et al. 1999, Matkovich et al. 2006, Galindo et al. 2009). In 
C57BL/6 wild type mice no sign of fibrosis (Saadane et al. 1999) or marginal fibrosis (Matkovich 
et al. 2006) was reported after a 14-day isoprenaline treatment. In the present study, 
preliminary results suggest that there is essentially no myocardial fibrosis in AAV β1i-injected 
β1i knockout mice after 7 days exposure to isoprenaline while this was present in an 
AAV Luci-injected control animal. Clearly, the validity of this finding must be corroborated in 
further studies. However, myocardial fibrosis potentially contributed to the observed diastolic 
dysfunction in the AAV Luci-injected β1i knockout mice, given the association of myocardial 
fibrosis with increased myocardial stiffness and hence impaired diastolic relaxation, as 
previously reported for this experimental hypertrophy model (reviewed in (Osadchii 2007)). 
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The development of myocardial fibrosis is either due to the remodeling of the extracellular 
matrix (reactive fibrosis) or the replacement of lost cardiomyocytes (replacement fibrosis) 
(reviewed in (Krenning et al. 2010)). Reactive fibrosis is predominantly observed in pressure 
overload-induced cardiac hypertrophy due to enhanced biomechanical stress resulting in the 
remodeling of the extracellular matrix (reviewed in (Fan et al. 2012)). On the contrary, 
replacement fibrosis compensates for lost cardiomyocytes due to apoptosis or necrosis for 
example after myocardial infarction or in the terminal stages of heart failure (reviewed in (Fan 
et al. 2012)). One characteristic feature of replacement fibrosis due to cardiomyocyte necrosis 
is the recruitment of inflammatory cells (Fan et al. 2012). Cardiac fibroblast proliferation as well 
as recruitment and differentiation of circulating bone-marrow-derived cells to cardiac fibroblast 
in replacement fibrosis results in the formation of fibrotic scar tissue (Fan et al. 2012). 
In the isoprenaline hypertrophy model, replacement fibrosis due to cardiomyocyte necrosis 
has been reported after acute treatment using high doses of isoprenaline (5 days, 
100 mg * kg-1 * d-1) in Swiss-Webster mice (Brooks et al. 2009) and A/J mice (Faulx et al. 
2005). Notably, the resulting fibrosis is strain-dependent, thus the extent of fibrosis in C57BL/6 
mice is much lower than that in A/J mice (Faulx et al. 2005). Replacement fibrosis has been 
further shown in C57BL/6 mice after chronic stimulation with a moderate dose of isoprenaline 
(10 days, 40 mg * kg-1 * d-1) (Galindo et al. 2009). The fibrosis observed upon isoprenaline 
treatment of AAV Luci-injected β1i-deficient mice (preliminary results) may represent the 
replacement fibrosis type, given the absence of cell debris or immune cells in the fibrotic tissue. 
Further analyses of preceding cardiomyocyte necrosis or apoptosis may elucidate the exact 
type of cardiac fibrosis in these animals. Considering the presence of marginal fibrosis in 
C57BL/6 mice after 14 days isoprenaline treatment at a dose of 30 mg * kg-1 * d-1 (Matkovich 
et al. 2006), the development of fibrosis in these animals may potentially be accelerated 
depending on the dose of and duration of treatment with isoprenaline. 
 
5.4 Sarcomeric proteins – targets of β1i-specific degradation upon isoprenaline 
treatment? 
In a previous study from our laboratory, an increased expression and incorporation of inducible 
proteasome subunits into proteasome complexes, enhanced assembly of 26S proteasomes 
resulting in the increase of all three 26S proteasome activities as well as an increased 
sensitivity of the 20S proteasome to activation via cAMP-dependent PKA has been reported 
for a 7-day treatment protocol with isoprenaline (30 mg * kg-1 * d-1) in mice (Drews et al. 2010). 
In the TAC model, an increase of the 26S chymotrypsin-like activity has previously been shown 
in mice 5 days to 3 weeks following the aortic constriction (Depre et al. 2006, Hedhli et al. 
2008). In another study using TAC in mice, the 26S proteasome activities were reduced for 2 
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to 4 weeks after the TAC procedure (Tsukamoto et al. 2006). Thus, regulation of the activity of 
the proteasome may depend on the level of aortic constriction resulting in a differing 
development of hypertrophy or transition towards heart failure, given that a decreased activity 
of the 26S proteasome is associated with heart failure in humans (reviewed in (Drews et al. 
2014)). Therefore, proteasome function and activity seems to be markedly altered in cardiac 
hypertrophy and heart failure. In the present study, proteasome subunit expression, assembly 
as well as activity were not significantly altered upon treatment with isoprenaline of 
β1i-deficient mice in which this subunit had been reintroduced by cardiac-specific gene 
transfer. 
Previously, increased expression of inducible proteolytic subunits was associated with 
enhanced incorporation of these subunits into (active) proteasome complexes upon exposure 
to isoprenaline in wild type mice (Drews et al. 2010). Thus, the uniform albeit insignificant 
elevation of the expression of the proteolytic subunits β1, β2, β5 and β5i in AAV Luci-injected 
β1i knockout mice may potentially be associated with an increased incorporation of these 
subunits into proteasome complexes, as shown by active site labeling. Moreover, this may be 
associated with the more pronounced pro-hypertrophic response to isoprenaline of these mice. 
Reintroduction of β1i influences the activity of the proteasome, given that the constitutive 
counterpart β1 accounts for the caspase-like activity, whereas the inducible subunit β1i 
contributes to the chymotrypsin-like activity of the proteasome. However, considering the 
preference of the activity-based probe MVB003 for proteasome subunits with 
chymotrypsin-like or trypsin-like activity, the proteasome subunit β1i was incorporated into 
proteasome complexes only to a small extent in relation to its constitutive counterpart β1 in 
AAV β1i-injected β1i knockout mouse hearts following β-adrenergic overstimulation. 
Contrariwise, the 26S and 20S caspase-like activities were both moderately albeit 
insignificantly reduced in these hearts, so that the level of incorporation of β1i into cardiac 
proteasome complexes did not correspond to the alterations in proteolytic activity. Thus, there 
must be additional mechanisms regulating proteasomal function. Considering the involvement 
of PKA in controlling proteasomal activity in this hypertrophy model (Drews et al. 2010), this 
might be regulated via phosphorylation, given that several phosphorylation sites exist both in 
the β1 and β1i subunit (reviewed in (Cui et al. 2014)). Alternatively, the slight difference in 
proteasomal function upon treatment with isoprenaline of AAV β1i as compared to 
AAV Luci-injected β1i-deficient mice might be associated with the differential regulation of 
several non-proteasomal proteins, resulting in the reduced development of hypertrophy and 
prevention of cardiac dysfunction. 
Chronic β-adrenergic stimulation by isoprenaline induces a (pathological) concentric cardiac 
hypertrophy. One characteristic of hypertrophic growth is the remodeling of cardiomyocytes 
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through the addition of sarcomeres. Consequently, the turnover of sarcomeric proteins is 
increased. The UPS likely accounts for the maintenance of cardiomyocyte function by the 
targeted degradation of structural, functional and signaling proteins (Drews et al. 2014). Thus, 
differences in the expression of sarcomeric proteins, which are targets of the UPS, potentially 
contribute to the observed systolic and diastolic dysfunction upon treatment with isoprenaline 
in AAV Luci-injected β1i-deficient mice. Sarcomeric contractile proteins that are targeted by 
the UPS comprise, e.g. actin (Solomon et al. 1996), β-myosin heavy chain (β-MHC) (Fielitz et 
al. 2007) and ventricular myosin light chain 2 (MLC2v) (Witt et al. 2005) as well as cardiac 
troponin I (Kedar et al. 2004). Moreover, sarcomeric structural proteins such as α-tubulin 
(Poruchynsky et al. 2008), desmin (Ye et al. 2014) or α-actinin (Spaich et al. 2012) can also 
be degraded via the UPS. Neither the abundance of actin, β-MHC or MLC2v nor that of 
α-tubulin were altered upon treatment with isoprenaline in AAV Luci as compared to 
AAV β1i-injected β1i-deficient mice. Thus, neither the myofilaments, which are part of the 
force-generating machinery, nor the microtubules, which alter cardiomyocyte contraction 
capacity due to modifying flexibility of the cytoskeleton, seem to be subjected to differential 
proteasomal degradation upon reintroduction of β1i, and therefore may not be related to the 
observed beneficial effects on cardiac function in these animals.  
In contrast, the level of cardiac troponin I seemed to be moderately decreased in AAV Luci as 
compared to AAV β1i-injected β1i-deficient mouse hearts. Troponin I is a key regulator of 
striated muscle contraction and relaxation due to its control of the actin-myosin cross bridge 
cycle. Previously, phosphorylation of cardiac troponin I via PKA upon β-adrenergic stimulation, 
resulting in accelerated relaxation (lusitropic effect), has been demonstrated (Zhang et al. 
1995). In addition to diastolic function, systolic function may also be improved through 
phosphorylation of cardiac troponin I via β-adrenergic stimulation (Takimoto et al. 2004). 
Moreover, deprivation of cardiac troponin I has been associated with diastolic dysfunction due 
to impaired cardiomyocyte relaxation (Fentzke et al. 1999). Thus, the moderately decreased 
level of cardiac troponin I in AAV Luci as compared to AAV β1i-injected β1i-deficient mouse 
hearts may have contributed to the observed systolic and diastolic dysfunction in these 
animals. Consequently, reincorporation of β1i into (active) proteasome complexes potentially 
reduces degradation of cardiac troponin I by the proteasome. This interesting hypothesis 
warrants further investigation.  
The overall abundance of α-actinin, which links adjacent sarcomeres at the Z-discs, and 
desmin, which aligns myofibrils to three dimensional networks at the Z-discs and intercalated 
disks, was not significantly altered in AAV Luci as compared to AAV β1i-injected β1i-deficient 
mouse hearts. However, the ordered localization of α-actinin and desmin is of particular 
interest, given that disorganization of desmin (Heling et al. 2000) and α-actinin (Hein et al. 
2009) has previously been shown in patients with heart failure. This was not altered following 
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isoprenaline exposure in the AAV Luci as compared to AAV β1i-injected β1i-deficient mouse 
hearts (α-actinin – data not shown). Moreover, atypical α-actinin clusters (Heling et al. 2000) 
or a disturbed cross-striation pattern of desmin (Hein et al. 2009), which have been shown in 
human failing hearts, were not observed following isoprenaline treatment in AAV Luci as 
compared to AAV β1i-injected β1i-deficient mouse hearts (α-actinin – data not shown). Thus, 
the observed systolic and diastolic dysfunction in AAV Luci-injected β1i knockout seems to be 
unrelated to a disorganization of the sarcomeres, given that sarcomere integrity was not 
disturbed. 
 
5.5 Increased 26S proteasome activities in the context of aging: effort to maintain 
protein homeostasis? 
Considering the regulation of proteasome function in cardiac hypertrophy and heart failure, the 
potential regulation of proteasome function in the context of aging is intriguing, given the 
increased prevalence of cardiac hypertrophy and heart failure in the elderly. While the E/A ratio 
(diastolic function) is decreased, ejection fraction (systolic function) is preserved in healthy 
humans (Lakatta et al. 2003). Similar alterations in cardiac function can be observed in aging 
mice (Dai et al. 2009). Moreover, a reduced regenerative capacity of the aged heart has been 
reported for both men (Bergmann et al. 2009) and mice (Senyo et al. 2013). Thus, cardiac 
aging in mice seems to recapitulate the alterations in the human heart with increasing age. 
Consequently, mice seem to be a suitable model for the analysis of cardiac aging.  
Previous studies reported an increase (Palpant et al. 2008, Hua et al. 2015) as well as no 
change (Li et al. 2007, Wu et al. 2007, Kiper et al. 2013) of the heart weight to body weight 
ratio (HW/BW ratio) in young versus old wild type mice. In the present study, the HW/BW ratio 
was not significantly altered in old as compared to young mice but in middle-aged mice this 
was significantly reduced (Kiper et al. 2013). Thus, cardiac aging may be not associated with 
marked alterations of cardiac morphology, such as cardiac hypertrophy, in general. Notably, 
systolic dysfunction was detected in 24 versus 2 months old mice despite no change in the 
HW/BW ratio (Kiper et al. 2013). In the present study, the 26 months old mice most likely had 
a rather poor general health status since they had to be sacrificed because of this. 
Contrariwise, no pathologic abnormalities were observed in 30 versus 3 months old mice by 
echocardiography analysis. Considering the similar alteration of the HW/BW ratio in the 26 and 
30 months old mice as compared to their young (4 or 3 months old) counterparts this parameter 
may not be suitable as a reliable indicator of normal cardiac function. 
Aging is associated with the accumulation and aggregation of damaged proteins, which can 
be cytotoxic, resulting in the reinforcement of the aging process. It is commonly hypothesized 
that proteasome function is impaired in the context of aging due to the key role of the UPS in 
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maintaining protein homeostasis (reviewed in (Kevei et al. 2014)). Moreover, the UPS 
accounts for the regulation of key regulator pathways of aging (reviewed in (Kenyon 2010)), 
such as the insulin or the insulin-like growth factor 1 (IGF-1) signaling pathway. For this 
purpose, the UPS regulates the stability of multiple components of the IGF-1 signaling pathway 
(Han et al. 2012). Thus, an impaired regulation of these regulatory pathways with aging 
potentially results in the reinforcement of the aging process due to a decline of the function of 
the UPS. However, the number of studies regarding this topic are rather limited. Regulation of 
the 20S proteasomal activities in the heart has been investigated in the context of aging in only 
one study (Bulteau et al. 2002) which revealed that the caspase-, trypsin- and 
chymotrypsin-like activities of the 20S proteasome were significantly reduced in the hearts of 
26 as compared to 8 months old rats. In the present study, the 20S proteasome activities were 
altered neither in hearts of 26 versus 4 months old mice nor in those of 30 versus 3 months 
old animals. These differing results may be explained by using different reference groups and 
a different general health status and/or cardiac performance and, most importantly, different 
species with a different normal life span. 
In contrast to the cardiac 20S proteasome, the caspase-, trypsin- and chymotrypsin-like 
activities of the 26S proteasome were strongly increased in old as compared to young mice. 
Interestingly, this difference was accentuated in the 26 versus 4 months old mice as compared 
to the 30 versus 3 months old animals, potentially related to the poorer general health status 
of the 26 months old mice. Previously, the decline of proteasome activity with age has been 
linked to the formation of protein aggregates, which interfere with the activity of the 
proteasome, e.g. in yeast (Andersson et al. 2013). Thus, impaired proteasome activity and 
protein aggregate formation are potentially induced if the degradation capacity of the 
proteasome is exceeded. Apparently, this threshold has not been reached in the old mice in 
the present study, given that the 26S proteasome activities were significantly higher than in 
young mice, and even higher when their general health status was quite poor. 
Proteasome activity is regulated by multiple mechanisms, such as the increased assembly of 
proteasome complexes, the association of regulatory particles or post-translational 
modifications (Jung et al. 2009). In the present study, the incorporation of proteolytic 
β-subunits, analyzed via active site labeling, was not altered, whereas the abundance of all 
proteolytic subunits, analyzed by Western blot, was uniformly elevated in 30 versus 3 months 
old mice. Thus, the age-related increase of proteasome activities in these animals seems to 
be regulated via alternative mechanisms, such as the association with regulatory particles or 
post-translational modifications. In addition, such a disparity between abundance and 
incorporation of proteasome subunits has previously been reported in the context of cardiac 
hypertrophy (Drews et al. 2010). In contrast, incorporation of proteolytic β-subunits was 
uniformly increased in 26 versus 4 months old mice in the present study. Thus, the markedly 
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higher increase of the 26S proteasome activities in the 26 months old as compared to the 
30 months old mouse hearts is potentially due to an increased assembly of proteasome 
complexes that may be associated with the comparatively poor general health status of these 
mice. Consequently, 26S proteasome activities are potentially increased through the 
association with regulatory particles or post-translational modifications with age in healthy 
mice, whereas the assembly of proteasome complexes may be linked to the manifestation of 
a poor general health status. 
Association of the 11S regulatory particle is potentially involved in the increase of the 26S 
proteasome activities, given that the 11S acts as an activator (Dubiel et al. 1992). Moreover, 
hybrid proteasomes consisting of a 20S core particles, capped by one 19S and one 11S 
regulatory particle, have been reported previously (Tanahashi et al. 2000). Post-translational 
modifications are a key regulatory mechanism of proteasome structure and function, such as 
proteolytic activity and interaction with associating partner proteins (reviewed in (Scruggs et 
al. 2012, Cui et al. 2014)). In this context, phosphorylation is one of the most frequent 
post-translational modifications in the proteasome (Cui et al. 2014). Moreover, several 
cardiac-specific phosphorylation sites have been reported (Cui et al. 2014) that are partially 
targeted by PKA and when phosphorylated cause an increase in proteasomal activity (Lu et 
al. 2008). Thus, the activity of the proteasome may be affected by changes in β-adrenergic 
signaling in the context of aging. 
Cardiac aging is associated with structural and functional changes of cardiomyocytes 
(reviewed in (Lakatta 2003)), resulting in alterations of cardiac function such as a decline in 
diastolic function. In the context of aging, the number of cardiomyocytes may be reduced due 
to necrosis or apoptosis resulting in the enlargement of the remaining cardiomyoyctes and 
myocardial fibrosis (reviewed in (Strait et al. 2012)). Moreover, cardiomyocyte contraction is 
modified with increasing age due to changes in the ion channel and intracellular Ca2+-handling 
properties of these cells (reviewed in (Feridooni et al. 2014)). Modifications of contractile 
proteins, such as a decreased phosphorylation of troponin I (Campbell et al. 2013) or a switch 
from the fast α-MHC to the slower β-MHC isoform (Wahr et al. 2000) contribute to alterations 
in contractility with increasing age. These extensive structural and functional changes also 
imply alterations of the cardiac proteome in the context of aging. In the present study, proteome 
analysis via total protein staining after 1D-gel electrophoresis revealed significant alterations 
in the proteome of aged hearts as compared to young hearts. Again, these alterations were 
more pronounced in the 26 months old mice as compared to the 30 months old animals, 
presumably due to their different general health status and the aforementioned differences in 
the 26S proteasome activities. 
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Previously, alterations of the cardiac proteome with increasing age have been investigated in 
rats and mice by way of 2D-gel electrophoresis and tandem mass spectrometry analyses (Dai 
et al. 2008, Richardson et al. 2008, Grant et al. 2009). In the present study, proteins were 
identified by comparison of their position (spot) on a 2D-gel with that in a published reference 
gel representing a cardiac proteome database (HP-2DPAGE: http://web.mpiib-
berlin.mpg.de/hp-2dpage/heart1.html). Notably, alterations in the cardiac proteome were 
quantified in 2D-gels of samples from young and aged hearts. The analysis revealed an 
increased abundance of myosin light chain 3 (MLC3) but not ventricular myosin light chain 2 
(MLC2v) and myoglobin in 26 versus 4 months mouse hearts. An increased abundance of the 
essential isoform MLC1/3 and of the regulatory isoform MLC2v as well as an enhanced 
expression of MHCs has previously been shown in the hearts of 34 versus 4 months old rats 
(Richardson et al. 2008). 
Considering the structure of the myosin complex, which is a hexamer consisting of two MHCs, 
two essential MLCs and two regulatory MLCs, cardiac expression of all components of this 
myosin complex was increased in the aged rats (Richardson et al. 2008). Contrariwise, 
abundance of the essential MLC, but not of the regulatory MLC2v, was higher in the hearts 
from the 26 months old mice in the present study. Thus, formation of the myosin complex may 
be impaired in these animals due to the limited abundance of the regulatory MLC2v or an 
alternative regulatory MLC isoform, which has not been identified or quantified, is incorporated 
into the myosin complex. It may be therefore that MLC isoforms are potentially switched with 
increasing age in mice as previously shown for MHC isoforms (Wahr et al. 2000). In the context 
of aging, cardiac contraction seems to be decelerated due to a switch from the α-MHC isoform 
to the slower β-MHC isoform (Wahr et al. 2000). Similarly, the ventricular MLC2 (MLC2v) 
isoform may be replaced by the atrial MLC2 (MLC2a) isoform, also resulting in an altered 
contractility (Pawloski-Dahm et al. 1998). 
A decreased abundance of myoglobin has previously been shown in 23 versus 3 months old 
mice (Dai et al. 2008). In contrast, myoglobin levels were increased in 26 versus 4 months old 
mice in the present study. Considering the role of myoglobin in the antioxidant defence of the 
heart (Flogel et al. 2004), the increased abundance of myoglobin in the heart of the 26 months 
old mice in the present study might be linked to the poor general health status of these animals 
The abundance of MLC2v in the 30 months old mouse hearts as compared to the 3 or 9 months 
old animals was not altered like in the 26 months old animals, arguing against an influence of 
the general health status. In contrast, abundance of the slow β-MHC was also markedly 
increased in 30 versus 3 months old mouse hearts, suggesting that this is the predominant 
MHC isoform in the heart of old mice (Wahr et al. 2000). Moreover, troponin I levels were 
moderately decreased in 30 versus 9 months old mouse hearts, implying that this is potentially 
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linked to the decline of diastolic function (Fentzke et al. 1999) in aged mice. Notably, the 
ubiquitin ligase muscle RING finger 1 (MuRF1) accounts for the targeted degradation of the 
slow β-MHC isoform (Fielitz et al. 2007) and of troponin I (Kedar et al. 2004). Consequently, 
targeted degradation of proteins via the UPS seems to be differentially regulated via additional 
regulatory mechanisms, given that β-MHC seems to be less avidly degraded, whereas 
degradation of troponin I appears to be upregulated in aged hearts. 
Deubiquitinating enzymes (DUBs) preserve ubiquitin-tagged proteins from proteasomal 
degradation via the removal of ubiquitin (reviewed in (Komander et al. 2009)). Thus, β-MHC 
might be shielded from proteasomal degradation by DUBs, whereas troponin I is directly 
degraded via the proteasome. In addition, protein synthesis of β-MHC and troponin I might be 
differentially regulated in the context of aging. Furthermore, the significantly increased 
26S proteasome activities might be associated with the differential regulation of proteins other 
than sarcomeric proteins due to the limited alteration of sarcomeric proteins with increasing 
age. Previously, an altered expression of multiple signaling, metabolic and antioxidant 
proteins, as well as proteins involved in the energy and fatty acid metabolism in the context of 
aging has been reported (Dai et al. 2008, Richardson et al. 2008, Grant et al. 2009). Thus, the 
observed increased 26S proteasome activities might be associated with the regulation of these 
proteins. This hypothesis warrants further investigation. 
 
5.6 Proposed model of proteasome function during the development of cardiac 
hypertrophy and aging  
In β1i knockout mice exposed to isoprenaline incorporation of the subunit β1i into cardiac 
proteasome complexes prevented the development of an exacerbated hypertrophy. Thus, the 
lack of β1i incorporation into cardiac proteasome complexes rather than systemic 
β1i deficiency most likely has resulted in the observed phenotype of the β1i-deficient mice 
when exposed to β-adrenergic overstimulation. In fact, increased incorporation of inducible 
subunits into cardiac proteasome complexes following hypertrophy induction, previously 
reported for wild type mice (Drews et al. 2010), seems to be an important mechanism in cardiac 
remodeling (Figure 42).  
The observed phenotype in the isoprenaline-treated β1i-deficient mice does not seem to be 
related to a disturbance of the sarcomeric structure while incorporation of β1i instead of β1 into 
the cardiac proteasome complexes seems to be associated with increased levels of troponin I 
compared to the control group, potentially contributing to maintenance of cardiac function. 
Alternatively, the observed phenotype may also be linked to a potential downregulation or 
desensitization of β-adrenergic receptors, as previously reported in patients with heart failure 
(reviewed in (Hamdani et al. 2012)). 
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Cardiac aging is associated with significant alterations within the cardiac proteome that may 
be exacerbated in the context of a poor general health status. Moreover, the extent of these 
alterations seems to be associated with an adaptive increase of the 26S proteasome activities, 
which may maintain protein homeostasis and cardiac function in the context of aging 
(Figure 42). Considering previous reports on a decline of proteasome activity with increasing 
age that is accompanied or caused by an enhanced formation of protein aggregates 
(Andersson et al. 2013), aggregate formation may occur if the capacity of the UPS is reached 
resulting in the impairment of proteasome function (reviewed in (Vernace et al. 2007)). 
 
 
Figure 42. Proposed model of proteasome function during aging and the development of 
cardiac hypertrophy.  
Incorporation of β1i into cardiac proteasome complexes prevents the development of an exacerbated 
hypertrophy and premature occurrence of systolic and diastolic dysfunction following continuous 
β-adrenergic stimulation. The 26S proteasome activity seems to rise with increasing age. This 
increase potentially limits the capacity of the UPS to counteract pro-hypertrophic stimuli in aged 
organisms potentially resulting in cardiac complications, e.g. pathological hypertrophy.  
 
In patients older than 60 years, cardiotoxicity of the proteasome inhibitor bortezomib, used in 
tumor therapy, has been reported (Enrico et al. 2007). Further case reports associate the 
pathogenesis of cardiac disorders with the utilization of proteasome inhibitors targeting all 
proteasome complexes in tumor therapy (reviewed in (Drews et al. 2014)). Contrariwise, 
maladaptive cardiac remodeling has been reported to be prevented and cardiac function 
preserved by proteasome inhibition in models of pathological hypertrophy (Depre et al. 2006, 
Hedhli et al. 2008, Stansfield et al. 2008). Notably, submaximal inhibition of proteasomal 
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activity in association with its duration seem to be critical for the beneficial effects of 
proteasome inhibition in the context of maladaptive cardiac hypertrophy. Considering the 
treatment regimen typically used for tumor therapy, cardiac proteasome inhibition is 
presumably more pronounced in tumor patients than in cardiac hypertrophy. 
Moreover, the difference in age also seems to be a critical factor. Considering the augmented 
26S proteasome activities with increasing age to maintain protein homeostasis and 
cardiomyocyte function, the more aggressive proteasome inhibition in tumor patients may limit 
the degradation capacity of the UPS, resulting in the formation of protein aggregates, which in 
turn exacerbate its impairment. About 50% of tumor patients with cardiac complications treated 
with proteasome inhibitors develop heart failure (Enrico et al. 2007). Thus, the increased 
prevalence of pathological cardiac hypertrophy in the elderly might be due to the limited 
capacity of the UPS to maintain protein homeostasis and thus cardiomyocyte function 
(Figure 42). Further studies on the beneficial or detrimental effects of proteasome inhibition on 
cardiac function are needed to minimize adverse effects of proteasome inhibitors used in tumor 
therapy or against other diseases. 
 
5.7 Perspectives 
Considering the aforementioned proposed model of proteasome function during the 
development of cardiac hypertrophy and aging, the following interesting questions arise which 
need to be answered by further investigations. 
a) What is the underlying mechanism responsible for the augmented cardiac hypertrophy 
and dysfunction in β1i-deficient mice following induction of hypertrophy? Further 
experiments have to be done to compare the changes, e.g. in heart weight, between 
the isoprenaline treated groups with sham treated mice. In addition, detected 
differences in troponin I levels between hearts of isoprenaline administered AAV β1i 
and AAV Luci-treated β1i knockout mice require statistical validation. Again, 
comparison with matching sham treated animals will indicate whether intracellular 
troponin I levels are comparable with those in wild type hearts and indeed decreased 
in cardiac hypertrophy. Other observations, such as the onset of fibrosis require 
validation as well. 
b) Can cardiac β1i overexpression in wild type mice (gain of function) decrease or even 
prevent the development of pathological hypertrophy following isoprenaline exposure? 
Cardiac function and morphology as well as proteasome regulation have to be 
analyzed. Verification that increased β1i incorporation into cardiac proteasome 
complexes is beneficial would reinforce interest in the underlying mechanism.  
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c) Is the increase of 26S proteasome activities with increasing age related to the 
deteriorating general health status? In order to confirm this hypothesis the abundance 
of proteins indicating increased cellular stress could be analyzed. Investigation of the 
pool of ubiquitinated and oxidized proteins might elucidate whether proteasome activity 
is increased in response to a higher demand in their turnover. In turn, this may be 
associated with increased levels of proteins participating in antioxidant defence or 
protein folding. 
d) Is AAV9-based gene transfer, e.g. of β1i, a realistic therapeutic option to maintain 
proteasome function and activity and hence protein homeostasis in the aging heart to 
prevent cardiac hypertrophy and/or its transition to heart failure? This is a particularly 
interesting question that requires the setting up of a cardiac hypertrophy model in aging 
mice with the potential of a transition to heart failure that are treated with the 
adeno-associated viral vector-based CMV/MLC0.26-driven β1i expression construct 
established herein. Mechanistically, this approach might also reveal whether there 
really is a link between the hypertrophy and age-related deterioration of cardiac 
function with regard to changes in the function and/or activity of the 26S proteasome 
that could only be marked off in the present study. 
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Appendix - Sequence of the AAV CMV/MLC0.26 βi1 vector 
       1  ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt 
      61  ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggaatt cacgcgtcgg 
     121  cggccgcttc gagctcgccc gacattgatt attgactagt tattaatagt aatcaattac 
     181  ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 
     241  cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc 
     301  catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 
     361  tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa 
     421  tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 
     481  ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta 
     541  catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 
     601  cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa 
     661  ctccgcccca tgcggccgct ctaggaccca gagcacagag catcgttccc aggccaggcc 
     721  ccagccactg tctctttaac cttgaaggca tttttgggtc tcacgtgtcc acccaggcgg 
     781  gtgtcggact ttgaacggct cttacttcag aagaacggca tggggtgggg gggcttaggt 
     841  ggcctctgcc tcacctacaa ctgccaaaag tggtcatggg gttattttta accccaggga 
     901  agaggtattt attgttccac agcaggggcc ggccagcagg ctccttgccc aagctttatt 
     961  gcggtagttt atcacagtta aattgctaac gcagtcagtg cttctgacac aacagtctcg 
    1021  aacttaagct gcagaagttg gtcgtgaggc actgggcagg taagtatcaa ggttacaaga 
    1081  caggtttaag gagaccaata gaaactgggc ttgtcgagac agagaagact cttgcgtttc 
    1141  tgataggcac ctattggtct tactgacatc cactttgcct ttctctccac aggtgtccac 
    1201  tcccagttca attacagctc ttaaggctag agtacttaat acgactcact ataggctagc 
    1261  ctcgacggta ccgcgggccc gggatccacc ggtgccacca tgctgcgggc aggagcacct 
    1321  accgccggct cgttccggac ggaagaagtc cacaccggga caaccatcat ggcagtggag 
    1381  tttgacgggg gtgtcgtggt gggctctgat tcccgggtgt cagcgggaac agcagtggtg 
    1441  aaccgcgtgt tcgacaagct ctcccctctg caccagcaca tcttctgtgc cctctcaggt 
    1501  tccgctgctg atgcccaagc catagctgac atggccgcct accagctgga gctacacggg 
    1561  ttggagctgg aggagccgcc cctcgttctg gctgctgcaa acgtggtgaa gaacatctcc 
    1621  tacaagtacc gtgaggactt gttagcgcat ctcatagtag ctggctggga ccaatgtgag 
    1681  gggggacagg tatatggaac catgggaggg atgctaattc gacagccctt taccatcggc 
    1741  ggttccggaa gctcctacat ttatggttat gtggacgcag cttataagcc aggcatgacc 
    1801  cctgaggagt gccggcgttt caccacagat gccatcactc tggccatgaa ccgagatggc 
    1861  tctagtgggg gtgtcatcta cctggtcacc atcacagctg ctggtgtgga ccatcgagtc 
    1921  atcctgggag atgagctgcc aaaattctac gatgagtgat gtacaagtaa agcggccgcg 
    1981  actctagatc ataatcagcc ataccacatt tgtagaggtt ttacttgctt taaaaaacct 
    2041  cccacacctc cccctgaacc tgaaacataa aatgaatgca attgttgttg ttaacttgtt 
    2101  tattgcagct tataatggtt acaaataaag caatagcatc acaaatttca caaataaagc 
    2161  atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat cttaaggcgg 
    2221  gaattgatct aggaacccct agtgatggag ttggccactc cctctctgcg cgctcgctcg 
    2281  ctcactgagg ccgcccgggc aaagcccggg cgtcgggcga cctttggtcg cccggcctca 
    2341  gtgagcgagc gagcgcgcag agagggagtg gccaa 
Figure 43. Sequence of the AAV CMV/MLC0.26 β1i vector within the inverted terminal repeats (ITR) 
(2375 bp of 5990 bp). 
The ITR (5’ ITR and 3’ ITR) (yellow), the genetically engineered promotor consisting of parts of the viral 
cytomegalovirus (CMVenh) immediate-early promotor (light purple) and a fragment of the tissue-specific myosin light 
chain promotor (MLC0.26) (dark purple), the β1i gene (green) and the Simian virus 40 polyadenylation signal (SV40 
polyA) (blue) are highlighted within the sequence. Sequenced area of the AAV CMV/MLC0.26 β1i vector is in bold. 
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